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CHAPTER I 
 
INTRODUCTION 
 
 
“Nothing in life is to be feared, it is only to be understood.  
Now is the time to understand more, so that we may fear less.”  
 
 
Marie Curie  
(°1867 - †1934, Physicist) 
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ABSTRACT 
The introduction starts with a short overview of the biopharmaceuticals and their booming 
business, as well as peptide pharmaceuticals which are established scaffolds within the scientific 
and industrial community. Then, the biopharmaceutical somatropin, a recombinant human 
growth hormone, is being discussed as the model compound within this doctoral research. The 
endogenous functions of somatropin are described, including new potential applications such as 
in oncology, as well as the positioning of GH within ligand-targeted antitumor medicines. During 
the development of biopharmaceuticals and peptides, one of the barriers of current interest is 
the blood-brain barrier (BBB), which is handled in the fourth section of this introduction. Our 
knowledge on the influence of modifications on biopharmaceuticals and their behaviour at the 
BBB, as well as the knowledge on the BBB transport behaviour of peptides is currently still 
limited. This barrier is therefore included during this research. The fifth section gives an overview 
of traditional and emerging techniques for the characterization of biopharmaceuticals and 
peptides. Their application and impact within research and industrial settings are positioned. 
Finally, the main goal and the related research objectives are formulated while the coherence of 
this doctoral dissertation is explained in the thesis outline section. 
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CHAPTER I 
INTRODUCTION 
1. PROTEIN AND PEPTIDE MEDICINAL PRODUCTS 
Since the marketing authorization of the first recombinant human insulin in 1982, humilin, the 
pharmaceutical biotech industry has firmly established itself as a major source of new human 
biopharmaceuticals. Important examples of biopharmaceuticals include human growth hormone (GH), 
monoclonal antibodies, as well as nucleic-acid based products and engineered cell or tissue-based 
products. A biopharmaceutical is defined as a pharmaceutical, inherently biological in nature and 
manufactured using biotechnology. A biopharmaceutical is thus categorized under the umbrella term 
“biologic” (Figure 1) [1, 2]. 
 
 
Figure 1: Overview of the medicinal products. Small molecules are given in orange, biologics in blue. In dark 
colour, the requirements of generics and biosimilars are given. 
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Protein medicinal products currently predominate the biopharmaceuticals. The production of proteins 
is based on the expression in different hosts going from prokaryotic cells (e.g. Escherichia coli), to 
eukaryotic cells (e.g. yeast and Chinese hamster ovary (CHO) cell lines), transgenic animals and plants 
[3-5]. Depending on the host and intra- or extracellular expression, post-translational modifications 
(PTM) can be introduced onto a protein by specific enzymatic steps. Phosphorylation, for example, is 
typically associated with intracellular proteins while glycosylation and disulphide linkage formation are 
the characteristics for extracellular proteins. Glycosylation is by far the most common and complex 
PTM associated with recombinant proteins, and this PTM can have an influence on the stability, 
conformation and pharmacokinetic profile of the protein [6, 7]. These possibilities created an evolution 
in the biopharma sector toward engineering of PTM and other chemical substances on proteins. More 
investment is made on the knowledge of their structure-function relationships and the development 
of supporting techniques and technologies, including analytical methodologies and advances in 
genomics, bioinformatics and proteomics [8]. 
As seen from the new drug approvals in 2015, the main focus of the pharmaceutical industry is situated 
in the ‘oncology’ therapeutic area, which accounted for more than 30% of the approvals [9]. 
Modifications of biopharmaceuticals with radioactivity, using direct or indirect radioiodination, 
radiometal-chelate coupling, indirect radiofluorination or 3H/14C-labelling, creates an efficient and 
selective way for the delivery of radioactivity to the tumour site for diagnostic and/or therapeutic 
purposes [10]. During research and development stages of such products, it is however necessary to 
chemically and functionally characterize the obtained products, because modifications can influence 
receptor binding [11]. It is therefore nearly impossible to predict a priori the functional outcome. 
 
Another class within the biologics are the biosimilars. After the patent expiry of the 
biopharmaceuticals, the way for the authorization of similar versions or biosimilars is opened. 
Biosimilars are copy-like versions of a reference product, i.e. highly similar but not identical. Similars 
present much greater developmental and regulatory challenges than generic versions of small 
molecule drugs owing to their structural complexity. The resulting similar medicinal product will 
display a degree of variability due to (i) the inherent variability of biological systems used as expression 
systems (‘the hosts’), (ii) the used raw materials (such as reagents, culture media, foetal calf serum, 
and buffers involved in chromatography), and (iii) the manufacturing process. As such, the biosimilar 
and originator biological medicine are not identical. Therefore, the traditional generic pharmaceutical 
regulatory pathways are not sufficient for the assessment and approval of such a biosimilar. 
Overall, biopharmaceuticals including engineered products and biosimilars, are a complex product 
class which have a challenging need for their chemical and functional characterization during 
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development and manufacturing. These needs come along with a need for more advanced analytical 
tools and further investment in their development. 
 
Next to the protein biopharmaceuticals, also smaller fragments, i.e. peptides, have made their way in 
the therapeutic area [12]. These compounds can be produced synthetically [13], which immediately 
reduces the production costs, are chemically more consistent and they are smaller, leading to a higher 
tissue penetration [14, 15]. Natural peptides can form excellent starting points for diagnostics and/or 
therapeutics [16]. They originate from different sources; for example, the human microbiome has 
recently received much interest because it can generate new peptides from proteins or/and can 
produce itself signalling peptides (quorum sensing peptides). 
 
 
 
2. SOMATROPIN 
2.1. The history of somatropin: a recombinant human growth hormone 
For ages, giants are the subjects of fascination as exemplified in the world literature. The killing of 
Goliath by David, for example, indicates the first physical disadvantage of the ‘giant’ pathological state. 
However, it was not until 1886 that the first scientific written observations in this regard were made. 
More specifically by the neurologist Dr. Pierre Marie from acromegalic patients [17], a condition known 
with unusual noncongenital hypertrophy of head, upper and lower extremities which arise after 
epiphyseal plate closure. Although Dr. Pierre Marie observed a large size of the pituitary gland of his 
subjects, the link between the pituitary gland and growth was not made by that time. It was only in 
the early 1900s that the concepts ‘hyperpituitarism’ and ‘hypopituitarism’ were introduced by Harvey 
Cushing, that hyposectomized dogs by Aschner Bernard led to negative effects on growth and sexual 
development in puppies, and that substances, first named as ‘secretins’ and later as ‘hormones’ were 
introduced, i.e. substances produced at one site and leading to a physiological effect at a distant site 
[18]. These concepts formed the foundation for the discovery of the growth promoting actions of the 
pituitary gland [19], which was later assigned to somatotropin or pituitary-isolated GH [20]. Further 
scientific advances in the radio-immunoassay technique set the cornerstone in the measurement of 
endocrine functions and characterization of GH secretion in normal and patients with growth 
disturbances [21, 22]. Acromegaly and gigantism, i.e. excessive growth during childhood, share the 
same pathogenic mechanism: chronic excessive levels of GH. 
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Opposite to excessive growth, people with short statures like Charles Sherwood Stratton (1838–1883), 
who was exhibited as General Tom Thumb, are often diagnosed with growth hormone deficiency. The 
progress toward GH replacement therapy was delayed due to some scientific struggles. The first 
attempts included the isolation of bovine [20, 23] and porcine GH [24], but lacked activity in primates 
due to the species cross reactivity. Knobil et al. demonstrated that GH isolated from humans and 
monkeys did show growth-promoting efficacy in primates [25, 26]. Shortly thereafter, already in the 
late 1950s, the first GH-deficient 17-year-old patient was treated with cadaveric pituitary GH and 
exhibited a significant increase in growth [27]. During the almost 30 years that followed, approximately 
3300 people have used cadaveric somatotropin in the United States and Canada [28]. However, in 1985 
there was an abrupt stop of cadaveric GH treatment due to the link between the use of cadaveric GH 
with Creutzfeldt-Jakob disease [29]. 
In the meantime, starting in the early 1970s, the era of recombinant DNA technology was emerging 
[30-32] and resulted in the cloning of cDNA encoding human GH (hGH) in 1979 [33]. The abrupt stop 
of cadaveric GH and the scientific progression at that time, led to the worldwide regulatory approval 
of a recombinant human GH (rhGH or somatropin) in 1985, i.e. somatrem (Protropin, Genentech) 
containing the 191 amino acid sequence of hGH with an additional N-terminal methionine residue 
(meth-hGH). The production in Escherichia coli (E. coli, bacteria) was performed with vectors for 
cytosolic production. Later, Lilly filed for another rhGH (Humatrope), produced via vectors with a 
designed secretion signal sequence that led to the removal of the sequence upon secretion from E. 
coli and hence, the production of a rhGH without N-terminal methionine. In 1987, Lilly obtained the 
marketing approval for its somatropin as a new medicine, based on the sequence difference with 
somatrem [34]. 
Later in 2006, the first biosimilars of somatropin received marketing approval in the European Union. 
Omnitrope (Sandoz) and Valtropin (BioPartners GmbH) were produced in E. coli and Saccharomyces 
cerevisiae (yeast), respectively, and demonstrated similarity in terms of quality, safety and efficacy to 
the reference medicinal product [35-37]. 
 
2.2. The biology of the growth hormone system 
Growth hormone - GH is a member of a large class of evolutionary related proteins such as the 
prolactins (PRL) and placental lactogens. The GH protein is encoded by the hgh-n or gh1 gene located 
on the long arm of chromosome 17q24.2 and is expressed in the somatotroph cells of the anterior lobe 
of the pituitary gland [38]. The expression of hgh-n or gh1 results in two mRNA splice variants leading 
to a 22kDa-GH (191 amino acids and further referred to as GH) and a 20kDa-GH (missing residues 32-
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46), which accounts for approximately 7% of the growth hormone in circulation [39]. GH has a three-
dimensional structure containing a four-helical bundle [40]. 
There exists different molecular variants of GH within the systemic circulation with unknown 
physiological significance, either as a result from genetic/transcriptional level or by PTMs [41]. For 
example, isoforms of GH have been reported such as an amino-acetylated form, a glycosylated form 
and two deamidated forms (positions 137 and 152) [42, 43], as well as a dimeric complex (Zn2+:hGH2) 
after binding of Zn2+ [44]. Moreover, GH and its different forms are believed to also act as prohormone: 
GH fragments produced in vivo (with or without translational modification) or in vitro by proteolysis or 
prepared by chemical synthesis have shown multiple and diverse biological activities [45]. However, 
further evidence on this prohormone hypothesis and the existence of functional in vivo cryptic 
peptides is still lacking. 
GH is stored in secretory granules in the somatotrophs and its secretion occurs in a pulsatile manner 
[46], under both positive and negative control of hypothalamic hormones (GH-releasing hormone or 
GHRH (stimulation) and somatostatin or somatotropin release–inhibiting factor (SRIF) (inhibition)) 
(Figure 2) [47, 48]. Ghrelin, a peptide produced by peripheral tissues such as the stomach, stimulates 
GH secretion after interaction with the secretagogue receptor [49]. Also insulin-like growth factor-1 
(IGF-1), i.e. the mediator of GH signalling, possesses a negative feedback on the GH expression. In 
addition, also extrapituitary GH synthesis sites have been reported and this extrapituitary GH acts 
more locally rather than as an endocrine [50, 51]. Major GH peaks are detected at the onset of slow-
wave sleep and less pronounced secretion a few hours after meal, but also during conditions of fasting 
and physical stress [52-54]. While GH secretion is maximal during midpuberty, the secretion declines 
with age [55] and adiposity [56]. 
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Figure 2: Regulation of GH expression and secretion (adopted from reference [57]). Systemic GH is secreted 
from the pituitary, under the positive regulation of episodic hypothalamic GHRH (growth hormone releasing 
hormone) secretion and the gastric peptide ghrelin, and under the negative regulation of hypothalamic 
somatostatin, respectively. The expression of GHRH and somatostatin is also regulated by the mediator IGF-1 
(insulin-like growth factor-1). 
 
 
Growth hormone receptor - GH can perform its actions by binding with high affinity to the growth 
hormone receptor (GHR) at the extracellular surface. The GHR is encoded by a single gene on the short 
arm of chromosome 5 in region p13.1-15 [58-60]. The receptor is expressed in the liver, as well as in 
muscle, adipose tissue, mammary gland, pancreas, heart, bone, kidney, embryonic stem cells, brain 
(hypothalamus, hippocampus and choroid plexus) and immune cells such as B cells, T cells and 
monocytic cells [61, 62]. 
GHR is a three-domain transmembrane protein comprising an extracellular ligand binding domain, a 
single transmembrane segment and an intracellular domain, and contains in total 620 amino-acids 
[63]. The extracellular part is composed out of two fibronectin III domains, each containing seven 
β strands arranged to form a sandwich of two antiparallel β sheets [64], a similar topology as found in 
immunoglobulins. Intracellularly, the receptor contains two short proline-rich boxes: box 1 is largely 
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constitutively bound to Janus kinase 2 (JAK2), while box 2, 30 residues distal to box 1, is less defined. 
However, deletion/mutation to one of these boxes abrogates GHR signalling [65, 66]. 
Next to this membrane bound receptor, also a soluble growth hormone binding protein (GHBp) exists 
separately in the blood circulation [67, 68], generated by limited proteolysis of the membrane bound 
receptor [69, 70]. It binds to a substantial part of plasma GH (40-50%) [71] and is hypothesized to 
contribute to the prolongation of the GH half-life. 
Nonsense (i.e. single base changes resulting in premature stop codons), missense (i.e. altered amino 
acid) and splice-site mutations (i.e. inactivation or activation of splice sites), as well as deletions in the 
GHR gene are reported to result in GH insensitivity (GHI-spectrum) disorders [72, 73]. 
 
GH signalling and the signal transduction cascade - When GH interacts with its receptor, a 1:2 complex 
will form with two receptor molecules giving GH:(GHR)2. GH has thus two receptor-binding sites 
located on opposite sides of the molecule, with the four-helical bundle being asymmetrical. This 
further implies that the two binding sites are different. The first binding site (site I) has the highest 
affinity, is more concave and it is formed by exposed residues mainly on helix 4, but also on helix 1 and 
with residues from the connecting segment between helix 1 and 2. The second receptor-binding site 
(site II) has exposed residues from helix 1 and 3, and it has a flatter shape than site 1. A third region 
that contributes to the stability of the 1:2 complex - also known as the binding site III - is the contact 
surface between the two COOH-terminal domains of the receptor [40, 74].  
Originally, it was proposed that the receptor binding occurred in a sequential-binding model [75]; 
however, evidence indicates that some cytokine receptors such as the GHR, also already exist in 
preformed dimers in the absence of the ligand on the cell surface [76, 77]. More specific, this implies 
that the GH-binding on the preformed GHR dimer induces a rotation of one receptor compared to the 
other, thereby activating JAK2 (i.e. a cytosolic tyrosine kinase) whereby JAK2 autophosphorylates both 
some of its own tyrosine residues [78, 79] and tyrosine residues on the cytosolic domain of GHR 
(Figure 3) [80]. These phosphorylated tyrosines on JAK2 and the GHR receptor serve as docking sites 
for, amongst others, signal transducers and activators of transcription containing an SH2 domain 
(STAT1, -3, -5), which are phosphorylated followed by subsequent dimerization and translocation to 
the nucleus for regulation of gene transcription.  
Although the JAK2 pathway is the classical route of GHR signalling [81], also proto-oncogene tyrosine-
protein kinase Src (SRC) is directly (and independent of JAK2) activated by GHR [82, 83]. The relative 
strength of the JAK2 and SRC signals is postulated to be dependent on cell type [82]. Besides, the 
extracellular signal-regulated kinase (ERK) pathway can be activated by SRC, phospholipase Cγ (PLCγ), 
Ras-specific guanine nucleotide-releasing factor (RASGRF) and Ras, or by JAK2 via the adaptors SH2-
domain containing transforming protein (SHC), growth factor receptor-bound protein (GRB) and son 
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of sevenless (SOS) (Figure 3). C-Jun N-terminal kinase (JNK) is activated by SRC via Ras-related protein 
(RAP) and the phosphoinositide 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) 
pathway is activated by JAK2 via insulin receptor substrate (IRS) phosphorylation [81].  
The signalling is terminated by internalization of the receptor after signal transduction [84], combined 
with proteasomal degradation and interaction with proteins that inhibit signalling such as 
phosphatases, suppressors of cytokine signalling (SOCSs) and protein inhibitors of activated STATs 
(PIAS) [66]. Next to its GHR interaction, GH also interacts with, and can induce signalling, via the 
prolactin receptor (PRLR) [85]. 
Furthermore, the GHR antagonist, pegvisomant, is able to bind to GHR, but is unable to induce 
productive receptor realignment because of steric hindrance and hence, lack of activation of the 
intracellular signal transduction cascade [86].  
 
 
 
Figure 3: Signalling pathway of human growth hormone (adopted from reference [77]). After binding of GH to 
the two GHR, an intracellular conformational change results in the activation of the signal transduction 
cascade. 
 
 
The physiological effects of GH - GH is a key hormone in growth and metabolism. The elucidation of 
its physiological effects coincided with the somatomedin hypothesis in 1957: a serum factor 
‘somatomedin’ controlled by GH, later identified as IGF-1, is responsible for the stimulation of sulphate 
incorporation in cartilage [87, 88]. The main action site of GH is the liver, where it stimulates the 
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expression of its mediator protein hormone IGF-1 [89]. In addition to their function as systemic 
hormones, GH and IGF-1 fulfil an autocrine and paracrine role in their target tissues. However, it is still 
difficult to distinguish whether the effect on the target tissues are caused by mainly GH or IGF-1, 
because the effects of both hormones are intertwined in normal physiology, therefore referred to as 
the GH/IGF-1 axis in literature. 
As the name implies, growth hormone is mostly known for its effects on linear growth: GH deficiency 
leads to dwarfism, while excess of growth hormone results in gigantism or acromegaly, depending on 
the time of onset during life. GH acts directly, or via its mediator IGF-1, on skeletal cells and stimulates 
their proliferation and differentiation, thereby determining longitudinal bone growth, skeletal 
maturation, acquisition and maintenance of bone mass [90]. GH also has a role in muscle 
development [91]. 
The most pronounced actions of GH in carbohydrate, protein and lipid metabolism occurs during 
fasting. GH then switches the fuel source from glucose to fatty acids by increasing the lipolytic activity 
and thereby establishes a preservation of protein, glycogen stores and lean body mass as well as a 
conservation of glucose as a brain fuel source. During the postprandial period, GH secretion is 
suppressed and insulin secretion increases [62, 92]. Because of its metabolic and cell 
proliferating/differentiating effects, GH has effects on all its target sites (or tissues with GHR 
expression) influencing the body composition [93], as well as hepatic lipid metabolism [94], heart 
function (e.g. induction of contractile protein synthesis and myocyte hypertrophy) [95] and the 
vascular function (e.g. endothelial NO formation) [96]. In adipose tissue, preadipocytes are affected by 
GH on their proliferation, differentiation and senescence [97, 98]. Also the anti-insulin activities or 
‘diabetogenic’ activities of GH are well described [99-102]. 
Next to these pronounced effects on growth and metabolism, expression of the GHR has been 
demonstrated in the brain (choroid plexus, hypothalamus, pituitary, hippocampus and putamen [103-
105]) and administration of growth hormone has established positive effects on the central nervous 
system (CNS) (e.g. improvements in concentration) [106, 107]. GH also stimulates the development 
and function of the immune system [108] by e.g. increasing natural killer cell activity [109] and 
activation of lymphocytes [110]. Furthermore, GH is hypothesized to have a direct role in the 
modulation of reproduction [111]. 
 
2.3. Current clinical use of somatropin and pegvisomant 
Growth hormone deficiency (GHD) in children was the first approved indication for treatment with 
somatropin in 1985, where the main objective was to reach a normal height. However, GHD may 
continue through or onset during the adult stage and testing of the GH/IGF-1 axis can therefore help 
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to decide whether to start somatropin treatment [112]. A summary of the GH treatment benefits in 
adults with GHD is given in Figure 4. 
The most common clinical efficacy outcome of somatropin treatment is an increase in growth velocity 
and normalization of height in children and adolescents, as well as prevention of hypoglycaemia for 
patients with congenital hypopituitarism and an increase in the lean body/fat ratio in children with 
Prader-Willi syndrome. 
 
In the current treatment of acromegaly, a GHR antagonist is used: pegvisomant [113]. It is a 
competitive antagonist for the GH signalling pathway. It abolish the generation of IGF-1 by binding to 
the GHR, but without inducing the conformational change that leads to signalling by means of an amino 
acid substitution at position 120 on GH (G120K). To prolong the elimination half-life, 4-5 PEG moieties 
are substituted to the molecule, increasing the half-life to 70 hours. Furthermore, nine engineered 
amino acid substitutions were incorporated to maintain the binding affinity to site I: e.g. K168A and 
K172R for avoiding PEGylation on these amino acids that would otherwise interfere with GHR site I 
binding [86, 114]. 
 
 
Figure 4: Clinical effects of GH replacement therapy in adults with GHD (adopted from reference [57]). The 
blue insets summarise the effects on the different target tissues. BMD: bone mineral density, IMT: intima–
media thickness, LDL: Low-density lipoprotein. 
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2.4. Potential clinical use of somatropin 
A potential indication for somatropin treatment is cystic fibrosis (CF). Cystic fibrosis (CF) is a genetic 
disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. It is caused 
by mutations in both genes for the cystic fibrosis transmembrane conductance regulator (CFTR) 
protein, resulting in thick secretions. This leads to malnutrition, caused by plugged pancreatic ducts, a 
lack of digestive enzymes and difficulty in absorbing nutrients. However, also growth failure manifest 
in CF patients [115]. Somatropin treatment gave promising results for enhancing growth, weight, bone 
mineral content and lean tissue mass [116]; however, the full clinical benefit and safety profile should 
be further investigated [117]. Next to CF, also applications such as somatropin treatment after 
transplantation [118] need to be further explored, as well as potential indications such as burns [119, 
120] and fibromyalgia [121]. 
 
The role of GH, its receptor and GH/IGF-1 axis in tumour progression was raised some decades ago. 
Endogenous and exogenous hormones have a recognized role in the etiology of some cancers, driving 
cell proliferation, increasing the number of cell divisions and the risk for random genetic errors [122]. 
The potential involvement of GH and GHR in oncology is supported by available data on 
patient/human, animal and in vitro level, as summarized hereafter. 
On human/patient level, a systematic review investigated the relationship between final height 
(> 1.75 m), which is related to GH and IGF-1 actions, and the occurrence of malignancies, which 
demonstrated a 20-60% increased risk for some cancers [123]. Also Danish girls in the top quantile of 
height at the age of 14, had a higher relative risk for breast cancer [124]. Although patients with 
acromegaly are not considered as good models for GH hypersecretion, due to the long time frame 
between the disease onset and diagnosis and other present hormonal abnormalities [91], some studies 
suggest that acromegaly is associated with an approximately doubled risk for colorectal cancer [125]; 
however, these studies fail to associate the cancer incidence in acromegalic patients with increased 
GH/IGF-1 levels. On the other hand, in patients with GH/IGF-1/GHR deficiencies a decreased risk for 
cancer is expected. Indeed, Guevara-Aguirre demonstrated the association between a reduced cancer 
incidence and 90 Ecuadorian subjects with severe GHR and IGF-1 deficiencies [126]. This result was in 
agreement with a study where a total absence of cancer was observed in a group of 222 patients with 
congenital IGF-1 deficiencies (i.e. Laron syndrome, GH gene deletion, GHRH receptor defects and IGF-
I resistance) [127]. 
The Safety and Appropriateness of Growth Hormone in Europe (SAGhE) study assembled cohorts of 
>20 000 patients treated in childhood with somatropin in eight European countries since the first use 
of treatment in the 1980s, and followed them on average 17.1 years for cause-specific mortality and 
cancer incidence investigation [128]. The investigators found increased mortality rates in the French 
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patient group, particularly in those who had received the highest doses (> 50 μg/kg/day) with 
incidences of cardiovascular disease, bone tumours and cerebral haemorrhage [129]. In contrast, using 
the patient data from Belgium, The Netherlands and Sweden, none of the patients died from cancer 
or from a cardiovascular disease [130]. Although there was some criticism on patient number and 
statistics within these studies [131], concerns have been raised about the long-term safety in children 
who received high-dose GH treatments. 
Evidence for the involvement of the GH, GHR and/or IGF-1 was also made from transgenic animal 
models. Two typical animal models used for these studies are the lit/lit mice (with GHRH mutation) 
and dwarf dw/dw rats (GH deficiency). Xenografts in the condition of reduced GH and IGF-1 levels led 
to reduced tumour growth compared to wild-type controls [132, 133] and the animals were more 
resistant to carcinogenesis after chemical induction [134, 135]. Also GHR knock out mice led to reduced 
mammary carcinogenesis [136]. Moreover, breast cancer xenografts in nude mice treated with a GH 
antagonist (pegvisomant) induced shrinkage of the tumour by a reduction in proliferation and increase 
in apoptosis [137]. 
Finally, also at the in vitro tissue- and cellular level, investigations towards the oncologic potential have 
been undertaken, with prostate, breast, melanoma and neuroendocrine tumours exemplified 
hereafter. 
In prostate carcinoma tissue, there was a 80% more expression of GHR than in benign prostate 
hyperplasia [138]. The expression of GH, GHR and GHBp was demonstrated in several prostate cancer 
cell lines such as PC3 and LNCaP [139], making it good models for the study of GH/GHR/IGF-1 in tumour 
promotion and progression. For example, a higher GHR was demonstrated in prostate cancer cell lines 
compared to normal prostate derived cell lines [140]. Exogenous administration of GH and IGF-1 to 
prostate cancer cells led to cell proliferation [140, 141]. Exogenous and autocrine GH augmented the 
migration and invasion of LNCaP cells [142]. 
Furthermore, higher GHR and GH expression was demonstrated in breast cancer tissue [143, 144]. Also 
breast cancer cell lines with autocrine GH expression resulted in an oncogenic transformation, e.g. 
enhanced anchorage-independent growth, increased proliferation and decreased apoptosis [145]. 
Quantification of the expression of GHR mRNA with real-time qPCR in a panel of 60 cancer cell lines 
from nine types of human malignancies (i.e. breast, central nervous system, colon, leukaemia, 
melanoma, non-small cell lung, ovarian, prostate and renal) demonstrated GHR expression in most 
cancer types; however, in the three investigated melanoma cell lines, a nearly 50-fold higher 
expression was observed when compared to the panel as a whole [146]. The expression of GHR was 
also demonstrated in melanomic tumour samples, with intracellular GHR/GHBp localization in the 
nucleus and Golgi apparatus [146, 147]. The GHR nuclear translocalization has been reported to 
   CHAPTER I – INTRODUCTION 
  
 
33 
correlate with high proliferative status in vivo and in vitro, with a dysregulation of proliferative arrest 
and induction of cell cycle progression, resulting in oncogenesis [148]. 
The results by Jukic et al. [149], indicated overexpression of GH and GHR in large cell neuroendocrine 
carcinoma from colon and rectum. Also other cancers show expression of GHR such as in glioma [150, 
151], hepatocellular [152] and colorectal carcinoma [153]. 
 
 
3. LIGAND-TARGETED ANTITUMOR MEDICINES 
The overexpression of GHR on different tumour cells, as well as the GHR cellular internalization after 
signal transduction [84] and the nuclear GHR-localization, which is associated with different cancers 
[147, 148, 152], opens the road for the development of targeted theranostics toward the GHR.  
Ligand-targeted antitumor medicines couple the non-selective diagnostics/therapeutics (e.g. 
radiometals, cytotoxic drugs) to antibodies or other ligands that recognize tumour-associated antigens 
or receptors [154]. This increases the selective targeting of the malignant cells, and reduces the 
exposure of normal cells, to the ligand-targeted diagnostics/therapeutics. The typical target (tumour-
associated antigen/receptor) is overexpressed on the cancer cell versus normal cells and the absolute 
expression must be efficient for the desired theranostic outcome [155]. The structure of a ligand-
targeted antitumor medicine is given in Figure 5 and is composed out of a targeting ligand, a linker or 
spacer, sometimes a cleavable bridge and a therapeutic or diagnostic head. An ideal candidate ligand 
has derivatizable functional groups for conjugation of the spacer, as well as a high affinity and 
selectivity for the target antigen or receptor to reduce toxicity [155].  
 
 
Figure 5: Structure of a ligand-targeted antitumor medicine, which is composed out of a targeting ligand, a 
spacer, sometimes a cleavable bridge and a therapeutic or diagnostic head (adopted from reference [155]). 
Uncleavable bridges are often preferred for imaging purposes, while cleavable bridges can be preferred for 
the delivery of cytotoxic agents within the cells.  
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The successes of antibody-based ligands are illustrated by marketed examples such as 90yttrium-
ibritumomab tiuxetan (Zevalin), which targets the CD20 antigen in non-Hodgkin’s lymphoma [156], 
trastuzumab emtansin (Kadcyla) directed against HER2 in Her2+ metastatic breast cancer [157], and 
brentuximab vedotin (Adcetris) directed as anti-CD30 in Hodgkin’s lymphoma and systemic anaplastic 
large cell lymphoma [158], as well as by the numbers of antibody-based ligands in the clinical pipeline 
[159]. 
The non-antibody based ligands come in many sizes and structures. They can be based on endogenous 
proteins, e.g. the denileukin diftitox (Ontak), an interleukin-2/diphtheria toxin fragment fusion protein, 
used for the treatment of cutaneous T-cell lymphoma, which expresses the CD25 component of the IL-
2 receptor [160]. Also the folate receptor is overexpressed on different cancer cells [161] and linkage 
of drugs/radionuclides to the small molecule folic acid (or analogues) are constituting a large 
proportion of the ligand-targeted antitumor medicines in clinical development as reviewed by 
Srinivasarao et al. [155]. The success of peptide based ligands is exemplified by the somatostatin 
analogues such as 111In-DTPA-octreotide, used for the imaging of somatostatin receptors on 
neuroendocrine tumours [10, 162]. However also nanoparticles, e.g. prostate specific membrane 
antigen-targeted nanoparticles [163], and immunoliposomes [154] offer potential scaffolds within the 
ligand-targeted antitumor medicines. 
 
 
4. THE BLOOD-BRAIN BARRIER 
Biopharmaceuticals and peptides are in general characterized by a high specificity and potency, which 
implies that only a few molecules can lead to a biological effect. One of the tissue barriers of current 
interest, also driven by its role in dementia-related diseases, is the blood-brain barrier (BBB) which is 
located at the endothelial cells of the brain capillaries and separates the CNS from the periphery 
(Figure 6) [164]. The main goal of the BBB is to maintain a constant environment within the CNS and 
provision of nutrient supply. It is thus important to include quantitative studies toward the BBB 
transport and tissue distribution within the brain during the discovery and development stages of 
biopharmaceuticals and peptides. 
Molecules that can readily pass from blood to brain under normal conditions are general small and 
lipophilic and cross the BBB by passive diffusion [165, 166]. Other routes of transport across the BBB 
are solute carriers, efflux pumps, adsorptive-mediated and receptor-mediated transcytosis [167, 168]. 
For example, specific transport systems are identified for different proteins, e.g. interleukins [169-
172], tumour necrosis factor α [173] and interferons [174]. Recently, also ~150 kDa antibodies were 
engineered to cross the BBB, having a bispecific modality for transferrin receptor binding and binding 
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to their target [175]. Moreover, it is already described that lipid solubility enhancing modifications of 
proteins and peptides increase their BBB transport. For example, trimethylation of the phenylalanine 
in the pentapeptide DPDPE increases the brain uptake [176]. Because modifications, including the 
number and position of the modifications, can influence their pharmacokinetic behaviour, the 
importance of the investigation of their behaviour at physiological barriers is underlined. 
 
 
Figure 6: The Blood-Brain Barrier (adopted from reference [166]). The blood–brain barrier (BBB) is formed by 
the tight junctions between the endothelial cells of the brain vasculature. The functional BBB is formed by the 
interaction of the endothelial cells with perivascular elements such as basal lamina, astrocytic end-feet 
processes, perivascular neurons (represented by an interneuron here) and pericytes.  
 
 
 
5. TRADITIONAL AND EMERGING ANALYTICAL TECHNIQUES  
The technological advancement has led to a broad analytical toolbox with traditional and emerging 
techniques to understand and characterize the complexity of proteins and peptides. In the early 1980s, 
the physicochemical characterization techniques available were Edman degradation, UV and visible 
spectroscopic methods, protein content, chemical content (e.g. nitrogen) and electrophoretic analysis 
(e.g. SDS-PAGE). Soon after the marketing approval of recombinant insulin, the number of 
physicochemical tests increased and included more sophisticated techniques (Table 1) [177].  
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Table 1: Physicochemical characterization tests (adopted from reference [177]). 
Parameter Analytical test 
Primary structure 
Amino acid composition analysis, MS, N/C-terminal sequencing, TPM and 
sequencing/MS 
Higher order structure 
CD, NMR, immunoreactivity with conformational-dependent antibodies, 
TPM/MS, biological assays 
Size AUC, field flow fractionation, MALDI-TOF MS, LC-ESI MS, SDS-PAGE, SEC-HPLC 
Charge CE, IEC, IEF 
Hydrophobicity HIC-HPLC, RP-HPLC 
Immunoreactivity Immunoprecipitation, western blot analysis 
PTM, e.g. for glycosylated products   
Glycosylation pattern/sequence CE, HPAEC-PAD, LC- ESI MS, MALDI-TOF MS, RP-HPLC 
Identification of glycosylation sites TPM/MS 
AUC, analytical ultracentrifugation; CD, circular dichroism; CE, capillary electrophoresis; ESI, electrospray ionization mass spectrometry; 
HPAEC-PAD, high pH anion exchange chromatography with pulsed amperometric detection; HIC, hydrophobic interaction column; IEC, ion-
exchange chromatography; IEF, isoelectric focusing gel electrophoresis; LC, liquid chromatography; MS, mass spectrometry; MALDI-TOF MS, 
matrix-assisted laser desorption/ionization-time of flight; NMR, nuclear magnetic resonance; RP-HPLC, reversed phase high-performance 
liquid chromatography; SEC, size exclusion chromatography; TPM, trypsin peptide mapping. 
 
Although physicochemical techniques in the quality evaluation, such as peptide mapping, provide us 
with some basic information, yet the critical functionality question remains unanswered “Is the protein 
or peptide product, with its modifications, impurities, structural characteristics, …, functional for its 
destined application?”. The general consensus states that more functionality tests lead to reduced 
preclinical and clinical studies, hence less “surprises” during use after approval in the clinical setting. 
This vision has led to the exploration and further development of techniques from solely 
physicochemical to a combined functional characterization, aiming at characterizing also ligand-ligand 
binding. 
 
Size-exclusion chromatography (SEC) is an example of a traditional physicochemical technique which 
is evolved to applications in functional quality characterization. SEC is generally used to evaluate the 
size (distribution) of species within the product and has applications in stability studies and detection 
of variations in the oligomeric state [178]. By the inclusion of a receptor or target within the sample, 
the functional quality characterization of the product can be established [179]: complexation, 
indicative for a functional product, increases the SEC-elution volume. Also mass spectrometry (MS), 
and more specific native MS, can contribute to the functional quality characterization. The 
combination of mass selectivity and analysis under non-denaturing conditions, allows the detection of 
the species within the product as well as the detection of a functional complex between the 
protein/peptide under investigation and its functionally relevant target [180, 181]. Another example 
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of a combined technique is circular dichroism (CD), a technique to assess the secondary structures of 
proteins and peptides, while it is nowadays also used for interaction analysis to a target protein [182]. 
 
Traditional functional techniques such as enzyme-linked immunosorbent assay (ELISA) and cell-based 
in vitro techniques are nowadays complemented with emerging techniques such as isothermal 
titration calorimetry (ITC) and biosensors, e.g. surface plasmon resonance (SPR) and surface acoustic 
wave (SAW) biosensors. These techniques allow the quantification of the interaction affinity (KD), 
kinetics (kon and koff) and offer several advantages: (i) no changes in the analyte (e.g. no radioactivity), 
(ii) monitoring in real time and (iii) specifically for biosensors, use of low concentrations of products 
within a crude sample [183-185].  
 
Nowadays, these emerging techniques have shifted from research labware to applications within the 
whole drug life cycle, such as during ligand fishing, high throughput screening (HTS), hit confirmation 
and lead optimization (Figure 7) [186, 187]. During HTS and hit confirmation, it is important that the 
binding constant is within a desired concentration range, typically within micromolar to nanomolar 
range [188]. Hits with slow off-rates are often preferred for further lead optimization [189]. Also the 
combination of MS and biosensor experiments is useful during the identification of the ligands and hits 
in target-driven drug discovery [190]. 
Also during pharmacodynamic and pharmacokinetic studies, biosensors can be applied. For example, 
interaction studies between a lead and biological membranes allows the investigation of the drug 
partition coefficient. Permeation of the biologically active compounds result in changes of the 
viscoelastic properties of the lipid bilayers in the immobilized model membranes, which can be 
detected [191]. Furthermore, the affinity of new leads for serum proteins, such as immobilized 
albumin, have shown to be suitable to perform early ADME studies [192]. Biosensors have also been 
successfully applied in the quantification of the drug serum levels [193]. In addition, these devices have 
the potential to be used in toxicity studies. Cell toxicity can easily be analysed with whole cell systems: 
cytoskeletal changes resulting in cellular volume retribution are detected with mass biosensors in a 
reproducible manner [194]. 
With the development of process analytical monitoring (PAT) within the biopharmaceutical industry, 
bioprocess monitoring using biosensors may permit the development of new methods for the 
automated, real time monitoring of critical quality attributes of a biotherapeutic throughout a 
bioreactor. An automated at-line SPR detection system has been described to monitor secreted 
protein in a bioreactor culture of transiently infected embryonic kidney cells [195]. 
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Until today, no guidelines on biosensor instrument qualification or in-use requirements are available 
or implemented within the Pharmacopoeia. 
 
 
Figure 7: Application areas for biosensors in the drug life cycle (adopted from reference [186]). Abbreviations: 
ID: identification, GLP: Good Laboratory Practice, GMP: Good Manufacturing Practice, MS: mass spectrometry, 
QC: quality control.  
 
 
 
6. OBJECTIVES 
With the growing evidence that GH is involved in tumour progression and that GHR is overexpressed 
on some tumours and/or cell lines, this research topic will explore the development of selected 
somatropin derivatives for theranostic applications. In this doctoral research, two groups of 
compounds are envisaged:  
(i) modifications of proteins with the chelating agent 1,4,7-triazacyclononane-1,4,7-triacetic 
acid (NOTA) to allow the incorporation of radiometals for SPECT/PET-diagnostic (67Ga, 
68Ga, 111In) or therapeutic (90Y) purposes; 
(ii) peptides originating from proteins owing to their low costs/chemical control. 
 
The main goal of this doctoral thesis is therefore to investigate the functional quality of NOTA-
modified somatropins and somatropin-derived peptides (SDPs). The functional quality is defined as 
the evaluation of a compound at the functional level (i.e. pharmacodynamics and pharmacokinetics) 
in relation to the quality (i.e. chemical characterization) and with emphasis on patient safety in the 
longer run. In order to investigate this main goal, the following specific research questions were 
formulated: 
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1. What is the chemical composition of the synthesised NOTA-modified somatropins? 
Chemical modification of biomolecules, such as the introduction of metal-chelators into 
proteins, can lead to heterogeneous product formation. The analytical characterization of 
somatropin modified on its lysine’s ε-amino groups with the acylating chelator S-2-(4-
isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) is 
described. 
2. Are NOTA-modified somatropins functional in in vitro settings? 
Inherent to the non-specific NOTA-modification, product mixtures with multiple substitution 
degree and positional isomer species require further investigation of the functional quality 
(i.e. target binding). In vitro techniques at molecular and cellular level are explored to assess the 
functional quality of these mixture products. 
3. Do NOTA modalities on proteins influence the blood-brain barrier behaviour? 
Numerous studies have already described the ability of proteins to cross the BBB. Currently, 
there is a lack of knowledge about the influence of bifunctional chelators when conjugated onto 
proteins and their BBB transport behaviour. Therefore, in order to verify whether NOTAs can 
positively or negatively influence the ability to cross the BBB, the BBB transport of somatropin, 
NOTA-somatropin and gallium-NOTA-somatropin is quantitatively evaluated. 
4. Can somatropin-derived peptides be theranostic alternatives for their protein counterpart? 
Compared to biologics, peptides are cheaper to produce by means of chemical synthesis and 
they are chemically more controlled. Therefore, SDPs are evaluated for their applicability using 
a chemically and stability characterization, as well as a pharmacodynamic (hGHBp/GHR binding 
potential) and pharmacokinetic (BBB kinetics and tissue distribution) evaluation. 
5. Are SAW biosensors new applicable tools in the functional quality control? 
Surface acoustic wave biosensors are emerging techniques used in the functional quality 
characterization of biologics and small molecules; however, they are not yet included in any 
pharmacopoeia. An analytical quality by design (aQbD) based approach is applied using 
somatropin, derivatives and an antibody interaction partner to evaluate the applicability of this 
technique within pharmaceutical functional quality research. 
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7. THESIS OUTLINE 
The structural outline of this thesis is presented in Figure 8, which provides a schematic presentation 
of the coherence between the different chapters. The chapters of this thesis are presented as stand-
alone texts, with the introduction specified for each individual topic.  
 
Figure 8: Thesis outline. 
 
In chapter II, the NOTA-modified somatropins are prepared and chemically characterized. The 
substitution degree (i.e. amount of NOTA groups on somatropin) and position isomers (i.e. which lysine 
residue is modified) are characterized by using analytical techniques such as direct separation and 
identification techniques (LC–MS and CE–MS), as well as peptide mapping after trypsin and 
chymotrypsin digestion. The modification hotspot is confirmed by in silico pKa-analyses. Finally, the 
chelation efficiency of gallium for the NOTA-modified somatropins is evaluated. 
Chapter III assesses the functionality of the NOTA-modified somatropins and gallium-chelated NOTA-
modified somatropins using in vitro techniques: (i) SEC to demonstrate the functional interaction with 
hGHBp, (ii) native MS to identify the interaction of hGHBp with a specific substitution degree species, 
and (iii) a hGHR bioassay to demonstrate the initiation of the signal transduction cascade. Emphasis is 
made on techniques such as SEC and MS, classically used in the physicochemical characterization of 
proteins, to be included in the functionality evaluation during drug discovery, development and quality 
control settings. 
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In chapter IV, the influence of NOTA- and gallium-chelated NOTA-modified somatropin on the BBB 
transport characteristics is investigated and compared to unmodified somatropin. The BBB influx 
kinetics are determined using an in vivo mice model, applying multiple time regression for studying the 
blood-to-brain influx and capillary depletion for determination of the distribution in the brain 
(capillaries versus parenchyma). Also the tissue distribution and the in vivo metabolic stability are 
investigated. 
Starting from chapter V, the somatropin-derived peptides are the focus. The peptides are rationally 
selected based on the interacting residues of somatropin to the GHR. The SDPs are chemically 
characterized and the metabolic stability of the SDP is determined in different tissues. The metabolites 
are identified in serum and brain homogenates. In parallel, the pharmacodynamics (hGHBp/GHR 
binding capacity) and pharmacokinetics (BBB transport characteristics) are characterized. 
According to the DruQuaR tradition, a regulatory quality aspect of this research is included. In chapter 
VI, we present the utility of a surface acoustic wave (SAW) biosensor within the functional quality 
evaluation, via an analytical quality by design (aQbD) based approach. Using techniques described in 
ICH Q2, Q5 and Q8-11, we evaluate the performance of this SAW biosensor technique from a 
pharmaceutical quality point of view.  
Chapter VII highlights the broader international context, relevance and future perspectives of this 
research. It shows the potential of the project to benefit society and to contribute to the achievement 
of specific, desired societal and scientific outcomes. 
Finally, the concluding chapter gives a short overview of the main findings of this work. 
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“An experiment is a question which science poses to Nature, and a 
measurement is the recording of Nature’s answer.”  
 
Max Planck  
(°1858 - †1947, Theoretical Physicist) 
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ABSTRACT 
Chemical modification of biomolecules like the introduction of metal-chelators into proteins can 
lead to heterogeneous product formation. The nature and extend of the modification is important 
in interpreting the biological properties of the bioconjugate, given their possible influence on the 
pharmacokinetics as well as on the binding affinity to the target. The present study describes the 
synthesis and analytical characterization of somatropin modified on its lysine’s ε-amino groups 
with the acylating chelator S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic 
acid (p-SCN-Bn-NOTA). Direct separation and identification techniques (i.e. RP-MS and CE-MS) and 
peptide mapping after trypsin and chymotrypsin digestion demonstrated that the use of higher 
amounts of p-SCN-Bn-NOTA during synthesis leads to a complex product composition with higher 
order substitution degrees (i.e. multiple NOTA-moieties per somatropin molecule), as well as the 
presence of different position isomers. From the nine lysine (Lys) residues in somatropin, Lys-70 
was experimentally found to be the modification hotspot under our synthesis conditions (pH = 9.0). 
This was supported by the in silico calculated lowest pKa value of 8.3 for Lys-70. Based on the crystal 
structure of somatropin in complex with the extracellular parts of the growth hormone receptor, 
the Lys-70 residue is positioned outside the binding pockets and will therefore not directly interfere 
with receptor binding. Gallium chelation by NOTA-somatropin resulted in a 100% complexation. 
The synthesis of NOTA-somatropin using p-SCN-Bn-NOTA and somatropin under our operational 
conditions is therefore a suitable synthesis procedure for the production of a target-specific 
radiopharmaceutical for further investigation toward treatment and visualization of growth 
hormone-specific cancers. 
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CHAPTER II 
ANALYTICAL CHARACTERIZATION OF 
NOTA-MODIFIED SOMATROPINS 
Main focus in this chapter: 
? Preparation of S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid  
(p-SCN-Bn-NOTA)-modified somatropins using different molar NOTA:protein ratios. 
? Perform a chemical characterization of the products. 
? Identification of the NOTA-modification hotspots on somatropin. 
 
1. INTRODUCTION 
The recent successes of biopharmaceuticals are changing the focus of the pharmaceutical industry. 
The US Food and Drug Administration (FDA) approved 41 and 45 new drugs in 2014 and 2015, 
respectively, whereof 27% represented biologics license applications (BLAs) [1]. As the patents of the 
high-profile and blockbuster biologics expire, the development of biosimilars come into play, which 
require advanced (bio)analytical tools for their characterization toward registration [2, 3].  
Cancer is still the largest therapeutic area nowadays [4, 5]. Tumour targeting in nuclear medicine is 
based on a target-specific radiopharmaceutical ligand for selective receptor binding in the disease 
tissue [6-8]. The targeting biomolecules can be used as therapeutics to deliver a toxic radioactive 
payload selectively to a tumour site (e.g. I-131 tositumomab or Y-90 ibritumomab), as well as 
diagnostic agents for non-invasive single photon emission computed tomography (SPECT) or positron 
emission tomography (PET) imaging (e.g. In-111 Capromab pendetide or In-111 pentetreotide) [9, 10] 
and playing an important role in cancer management as a form of personalized medicine [9, 11].  
One of the biomolecules of current interest is human growth hormone (hGH). In the late 1950s, severe 
growth hormone deficiencies (GHD) in children were treated by cadaveric pituitary hGH or 
somatotropin extracts. However, several cases were reported which correlated the use of cadaveric 
somatotropin with Creutzfeldt-Jakob disease, leading to an abrupt stop of hGH extract treatment [12]. 
This led to the worldwide regulatory approval of recombinant hGH. Recombinant hGH or somatropin 
is nowadays used for the treatment of GHD, as well as the treatment of Turner Syndrome and AIDS 
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associated catabolism [13]. Recently, biosimilar somatropin formulations were also globally approved 
[14-16]. Moreover, somatropin and analogues are often encountered as spurious/falsely-
labelled/falsified/counterfeit (SFFC) medicines [17-19] and drug abuses in sports [20, 21], agriculture 
[22] and anti-aging [23] have been reported. 
Somatropin can perform its actions by binding with high affinity to the extracellular domains of two 
identical molecules of human growth hormone receptors (hGHR) [24-27], which are widely expressed 
in liver tissue, but are also aberrantly overexpressed in numerous cancers such as prostate [28, 29], 
breast [30] and colon cancer [31]. The potential involvement of the GH system in tumour promotion 
and progression, which has been critically reviewed in references [32] and [33], as well as the 
internalization of the receptor-ligand complex [34], makes hGHR a potential tumour target for the 
development of somatropin-based radiopharmaceuticals.  
Modifications with bifunctional chelating agents (BFCA) like S-2-(4-isothiocyanatobenzyl)-1,4,7-
triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) allow the incorporation of radiometals for 
SPECT/PET-diagnostic (67Ga, 68Ga, 111In) or therapeutic (90Y) purposes [9, 35, 36]. However, because 
somatropin has nine potential lysine-amino binding sites for p-SCN-Bn-NOTA, it is important to 
characterize the obtained product under different synthesis procedures. We present the analytical 
characterization of NOTA-modified somatropins with special attention to the operational strategy and 
procedure which are widely applicable to other protein systems containing multiple modification sites 
toward other bifunctional chelators (e.g. DOTA, DTPA, MAMA) or fluorescent labels (e.g. 
fluorescein) [9]. 
 
2. MATERIALS AND METHODS 
2.1. Materials and equipment 
The p-SCN-Bn-NOTA was purchased from Macrocyclics Inc. (Dallas, TX, USA). Zomacton® 4 mg, (Ferring, 
somatropin Ph. Eur.) was purchased at the Ghent University Hospital (Ghent, Belgium). The enzymes 
for peptide mapping, L-1-tosylamide-2-phenylethyl chloromethyl ketone (TPCK)-treated trypsin 
solution and S. aureus V-8 protease solution were purchased at Pierce (Erembodegem, Belgium); 
immobilized chymotrypsin solution was from Sigma Aldrich (Diegem, Belgium). PD-10 sephadex G-25M 
columns were obtained from GE healthcare (Diegem, Belgium). Water was purified in-house using an 
Arium 611 purification system (Sartorius, Göttingen, Germany), yielding ≥ 18.2 MΩ × cm quality water. 
Other chemicals and solvents were purchased from Merck (Overijse, Belgium), Sigma Aldrich (Diegem, 
Belgium) or Fischer Scientific (Erembodegem, Belgium), all high quality (>98% purity) and/or HPLC/MS 
grade. Freeze-drying was done using a Christ gamma 1-16 LSC freeze dryer (Qlab, Vilvoorde, Belgium). 
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The HPLC-UV-MS apparatus consisted of a SpectraSystem separations module, a Finnigan LCQ Classic 
ion trap mass spectrometer in positive ion mode (all Thermo, San José, CA, USA) equipped with a 
Waters 2487 dual wavelength absorbance UV detector (Waters, Milford, MA, USA) and Xcalibur 2.0 
software (Thermo, San José, CA, USA) for data acquisition. For CE-MS, a P/ACE MDQ capillary 
electrophoresis instrument (Beckman Coulter Inc., Brea, CA, USA) was used for separations, whereas 
a micrOTOFQ orthogonal accelerated time-of-flight (ToF) mass spectrometer (Bruker Daltonics, 
Bremen, Germany) was used for detection and identification.  
2.2. Synthesis 
1 mg of somatropin (eq. to 45 nmol) was dissolved in 200 μL carbonate buffer (pH 9.0; 0.1 M), added 
to different volumes of 20 mM p-SCN-Bn-NOTA and diluted to 350 μL with carbonate buffer to obtain 
molar equivalents of 1:1 NOTA:somatropin, 3:1 NOTA:somatropin and 10:1 NOTA:somatropin. The 
mixtures were incubated for 20 h at 20°C in the dark, while shaking at 300 rpm. The sample was loaded 
onto a PD-10 sephadex G-25M column (equilibrated with digestion buffer consisting of 10 mM ACES, 
20 mM CaCl2, pH 7.0). After collection of the protein fraction, the samples were freeze dried awaiting 
analytical characterization.  
2.3. Direct analysis of NOTA-somatropins 
NOTA-labelling of the 3:1 sample was monitored during the 20 h incubation period, by taking 30 μL of 
sample after 1, 3, 5, 8, 10, 12.5, 17, 20 and 22 h. The samples were diluted to 100 μL using carbonate 
buffer (pH 9.0; 0.1 M) and characterized using LC-MS. For the analysis of the different NOTA-
somatropins, 0.1 mg of lyophilized 1:1 NOTA:somatropin, 3:1 NOTA:somatropin and 10:1 
NOTA:somatropin (4.5 nmol protein) was dissolved in 100 μl water. Samples were analysed via LC-MS. 
A Vydac Everest MS RP-C4 (250 mm × 4.6 mm I.D., 5 μm particle size, 300 Å) column (Grace Vydac, 
Hesperia, CA, USA) was used and temperature controlled during analysis (35°C). The injection volume 
was 20 μL. The flow rate was set to 0.5 mL/min and the following gradient was used for the separation 
of the different somatropin derivatives (A: 50 mM ammonium bicarbonate pH 7.5 and B: 1-propanol): 
for 60 min, a linear gradient was applied from 70% A (v/v) + 30% B (v/v) to 50% A (v/v) + 50% B (v/v), 
followed by a 10 min isocratic section (50:50 A:B (v/v)). The method also included a rinsing step out of 
60% 1-propanol, followed by returning to the initial conditions and re-equilibration. ESI was conducted 
with a capillary voltage of 4.5 kV. Nitrogen was used as the sheath and auxiliary gas; the temperature 
of the heated capillary was set to 280°C. MS and MS/MS spectra were used for identification and 
obtained by collision induced dissociation (CID) of the parent m/z, with the relative collision energy set 
to 35%. UV detection and quantification were performed at 220 nm. 
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The CE-MS analysis was performed using fused-silica capillaries (800 mm × 50 μm I.D., Polymicro 
Technologies, Phoenix, AZ, USA) coated with a bilayer of polybrene and poly(vinyl sulfonic acid) as 
previously described [37]. Sample injections were performed at 1 psi for 12 s. The separation voltage 
was set at 30 kV and the capillary temperature was set at 20°C. The background electrolyte (BGE) was 
75 mM ammonium hydroxide adjusted to pH 8.5 using 1% (v/v) formic acid in deionized water. As 
sheath liquid, a mixture of isopropanol-water-acetic acid (75/22/3 v/v/v) was used at 4 μL/min. ESI was 
conducted in positive ionization mode with a capillary voltage of 4.5 kV. To assure proper ion transfer, 
the analysis of somatropin was performed with a capillary exit and skimmer voltage of 250 and 83 V, 
respectively. CE-MS data were analysed using Bruker Daltonics data analysis software. Molecular 
weight determinations of the proteins were performed using the “charge deconvolution” utility of the 
data analysis software. Quantification of the conjugates was performed using the construction of an 
extracted-ion electropherogram. Each detected conjugate showed the same charge state distribution 
profile, with (M+9H)9+ and (M+10H)10+ as most abundant ions. The relative abundance of each 
conjugate in the analysed preparation was established by calculating the ratio of the conjugate peak 
area to the total peak area. 
2.4. Peptide mapping 
The unmodified somatropin (i.e. control) and NOTA-modified somatropins (45 nmol protein) were 
dissolved in 1000 μL 6 M guanidine HCl, 35 mM Tris, 20 mM dl-dithiothreitol at pH 7.5 and incubated 
for 30 min at 37°C, while shaking at 300 rpm. S-carboxymethylation of cysteine residues was performed 
by addition of 20 μL of iodoacetate (pH 7.2; 58 mM) and subsequent incubation for 30 min at 37°C (at 
300 rpm). One hundred microliters of dl-dithiothreitol (1 M) was added and mixed. The sample was 
loaded onto a PD-10 column sephadex G-25M (equilibrated with digestion buffer consisting of 10 mM 
ACES, 20 mM CaCl2, pH 7.0). After collection of the protein fraction in 2.0 mL, 1.0 mL was transferred 
into 100 μL of immobilized TPCK-treated trypsin solution (20 TAME units), mixed and incubated for 4 h 
at 37°C (300 rpm). The other 1 mL of the protein fraction was transferred to 200 μL of immobilized 
chymotrypsin solution (8.3 ATEE units) as well, mixed, and incubated for 24 h at 37°C (300 rpm).  
For the peptide mapping using a combination of trypsin and chymotrypsin and the peptide mapping 
with S. aureus V8 protease, the same procedure for the S-carboxymethylation and subsequent PD-10 
purification was performed as described above on somatropin and 3:1 NOTA:somatropin. 
Approximately 22.5 nmol of the protein fraction was transferred to 300 μL of immobilized trypsin and 
chymotrypsin solution (20 TAME and 8.3 ATEE units resp.), mixed and incubated for 24 h at 37°C 
(300 rpm). For S. aureus V8 protease, 22.5 nmol protein was transferred to 125 μL V8 protease solution 
(6 ± 1.6 units, Pierce, Erembodegem, Belgium), mixed and incubated for 18 h at 37°C (300 rpm).  
  CHAPTER II – ANALYTICAL CHARACTERIZATION OF NOTA-MODIFIED SOMATROPINS 
 
 
63 
After incubation with the enzymes, the solutions were centrifuged at 100 g for 10 s. One milliliter of 
the supernatant was transferred to 10 μL of formic acid (10% v/v), mixed and centrifuged at 20 000 g 
for 10 min. The supernatant was analysed by LC-MS. 
ESI was conducted using a needle voltage of 3 kV. Nitrogen was used as the sheath and auxiliary gas 
with the heated capillary set at 250°C. Positive mode mass spectra were obtained in the range of m/z 
from 100 to 2000. MS/MS spectra were obtained by collision induced dissociation (CID) of the parent 
m/z, with the relative collision energy set to 35%. UV detection was performed at 195 nm. A Vydac 
Everest RP-C18 (250 mm × 2.1 mm I.D., 5 μm particle size, 300 Å) column (Grace Vydac, Hesperia, CA, 
USA) in an oven set at 45 °C, with a mobile phase consisting of (A) 0.1% (w/v) formic acid in water and 
(B) 0.1% (w/v) formic acid in acetonitrile was used in this experiment. The linear gradient program 
started with a 5 min isocratic hold at 96% (v/v) A and 4% (v/v) B, followed by a linear gradient to 
60% (v/v) A + 40% (v/v) B at 113 min. The method also included a rinsing step at 60% B, followed by 
returning to the initial conditions and re-equilibration. The flow rate was set at 0.2 mL/min and a fixed 
injection volume of 20 μL was applied. Prediction of peak identity was performed upon comparison of 
m/z values with the SEQUEST algorithm of the Thermo BioWorks software (San José, CA, USA). 
Peptides with a probability of more than 95% were reported and individually verified. Quantification 
occurred via ion-extracted chromatography (IEC) of the most abundant peptide charge responses. 
Peptide responses were normalized to the sum of all responses. The following calculations were made: 
 
ܵ݁ݍݑ݁݊ܿ݁ ܿ݋ݒ݁ݎܽ݃݁ ሺ%ሻ ൌ  ே௨௠௕௘௥ ௢௙ ௔௠௜௡௢ ௔௖௜ௗ ௥௘௦௜ௗ௨௘௦ ௙௢௨௡ௗ்௢௧௔௟ ௡௨௠௕௘௥ ௢௙ ௔௠௜௡௢ ௔௖௜ௗ ௥௘௦௜ௗ௨௘௦ ௜௡ ௦௢௠௔௧௥௢௣௜௡ ሺୀଵଽଵሻ  ൈ100    (1) 
 
ܮݕݏ݅݊݁ ܿ݋ݒ݁ݎܽ݃݁ ሺ%ሻ ൌ  ே௨௠௕௘௥ ௢௙ ௟௬௦௜௡௘ ௥௘௦௜ௗ௨௘௦ ௙௢௨௡ௗ்௢௧௔௟ ௡௨௠௕௘௥ ௢௙ ௟௬௦௜௡௘ ௥௘௦௜ௗ௨௘௦ ௜௡ ௦௢௠௔௧௥௢௣௜௡ ሺୀଽሻ  ൈ100    (2) 
 
ܮݕݏܺ ܿ݋ݒ݁ݎܽ݃݁ ሺ%ሻ ൌ  ே௨௠௕௘௥ ௢௙ ௣௘௣௧௜ௗ௘௦ ௖௢௡௧௔௜௡௜௡௚ ௅௬௦௑ே௨௠௕௘  ௢௙ ௣௘௣௧௜ௗ௘௦ ௖௢௡௧௔௜௡௜௡௚ ௟௬௦௜௡௘ ௥௘௦௜ௗ௨௘  ൈ100    (3) 
 
ܱܰܶܣ െ ܮݕݏܺ ݉݋݂݀݅݅ܿܽݐ݅݋݊ ݕ݈݅݁݀ ሺ%ሻ ൌ   ஺௥௘௔ ௢௙ ேை்஺ି௅௬௦௑ௌ௨௠ ௔௥௘௔ ௢௙ ௔௟௟ ௅௬௦௑  ൈ100     (4) 
 
ܱܰܶܣ െ ܮݕݏܺ ݀݅ݏݐݎܾ݅ݑݐ݅݋݊ ݕ݈݅݁݀ ሺ%ሻ ൌ  ஺௥௘௔ ௢௙ ேை்஺ି௅௬௦௑ௌ௨௠ ௔௥௘௔ ௢௙ ௔௟௟ ேை்஺ ௠௢ௗ௜௙௜௘ௗ ௟௬௦௜௡௘௦  ൈ100   (5) 
 
2.5. In silico pKa calculations 
Structure-based pKa calculations were performed using the Adaptive Poisson−Boltzmann Solver (APBS 
version 1.1.0) [38], in which the pKa per titratable residue is determined as the sum of an unperturbed 
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model value [39] and a perturbational shift reflecting the transfer of the amino acid from solution to 
the protein environment. The latter is calculated through a rigorous free energy cycle and numerical 
solution of the linearized Poisson−Boltzmann equaƟon [40]. All calculations were carried out at  
298.15 K with a solvent dielectric constant of 78.54 and a protein dielectric constant of 20. pKa 
calculations were performed on the protein structure only, taken from the last frame of a molecular 
dynamics (MD) simulation. Appropriate PQR files were generated with the aid of PDB2PQR version 
1.4.0 [41, 42], employing the CHARMM [43, 44] parameterization. 
Prior to the pKa calculations, structural calculations were performed using NAMD version 2.6 [45] and 
the CHARMM forcefield [43, 44], starting from the 1HGU crystal structure of the human somatotropin 
[46]. Optimal protonation states were assigned and missing atoms were added. In an ensuing 5000-
step conjugate-gradient energy minimization only these atoms were allowed to move, while 
constraining all other atoms. Twelve amino acids were then mutated in accordance with the 
somatropin sequence (Q11D, E29Q, A47N, A50T, Q66E, A67T, Q75E, G91Q, D109N, A138I, A144S, 
A148T) followed by 5000 steps of conjugate-gradient minimization of the atoms of the mutated 
residues only. The resulting structure was solvated with 20.442 water molecules in an orthogonal box 
of size 83.1 x 86.5 x 95.1 Å3 and made charge neutral by adding six sodium ions. The entire structure 
was subject to energy minimization (5000 conjugate gradient steps) with constraints on all protein 
atoms. This was followed by an unconstrained MD equilibration run of 50 ps (1 fs time step) in the NVT 
ensemble at 300 K, employing Langevin dynamics with a damping coefficient of 1 ps-1 to control 
temperature. Electrostatics were treated with particle-mesh Ewald (PME) [47]. A short-range cutoff of 
14 Å was maintained, and electrostatic and van der Waals interactions were gradually switched off 
starting from 10 Å. Neighbor lists were updated every 2 fs using a cutoff of 16.5 Å. The final production 
MD simulation totalled 1 ns with identical parameters. 
2.6. Gallium labelling and quality control 
For the labelling of 3:1 NOTA-somatropin with gallium, 45 nmol lyophilized protein sample was 
dissolved in 450 μL of 0.6 mM GaCl3, 0.1 M HCl to obtain a 2:1 molar excess compared to the initial p-
SCN-Bn-NOTA concentration. Then, 20 μL of 2 M NaOH and 40 μL of 0.1 M ammonium acetate, 0.2 mM 
acetylacetone solution (pH 5.5) were added and the solution was mixed and incubated for 1 h at 20°C 
protected from light, while shaking at 300 rpm. The chelation efficiency with gallium was analysed via 
peptide mapping as discussed in Section 2.4. 
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3. RESULTS AND DISCUSSION 
3.1. Production of NOTA-somatropin 
Successful clinical use demands that a bifunctional chelating agent (BFCA) is both capable of 
maintaining a stable complex with a radionuclidic metal in vivo, e.g. Ga(III), while possessing a 
functional group which can be used for protein attachment. p-SCN-Bn-NOTA is a well-established 
hexadentate BFCA, forming an exceedingly stable complex with Ga(III) (log K = 30.98) [48]. The 
isothiocyanate function (R-NCS) allows formation of stable thiourea bonds at alkaline pH with free 
amines (Figure 1). Somatropin has nine potential reaction sites (lysine’s ε-amino residues) for the 
addition of p-SCN-Bn-NOTA. We have used a pH of 9.0 during synthesis: higher pH values will tend to 
accelerate the degradation of somatropin [49] and the R-NCS reagent, while lower pH values will lower 
the concentration of the free base form of the amines. These nine sites can lead to heterogeneous 
product formation consisting of different substitution degrees (i.e. the amount of bound NOTA-
molecules per somatropin protein). Moreover, for a somatropin entity that has a single NOTA-
molecule attached, the NOTA-moiety may be attached at different amine sites. This creates the 
potential for a large number of position isomers as the degree of substitution increases (Figure 2A) 
[50]. Analytical characterization of the heterogeneous production is very important as special attention 
must be paid to the lysine residues that are modified, since chemical modification can influence 
receptor binding and hence, the outcome of biological assays [51]. We applied three different synthesis 
ratios of p-SCN-Bn-NOTA based on references [52, 53]: equimolar amounts of p-SCN-Bn-NOTA and 
somatropin (1:1 NOTA:somatropin), three times molar excess of p-SCN-Bn-NOTA (3:1 
NOTA:somatropin) and 10 times molar excess of p-SCN-Bn-NOTA (10:1 NOTA:somatropin) were 
applied. 
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Figure 1: Synthesis of gallium labelled NOTA-modified somatropin. 
 
 
 
 
Figure 2: NOTA-modified somatropins product composition. (A) Scheme of the possible products with different 
substitution degrees and position isomers. (B) Substitution degree of the 3:1 NOTA:somatropin preparation 
during 22 h of incubation, product composition after 20 h of incubation indicated in gray. 
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3.2. Direct analytical characterization of the products 
A single analytical technique for the characterization of biologicals is generally not sufficient [54, 55]. 
Therefore, a combination of LC-MS and CE-MS was applied to investigate the NOTA-somatropin 
products. In the biopharmaceutical field, LC is used for both the assessment of protein batch purity, 
protein modification (e.g. glycosylation) and aggregation [3, 56]. In combination with MS, precise and 
complementary information is generated. In this direct analytical approach, intact protein molecular 
ions generated by electrospray (ESI) or matrix-assisted laser desorption (MALDI) are introduced into 
the mass analyser [57]. 
We have initially based our method on the related protein test described in the European 
Pharmacopoeia for somatropin (Ph. Eur. 8.0: 01/2008:0951) [58]: an isocratic LC-method using a 
mixture of 1-propanol and 0.05 M Tris-hydrochloride buffer solution pH 7.5 (29:71 v/v) as the mobile 
phase. As the tris-hydrochloride buffer is not MS compatible, an ammonium bicarbonate buffer pH 7.5 
was used. During pilot development, we have used isocratic methods with different mobile phase 
compositions (i.e. 20%, 30% and 35% organic mobile phase) and studied the somatropin retention time 
(RT: 49, 11 and 7.5 min, respectively). Based on the retention time of somatropin in the isocratic 
methods and the fact that the hydrophobicity of somatropin decreases upon NOTA labelling, we have 
used a 60 min linear gradient going from 30% to 50% 1-propanol. This method enabled us to 
characterize the NOTA:somatropin substitution degrees.  
The NOTA-labelling was quantitatively monitored over time for 22 h for the 3:1 NOTA:somatropin 
sample using our RP-C4 method (Figure 2B). The complexity of the product composition was confirmed 
by a decrease of unmodified somatropin and an increase of higher order substitution degrees over 
time. Steady state was reached after 20 h of incubation. Using this incubation period during synthesis, 
the unmodified somatropin was completely absent in the 10:1 NOTA:somatropin sample (Figure 3A). 
The highest yield of the mono- and di-NOTA-somatropin (substitution degree +1 and +2) were obtained 
in the 3:1 sample (58%). Higher order modifications (substitution degree of more than 2) were heavily 
represented in sample 10:1 (98%). For some substitution degrees, different position isomers could be 
detected. The total peak recovery (peak balance) was found between 90-110%, confirming the 
analytical characterizing capacity of the method. 
Our findings were confirmed by CE-MS (Figure 3B), a technique also included in the somatropin 
monograph of the European Pharmacopoeia (Ph. Eur. 8.0: 01/2008:0951) [58]. In CE, the separation is 
based on charge differences [59], in our case a loss of one positive charge of lysine with the 
simultaneous addition of negative charges of NOTA, whereas in RP HPLC mainly the decrease in 
hydrophobicity due to the attachment of NOTA leads to the separation [56]. Overall, the 1:1 and 3:1 
samples show similar degrees of somatropin modification as measured with CE-MS compared to LC-
MS (Figure 3). In the 10:1 sample, CE-MS revealed somatropin with NOTA substitution degrees ≥5 
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(amounted for 3%). As these highly polar compounds end up in the LC dead time, they were not 
detected, whereas in CE they migrate later and, therefore, could be detected. In general, we can 
conclude that both CE-MS and LC-MS techniques lead to similar conclusions regarding the extent of 
modification. However, higher order substitution degrees are detectable using CE-MS. 
 
 
Figure 3: Analytical results of the substitution degree of NOTA-modified somatropin obtained with RP-C4 (A) 
and CE (B). A typical LC chromatogram (A: 50 mM ammonium bicarbonate pH 7.5 and B: n-propanol: a 60 min 
linear gradient from 70% A (v/v) + 30% B (v/v) to 50% A (v/v) 50% B (v/v)) and CE electropherogram of the 3:1 
NOTA-somatropin sample are given. 
 
3.3. Peptide mapping of the NOTA-modified somatropins 
The current gold standard in protein characterization is the “bottom-up approach”. This method relies 
on the digestion of a mixture of proteins of interest and subsequent analysis of the digested peptides 
by LC-MS. All peptides were identified based on their peptide mass fingerprint (m/z value) and CID 
fragmentation pattern, thereby establishing the validity of these patterns for peptide identification 
and structural elucidation of the protein modification (Figure 4). Peptides containing the NOTA-label 
are characterized by a mass increase of 449.52 Da and specific NOTA-losses in their CID spectra 
(Figure 4A and 4B). Another observation made was the lower residual protein quantity upon the 
different modification and chelation steps, which are each followed by a desalting step and a 
lyophilisation step in case of NOTA-modification. Therefore, the UV absorption upon NOTA-
modification (going from A to B) is lower.  
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The monograph of somatropin in the European Pharmacopoeia (Ph. Eur.) includes a peptide mapping 
method using trypsin (Ph. Eur. 8.0: 01/2008:0951) [58]. It is commonly known that trypsin is a specific 
protease that cleaves at the C-terminal of arginine and lysine residues [60]. This yields theoretically 21 
peptide fragments for somatropin (PeptideCutter [61]). However, trypsin skips lysine cleavage sites 
when NOTA-modifications are present, e.g. for the NOTA-labelled Lys-158 protein fragment (fragment 
146-164) one trypsin cleavage site was missed. The individual peptides with NOTA-modification are 
given in Table 1. They represent modifications of lysine residues at Lys-70, Lys-158, Lys-140 and Lys-
172, with Lys-70 found in all samples. The sequence coverage of the trypsin digest was more than 95% 
for the control (i.e. unmodified somatropin sample) and more than 90% for the NOTA-labelled 
somatropin samples; all lysine residues were recovered (100% lysine coverage) in the control and 
NOTA:somatropin samples. The NOTA-Lys-70 modification yield was very high in all samples (94-
100%). The Lys-70 coverage amounted for 6% (i.e. the ratio between number of peptides containing 
Lys-70 and number of peptides containing a Lys residue), which is half of the theoretical specific Lys 
coverage of 11%. This means that relatively less fragments with Lys-70 were recovered compared to 
the other Lys-peptides. Indeed, for Lys-140, Lys-158 and Lys-172, the specific lysine (LysX) coverage 
was more than 11%. 
Not only in HPLC but also in the hydrolysis step of the peptide mapping, orthogonal systems can be 
used to further analyse the modification yield from the different molar ratios. Chymotrypsin mainly 
cleaves peptide bonds in which the carboxyl group is contributed by phenylalanine, tryptophan and 
tyrosine, theoretically also yielding 21 fragments for somatropin [61]. In addition, leucine and 
methionine may be cleaved as well, although at a much lower rate. This would theoretically yield 54 
somatropin fragments [61]. Results are given in Table 1. A relatively low overall sequence coverage 
was obtained after chymotryptic peptide mapping of control and NOTA-modified samples (below 
80%). The Lys-70 residue was found in 37% of the Lys-containing peptide fragments, i.e. a much higher 
Lys-70 coverage compared to trypsin-cleaved peptide mapping, but at the expense of Lys-158 with a 
LysX coverage of 0%. The NOTA-LysX distribution yield in sample 3:1 NOTA:somatropin was also found 
mostly on Lys-70 (86%) followed by Lys-140 (14%), with NOTA-LysX modification yields of 50% and 
67%, respectively. The use of chymotrypsin therefore gives another perspective on the modification 
yield compared to trypsin (94% vs 50% for Lys-70), confirming the structural information. Similar 
conclusions were also obtained with an enzyme combination of trypsin and chymotrypsin (Table 1). 
The use of S. aureus V8 protease was not suited for peptide mapping: the sequence coverage was 
below 40% and the lysine coverage amounted 22% for NOTA-labelled somatropin and control. 
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Table 1: Peptide mapping results of the individual peptides with NOTA modification 
Product Sequence 
Th. mass 
(Da) (z) 
Exp. mass 
(Da) 
RT 
(min) 
NOTA-LysX 
distribution 
yield (%) 
NOTA-LysX 
modification 
yield (%) 
Trypsin 
1:1 EETQQK70SNLELLR + NOTA 680.07 (3) 680.13 56.16 100 100 (n=1) 
3:1 
EETQQK70SNLELLR + NOTA 680.07 (3) 680.28 52.95 64 94 (n=4) 
FDTNSHNDDALLK158NYGLLY + NOTA 888.61 (3) 888.68 72.37 
30 24 (n=4) 
DTNSHNDDALLK158NY + NOTA 690.71 (3) 691.03 77.37 
DMDK172VETFLR + NOTA 568.64 (3) 568.71 67.53 4 7 (n=4) 
TGQIFK140QTY + NOTA 768.36 (2) 768.45 59.69 2 4 (n=4) 
10:1 
EETQQK70SNLELLR + NOTA 680.07 (3) 680.25 55.61 80 100 (n=1) 
DTNSHNDDALLK158NY + NOTA 690.71 (3) 691.1 80.02 13 100 (n=1) 
TGQIFK140QTY + NOTA 768.36 (2) 768.52 56.75 7 8 (n=1) 
Chymotrypsin 
1:1 SESIPTPSNREETQQK70S + NOTA 790.17 (3) 789.59 39.12 100 100 (n=1) 
3:1 
NREETQQK70SNL + NOTA 599.64 (3) 599.75 31.88 
86 50 (n=3) SESIPTPSNREETQQK70S + NOTA 790.17 (3) 790.25 36.30 
SESIPTPSNREETQQK70SNL + NOTA 865.91 (3) 865.99 45.47 
K140QTY + NOTA 495.02 (3) 495.23 34.85 14  67 (n=3) 
1:10 
NREETQQK70SNL + NOTA 599.64 (3) 599.86 36.06 
100 20 (n=1) 
SESIPTPSNREETQQK70S + NOTA 790.17 (3) 790.22 39.25 
Combination of trypsin and chymotrypsin 
3:1 
EETQQK70S + NOTA 433.77 (3) 433.89 21.89 33 5 (n=1) 
DMDK172VE + NOTA 593.65 (2) 593.65 48.76 
67 6 (n=1) 
DMDK172VETF + NOTA 478.84 (3) 479.01 0.38 
Product: molar ratio of NOTA over somatropin. NOTA-LysX distribution yield: percentage NOTA of LysX among all NOTA 
modified lysine residues. NOTA-LysX modification yield: percentage of LysX that is NOTA modified (i.e. lysine site depicted in 
bold in the sequence). 
 
Our data indicate that Lys-70 is a hotspot for NOTA-modification (Table 1), which was also suggested 
by Sakal et al. after modification of somatropin with fluorescein isothiocyanate (FITC) [62]. Our in silico 
ab initio pKa calculations revealed that the Lys-70 residue has a lower pKa value (pKa = 8.3) than the 
other eight Lys-residues and is therefore more reactive under our modification conditions (Figure 5). 
In addition, Lys-70 is positioned outside the binding pocket of the somatropin:hGHR interaction: 
modification of this lysine residue will therefore not directly interfere with receptor binding (Figure 5). 
According to our data, i.e. the NOTA-LysX distribution yield and modification yield, we conclude that 
Lys-70 followed by Lys-158 are most reactive towards p-SCN-Bn-NOTA and Lys-140 and Lys-172 are the 
less reactive lysine residues. Except for Lys-172, all found lysine residues lie outside the binding pocket 
with the receptor. 
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Figure 4: LC chromatogram of the tryptic digest and MS2 spectra of the peptide EETQQKSNLELLR (A) with NOTA-
modification (B) and gallium labelling (C), indicated by a black circle. Inset: MS spectra, with the selected 
precursor ion indicated by a black circle. 
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Figure 5: Position of lysine residues on somatropin in complex with hGHR (PDB: 3HHR) [26]. Yellow: 
somatropin; blue: hGHR (site I); green: hGHR (site II). In silico calculated pKa values for each lysine residue are 
indicated. 
 
 
3.4. Analysis of gallium labelled NOTA-somatropin 
For the complexation of gallium in NOTA, two times molar excess of gallium was used compared to the 
used amount of p-SCN-Bn-NOTA during NOTA:somatropin synthesis. Similar results as for NOTA-
modified somatropin (Section 3.3) were obtained: the overall sequence coverage after tryptic peptide 
mapping was 96%, with 100% lysine coverage. Tryptic peptide mapping of gallium labelled NOTA-
somatropin demonstrated that all NOTA molecules were complexed with gallium (Figure 4C), resulting 
in labelling efficiencies of 100%.  
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4. CONCLUSIONS 
The presence of multiple reactive sites on biomolecules toward chemical modifications during 
conjugation reactions can have a great impact on the product composition, and hence, the biological 
activity. Therefore, it is important to analytically characterize the products originating from different 
synthesis procedures. Direct analytical and bottom-up approaches were used to profile the different 
modified somatropin proteins and demonstrated that higher amounts of p-SCN-Bn-NOTA during 
synthesis led to a heterogeneous product with higher order substitution degrees, as well as different 
position isomers. The 1:1 NOTA:somatropin synthesis procedure yielded the highest mono-NOTA-
somatropin fraction (42%) with less higher order substitution degrees (≥2 NOTA, 12%); Lys-70 was 
found to be the modification hotspot toward p-SCN-Bn-NOTA. We conclude that Lys-70 followed by 
Lys-158 are most reactive towards p-SCN-Bn-NOTA and Lys-140 and Lys-172 are the less reactive lysine 
residues. Except for Lys-172, all found lysine residues lie outside the binding pocket with the receptor. 
The synthesis of NOTA-somatropin is a suited synthesis procedure for the production of target-specific 
radiopharmaceuticals for further investigation of the treatment and visualization of growth hormone 
receptor overexpressing cancers. 
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“What we observe is not nature itself, but nature exposed to our method  
of questioning.”  
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(°1901 - †1976, Theoretical Physicist) 
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ABSTRACT 
Chemical modifications on protein biopharmaceuticals introduce extra variability in addition to 
their inherent complexity, hence require more comprehensive analytical and functional 
characterization during their discovery, development and manufacturing. Somatropin (i.e. 
recombinant human growth hormone, rhGH) modified with the chelating agent S-2-(4-
isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) allows the 
incorporation of radiometals for research and possible theranostic purposes. We previously 
demonstrated that this conjugation leads to multiple substitution degrees and positional isomers 
within the product. In vitro techniques at molecular and cellular level were applied to assess their 
functional quality: (i) size exclusion chromatography (SEC) demonstrated functional complexation 
with human growth hormone binding protein (hGHBp) to the different NOTA-modified 
somatropins, as well as to gallium chelated NOTA-functionalities (Ga-10:1 NOTA:somatropin), (ii) 
native MS offered in-depth information: a substitution degree up to four NOTAs was functional and 
(iii) a hGHR bioassay demonstrated initiation of the signal transduction cascade, after binding of all 
modified products to the receptor presented on cells with a similar potency (between 179 pM and 
278 pM) and efficacy, which were not significantly different from the unmodified somatropin. We 
can conclude that the NOTA-modified somatropins do not possess a significantly different in vitro 
functionality profile compared to unmodified somatropin. Techniques such as SEC and MS, 
traditionally used in the physicochemical characterization of proteins, have a demonstrated 
potential use in the functionality evaluation in drug discovery, development and quality control 
settings. 
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CHAPTER III 
IN VITRO FUNCTIONAL QUALITY 
CHARACTERIZATION OF NOTA-MODIFIED 
SOMATROPINS 
Main focus in this chapter: 
? Assess the functional quality at molecular and cellular level and compare the functionality of 
NOTA-modified somatropins to somatropin. 
? Emphasise the use of classical physicochemical techniques (SEC and MS) in the functionality 
evaluation during drug discovery, development and quality control settings. 
 
1. INTRODUCTION 
Protein biopharmaceuticals are an established class within the medicinal product landscape and their 
members include complex molecules such as hormones, cytokines, monoclonal antibodies (mAbs), 
fusion proteins and therapeutic enzymes [1-3]. Compared to small molecules, the protein 
biopharmaceuticals form a more complex product class inherent to (i) their size, e.g. mAbs are 
approximately 150 kDa consisting of different chains, and (ii) their chemical and/or enzymatic 
modifications/truncations originating from expression, manufacturing and/or storage [4, 5]. One 
cloned recombinant protein can thus lead to many variants that each contribute to the overall quality, 
safety and efficacy of the product. In comparison to the unmodified protein biopharmaceuticals, 
additional chemical modifications such as polyethylene glycol (PEG), bifunctional chelating agents (e.g. 
1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)) and drug conjugations, render the protein 
additional functionalities. These modifications can, for example, influence the protein efficacy and 
create opportunities to deliver a payload such as a radionuclide or cytotoxic drug [6]. These chemical 
modifications typically target different reactive amino acid residues throughout the protein sequence 
such as lysine and cysteine residues, leading to different substitution degrees and positional isomers 
within the product, hence introducing more heterogeneity to the product [7, 8]. Control of a specific 
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conjugation site is usually impossible and conjugation at the target-binding interface can lead to 
unwanted or abolished interactions, as well as an altered pharmacokinetic profile [9, 10]. 
The development of a heterogeneous active pharmaceutical ingredient (API) into a medicinal product 
requires more regulatory effort and a thorough chemical and functional characterization during 
development and manufacturing prior to clinical or commercial release. These requirements come 
along with the need for more advanced analytical tools and further investment in their development. 
Chromatographic, electrophoretic and mass spectrometric approaches are traditionally applied for the 
physicochemical characterization (e.g. substitution degree, position isomers, oligomerization, 
molecular weight, etc.) [11-13], while classical biochemical and cellular assays [14] as well as emerging 
techniques such as biosensors [15, 16] have been applied in the functional characterization. Nowadays, 
a combined approach within analytical techniques is made from solely physicochemical to a combined 
functional characterization. 
Growth hormone (GH) is a key anabolic hormone, known to stimulate lipolysis during fasting [17, 18], 
to regulate skeletal muscle metabolism [18, 19] and to have an important role in bone metabolism 
throughout life [20]. The last decades, the interest in the actions of GH and the GH receptor (GHR) in 
cancer progression is growing [21-29]. For example, a higher GHR expression was observed in prostate 
carcinoma [30] and breast cancer tissue [31], as well as a higher GHR and GH expression in prostate 
cancer cell lines [32] and in large cell neuroendocrine carcinoma tissue [33]. The pleiotropic effects of 
GH are mediated after binding to a predimerized receptor presented at the cell surface of target cells, 
thereby forming a functional 2:1 GHR:GH complex and initiating the signal transduction cascade [19, 
29, 34]. 
Modification of biological substances with chelating agents (e.g. NOTA) allow the incorporation of 
radiometals for single-photon emission computed tomography/positron emission tomography 
(SPECT/PET)-research, diagnostic or therapeutic purposes. Such NOTA-somatropins have been 
previously developed and chemically characterized [8]. In this study, we evaluated the in vitro 
functional quality by means of traditional physicochemical techniques and cellular techniques. 
 
2. MATERIALS AND METHODS 
2.1. Chemicals and materials 
The S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) was 
purchased from Macrocyclics Inc. (Dallas, TX, USA). Zomacton® 4 mg, (Ferring, somatropin Ph.Eur.) was 
obtained from the Ghent University Hospital (Ghent, Belgium) and human growth hormone binding 
protein (hGHBp) from MyBiosource (San Diego, USA). PD-10 sephadex G-25M columns were acquired 
  CHAPTER III – IN VITRO FUNCTIONAL QUALITY CHARACTERIZATION OF NOTA-MODIFIED SOMATROPINS 
 
 
83 
from GE healthcare (Diegem, Belgium). Water was purified in-house using an Arium Pro VF TOC 
purification system (Sartorius, Göttingen, Germany), yielding 18.2 MΩ*cm and ≤ 5 ppb TOC quality 
water. Other chemicals and solvents were purchased from Merck (Overijse, Belgium), Sigma Aldrich 
(Diegem, Belgium), Biosolve (Valkenswaard, The Netherlands) or Fischer Scientific (Erembodegem, 
Belgium), all high quality (>98% purity) and/or HPLC/MS grade. For size exclusion chromatography 
(SEC) a Waters Alliance 2695 HPLC, equipped with a photodiode array detector 2996 and Waters multi 
λ fluorescence detector 2475 was used. Native mass spectrometry (MS) studies were conducted on a 
Waters Synapt G2-Si high-resolution quadrupole time of flight mass spectrometer (Waltham, MA) 
equipped with a LockSpray dual electrospray ion source. The PathHunter Cytosolic Tyrosine Kinase 
(CTK) assay with JAK2 target was from DiscoverX (Fremont, USA). 
2.2. Synthesis of NOTA-modified somatropin and complexation with gallium 
The synthesis procedure of 1:1 NOTA:somatropin, 3:1 NOTA:somatropin and 10:1 NOTA:somatropin 
was previously detailed in [8] and are the resulting products of respectively equimolar, three times and 
ten times molar excess of p-SCN-Bn-NOTA over somatropin during synthesis. For the gallium labelling 
of 10:1 NOTA:somatropin, approximately 40.5 nmol lyophilized protein was dissolved in 0.1 M 
ammonium acetate solution pH 5.5. A GaCl3 solution was made as follows: 285 μL of a 4 mM GaCl3 bulk 
solution in 0.1 M HCl was added to 570 μL 0.05 M NaOH and 1140 μL ammonium acetate solution pH 
5.5, supplemented with 0.2 mM acetylacetone. 1500 μL of this solution was transferred into a 2 mL 
Protein LoBind Eppendorf tube, containing 450 μL of the 10:1 NOTA:somatropin solution (40.5 nmol). 
The solution was mixed and incubated for 1 h at 37°C in the dark, while mixing at 750 rpm. The sample 
solution (1.950 mL) was loaded onto a PD-10 column (previously rinsed using 25 mL of PBS, pH 7.4). 
Before elution, the column was washed with 550 μL of PBS and then gallium labelled NOTA-somatropin 
was eluted using 2 mL of PBS, pH 7.4, into a 15 mL tube. Chemical quality control (QC) of the NOTA-
conjugation and gallium chelation using trypsin and chymotrypsin peptide mapping was performed as 
described in [8] with analogous results. 
2.3. Analytical size-exclusion chromatography 
Analytical SEC was performed with two columns, both equipped with suitable guard columns: 
(1) BioSep-SEC-S 2000, 7.8 (i.d.) x 300 mm (5 μm) (Phenomenex, Utrecht, The Netherlands); (2) a YMC-
Pack Diol-120, 4.6 (i.d.) x 150 mm (3 μm) (Achrom, Machelen, Belgium). The analysis used 0.2 M 
anhydrous potassium phosphate monobasic (KH2PO4) and 0.2 M anhydrous potassium phosphate 
dibasic (K2HPO4), pH 6.7-7.2 mobile phase at a flow rate of 1 mL/min and 0.5 mL/min, respectively. The 
injected sample volume was 20 μL (column 1) and 10 μL (column 2). Chromatography was performed 
at 22°C ± 3°C. Fluorescence detection was used with excitation and emission wavelengths of 280 nm 
CHAPTER III – IN VITRO FUNCTIONAL QUALITY CHARACTERIZATION OF NOTA-MODIFIED SOMATROPINS 
 
 
84 
and 340 nm, respectively. Complex standard (hGHBp + somatropin) and complex samples (hGHBp + 
NOTA-modified somatropins) were prepared at equal volumes of 50 μL using a fixed concentration of 
hGHBp (130 nM) and addition of somatropin, 1:1 NOTA:somatropin, 3:1 NOTA:somatropin, 10:1 
NOTA:somatropin or Ga-10:1 NOTA:somatropin at 29.5, 59, 118 or 237 nM (final concentration). The 
single proteins were evaluated under the same conditions. The protein stocks and dilutions were made 
in a 0.01% m/V polysorbate 20 solution in mobile phase. The relative affinities of the NOTA-modified 
somatropins were calculated according to Roswall et al. [35], assuming no changes in response factor 
after gallium chelation and NOTA-conjugation of somatropin: 
 
ܴ݈݁ܽݐ݅ݒ݁ ݄ܩܪܤ݌ ܾ݅݊݀݅݊݃ ݂݂ܽ݅݊݅ݐݕ ൌ  ௉௘௔௞ ௔௥௘௔ ଶ:ଵ ௖௢௠௣௟௘௫೎೚೘೛೗೐ೣ ೞೌ೘೛೗೐௉௘௔௞ ௔௥௘௔ ଶ:ଵ ௖௢௠௣௟௘௫೎೚೘೛೗೐ೣ ೞ೟ೌ೙೏ೌೝ೏  ൈ 
௉௘௔௞ ௔௥௘௔ ௦௢௠௔௧௥௢௣௜௡ೞ೔೙೒೗೐ ೛ೝ೚೟೐೔೙ ೞ೟ೌ೙೏ೌೝ೏
௉௘௔௞ ௔௥௘௔ ேை்஺:௦௢௠௔௧௥௢௣௜௡ೞ೔೙೒೗೐ ೛ೝ೚೟೐೔೙ ೞೌ೘೛೗೐ (1) 
 
2.4. Native MS analysis 
A Waters Synapt G2-Si high-resolution quadrupole time of flight mass spectrometer (Waltham. MA) 
equipped with a LockSpray dual electrospray ion source was used to acquire non-denaturing MS data 
of standard (i.e. somatropin) and samples (i.e. NOTA-modified somatropins) in positive mode (ESI+). A 
leucine enkephalin solution (200 pg/μL leucine enkephalin in 50/50 V/V ACN/H2O + 0.1% m/v formic 
acid) was used as the lock mass during the experiment, generating a reference ion for positive ion 
mode ([M + H]+ = 556.2771). Standards and samples were injected (10 μL) and directly infused (i.e. 
without chromatographic separation) at a flow rate of 10 μL/min. The optimized conditions of analysis 
were as follows: the source temperature was set at 150°C, desolvation gas temperature was 300°C, 
cone gas flow was 150 l/h, desolvation gas flow was 800 l/h, capillary voltage was 2.5 kV and sampling 
cone voltage was 50.0 V. Data were acquired between m/z 500 and 5000 Da. The concentration of 
standard/sample and hGHBp during analysis were fixed at 666 nM and 365 nM, respectively. All 
compounds were dissolved in a 25 mM ammonium acetate solution pH 6.8-7.0. 
The data between m/z 3000-4000 of the complex sample and complex standard were further analysed 
using Python programming language (supplementary information S3). Data were smoothed using a 
moving average filter (301 points). The baseline was fitted in regions without protein signal with a 
quadratic function. Peak deconvolution was performed on offset data (i.e. baseline subtracted) using 
the sum of exponential Gaussian peak algorithm, using the least-squares fitting technique. 
2.5. In vitro GHR bio-assay 
The PathHunter Cytosolic Tyrosine Kinase (CTK) Functional Assay (JAK2 target) was used for the 
profiling of NOTA-modified somatropins in agonist and antagonist format. The cells (U2OS cell 
background) were seeded in a total volume of 20 μL Cell Plating Reagent (i.e. 1% Charcoal/Dextran-
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treated Fetal Bovine Serum) into 384-well microplates. For agonist determination, cells were incubated 
with sample to induce a response. An intermediate dilution of sample stocks was prepared to generate 
5X sample in assay buffer (0.1% BSA in PBS). Five microliter of 5X sample was added to each well and 
incubated for three hours. In antagonist mode, cells were pre-incubated with sample for 60 min at 
37°C, followed by hGH agonist incubation for three hours (EC80 challenge; 0.012 μg/mL hGH). Assay 
signal was generated through a single addition of 12.5 or 15.0 μL (50% V/V) of PathHunter Detection 
reagent cocktail for agonist and antagonist assays respectively, followed by a one hour incubation at 
room temperature. The microplates were read and signals were generated with a Perkin Elmer 
EnvisionTM instrument for chemiluminescent signal detection in relative luminescence units (RLU). 
Human GH and INCB018424, i.e. a potent, selective and orally bioavailable inhibitor of JAK1 and JAK2 
[36, 37], were used as positive controls in agonist and antagonist format, respectively. 
 
For agonist mode assays, percentage activity was calculated using the following formula: 
% Activity ൌ 100% ൈ ሺ୫ୣୟ୬ ୖ୐୙ ୭୤ ୲ୣୱ୲ ୱୟ୫୮୪ୣ ି ୫ୣୟ୬ ୖ୐୙ ୭୤ ୠ୪ୟ୬୩ሻሺ୫ୣୟ୬ ୑୅ଡ଼ ୖ୐୙ ୡ୭୬୲୰୭୪ି ୫ୣୟ୬ ୖ୐୙ ୭୤ ୠ୪ୟ୬୩ሻ       (2) 
 
For antagonist mode assays, percentage inhibition was calculated using the following: 
% Inhibition ൌ 100% ൈ ଵିሺ୫ୣୟ୬ ୖ୐୙ ୭୤ ୲ୣୱ୲ ୱୟ୫୮୪ୣ ି ୫ୣୟ୬ ୖ୐୙ ୭୤ ୠ୪ୟ୬୩ሻሺୖ୐୙ ୉େ଼଴ ୡ୭୬୲୰୭୪ି ୫ୣୟ୬ ୖ୐୙ ୭୤ ୠ୪ୟ୬୩ሻ       (3) 
 
Data was further analysed using non-linear regression (least square regression) to calculate the RC50 
(i.e. EC50 or IC50) and Emax values (Prism 5 software, Graphpad, La Jolla, USA): 
ܧ ൌ ܧ݂݂݁ܿݐ ൌ  ܧ௠௜௡ ൅  ா೘ೌೣି ா೘೔೙ଵାଵ଴ሺሾౢ౥ౝ ሺೃ಴ఱబሻష೉ሿ ൈ ೓೔೗೗ ೞ೗೚೛೐ሻ       (4) 
 
 
3. RESULTS 
3.1. Analytical size-exclusion chromatography 
Analytical size exclusion chromatography (SEC) allows to evaluate the in vitro binding capacity of 
NOTA-modified somatropins to the soluble form and extracellular part of the human GHR, i.e. human 
growth hormone binding protein (hGHBp). The suitability of this method, known as the High 
Performance Receptor Binding Chromatography (HPRBC) method [35], was confirmed using the 
unmodified somatropin standard and hGHBp on two SEC columns. Figures 1A and 1B show the 
stoichiometric analysis of hGHBp and somatropin, i.e. the concentration dependent dimerization 
mechanism with 2:1 hGHBp:somatropin complexes in excess hGHBp conditions and increasing 1:1 
complexes in excess somatropin (analyte) conditions. The 2:1 hGHBp:somatropin complex elutes first, 
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followed by the 1:1 complex, somatropin and hGHBp, which is in agreement with the observations 
made in previous work [35, 38]. The hGHBp single protein chromatogram has several peaks indicating 
that the applied hGHBp consisted of a mixture of hGHBp-isoforms and impurities, including hGHBp 
oligomers (Figure 3). Indeed, analysis on SDS-PAGE confirmed the presence of higher molecular weight 
substances (supplementary information S1). 
 
 
 
Figure 1: Analytical SEC analysis of (NOTA-modified) somatropin and hGHBp. (A) Overlay chromatograms of 
the stoichiometric analysis of somatropin standard and hGHBp on column 1 and (B) column 2. (C) Functional 
activity evaluation of NOTA-modified somatropin samples with a two times molar excess of hGHBp on column 
1, and (D) a 4.5 times molar excess on column 2. (1): Impurity from the hGHBp sample, (2): 
2:1 hGHBp:somatropin, (3): 1:1 hGHBp:somatropin, (4): somatropin and (5): hGHBp. 
 
All NOTA-modified somatropins were in a 2:1 complex when approximately 2 - 4.5 times molar excess 
of hGHBp was used (Figure 1C and 1D), which demonstrated the binding-functionality and dimerization 
capacity of these NOTA-modified somatropins, as well as of the gallium chelated NOTA-modified 
somatropin towards hGHBp (Figure 1D). The relative affinity of the samples increased upon NOTA-
modification (1.21, 1.35, 1.42 and 1.81 for 1:1 NOTA:somatropin, 3:1 NOTA:somatropin, 
10:1 NOTA:somatropin and Ga-10:1 NOTA:somatropin, respectively). The formation of a 1:1 
hGHBp:analyte complex was also observed when the NOTA-modified somatropin samples were in 
excess relative to hGHBp (Figure 2). 
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Figure 2: Overlay chromatograms of the stoichiometric analysis of NOTA-modified somatropin and hGHBp on 
column 1 (right) and column 2 (left). (1): Impurity from hGHBp sample, (2): 1:2 analyte:hGHBp, (3): 
1:1 analyte:hGHBp, (4): analyte, (5): hGHBp and (6): analyte with higher NOTA-substitution degree. 
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A comparison of both silica based SEC columns is enclosed in Table S2 (supplementary information). 
They both have a different molecular weight range, but overlap in the region of interest (22 – 78 kDa). 
The single proteins were also analysed (Figure 3). Each NOTA-conjugation increases the molecular 
weight with 449.5 Da and, as previously observed, the substitution degree increases in the samples 
from 1:1 to 10:1 NOTA:somatropin [8]. We observed a longer elution time for the NOTA-modified 
somatopins. The increased polarity (addition of three negative charges and removal of one positive 
charge) as a result of the NOTA-substitution, likely creates more interactions with the hydrophilic 
deactivated stationary phases, hence resulting in an increased elution volume. The hGHBp 
(Mw: 29 kDa) and somatropin (Mw: 22 kDa) single protein standards elute at different elution times 
on column 1, thereby complementing the information provided by column 2 and simplifying the 
identification of excess somatropin or hGHBp in the different complex samples.  
 
Figure 3: Overlay chromatogram of the single protein injections. Left: column 1, right: column 2. 
 
3.2. Native MS analysis of protein complexes 
Confirmation and more in depth exploration of the SEC results, i.e. interrogation of the different 
product species (somatropins containing one, two or more NOTA-substitutions) for hGHBp-binding, 
was done by native MS. Native MS, also referred to as non-denaturing MS, allows the detection of the 
different substitution species-hGHBp-complexes in a single mass spectrum under non-denaturing 
conditions (i.e. typically volatile solutions such as ammonium acetate with reduced formation of 
adducts in the gas phase [39]).  
In general, the observed percentage substitution degree within the NOTA-modified somatropin 
samples (Figure 4E and Figure 5) are in agreement with previously reported data [8]. The spectra of 
the standard and sample complex solutions are given in Figure 4. In the standard complex, ions 
corresponding to 1:1 (Figure 4A) and 2:1 hGHBp:somatropin (Figure 6) complexes are detected. 
However, the increasing species complexity within the 1:1 to the 10:1 NOTA:somatropin samples leads 
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to a lower concentration of a single substitution degree species, and hence, a lower signal of the 
different hGHBp-complex species. Moreover, using a ~2 times molar excess of analyte relative to 
hGHBp creates a large fraction of 1:1 hGHBp:analyte complex, as observed in our analytical SEC data. 
Analyte with a substitution degree up to four NOTAs, was still able to form a complex with hGHBp. The 
semi-quantitative substitution degree species distribution in the single protein analyte samples (Figure 
4E) suggests a similar distribution within the hGHBp:analyte complexes (Figure 4F). There were no free 
hGHBp ions detected in the complex samples, indicating the hGHBp-binding functionality of the 
different species within the samples. 
 
Figure 4: Native MS spectra analysis of the complex samples. A-D: Deconvolution analysis of the 1:1 complex 
standard/samples, analyte:hGHBp ions (z=15) are shown. The upper part of each curve shows the raw data in 
gray, the smoothed data in red and the total sum of the peak deconvolution in black. At the bottom of each 
curve is the baseline subtracted peak deconvolution shown, with orange: unmodified somatropin:hGHBp 
complex, green: 1 NOTA-somatropin:hGHBp complex, blue: 2 NOTA-somatropin:hGHBp complex, dark red: 
3 NOTA-somatropin:hGHBp complex and black: 4 NOTA-somatropin:hGHBp complex. (A) Analyte: somatropin 
standard. (B) Analyte: 1:1 NOTA:somatropin. (C) Analyte: 3:1 NOTA:somatropin. (D) Analyte: 
10:1 NOTA:somatropin. (E) Species distribution analysis of the single protein standard and samples (z=10). 
(F) Species distribution analysis within the analyte:hGHBp complex (z=15); analytes are shown on the x-axis. 
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Figure 5: MS spectra of the standard and sample single proteins and complexes. (A) Somatropin analyte, (B) 1:1 
NOTA:somatropin analyte, (C) 3:1 NOTA:somatropin analyte and (D) 10:1 NOTA:somatropin analyte. Insets: 
zoom on region between 3000-4000 m/z. Colour codes for substitution degree species, orange: unmodified 
somatropin, green: 1 NOTA on somatropin, blue: 2 NOTAs on somatropin, red: 3 NOTAs on somatropin and 
black: 4 NOTAs on somatropin. 
A 
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Figure 5 (continued): MS spectra of the standard and sample single proteins and complexes. (A) Somatropin 
analyte, (B) 1:1 NOTA:somatropin analyte, (C) 3:1 NOTA:somatropin analyte and (D) 10:1 NOTA:somatropin 
analyte. Insets: zoom on region between 3000-4000 m/z. Colour codes for substitution degree species, orange: 
unmodified somatropin, green: 1 NOTA on somatropin, blue: 2 NOTAs on somatropin, red: 3 NOTAs on 
somatropin and black: 4 NOTAs on somatropin. 
B 
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Figure 5 (continued): MS spectra of the standard and sample single proteins and complexes. (A) Somatropin 
analyte, (B) 1:1 NOTA:somatropin analyte, (C) 3:1 NOTA:somatropin analyte and (D) 10:1 NOTA:somatropin 
analyte. Insets: zoom on region between 3000-4000 m/z. Colour codes for substitution degree species, orange: 
unmodified somatropin, green: 1 NOTA on somatropin, blue: 2 NOTAs on somatropin, red: 3 NOTAs on 
somatropin and black: 4 NOTAs on somatropin. 
C 
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Figure 5 (continued): MS spectra of the standard and sample single proteins and complexes. (A) Somatropin 
analyte, (B) 1:1 NOTA:somatropin analyte, (C) 3:1 NOTA:somatropin analyte and (D) 10:1 NOTA:somatropin 
analyte. Insets: zoom on region between 3000-4000 m/z. Colour codes for substitution degree species, orange: 
unmodified somatropin, green: 1 NOTA on somatropin, blue: 2 NOTAs on somatropin, red: 3 NOTAs on 
somatropin and black: 4 NOTAs on somatropin. 
D 
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Figure 6: MS spectrum of hGHBp2:somatropin (z=19). 
 
3.3. In vitro GHR bio-assay 
The functional quality of NOTA-modified somatropin for binding to the full length human GHR and 
activation/inhibition of the signal transduction cascade was evaluated using a PathHunter Cytosolic 
Tyrosine Kinase (CTK) functional GHR bioassay. This bioassay involves the intracellular JAK2 target, 
because this JAK2 pathway is the classical route of GHR signalling [40].  
An overview of the results is given in Figure 7 and Table 1. All NOTA-modified somatropins were able 
to bind to the hGHR in agonist mode. No antagonistic effects were found at concentrations up to 
10 nM, not even for the 10:1 NOTA:somatropin sample in which no unmodified somatropins were 
detected [8]. The efficacy of all samples in the agonist format is statistically not significantly different 
(p>0.05), as well as the potency of all NOTA-modified somatropins are in the same order of magnitude 
and are not significantly different from unmodified somatropin (ranging between 179 pM and 278 pM) 
(p>0.05).  
 
 
Figure 7: Dose response curves of the hGHR bioassay in agonist format. 
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Table 1: Overview of the hGHR bioassay results 
Compound Name Assay Format 
Result 
type 
RC50 (nM) Hill 
Curve Bottom 
(%) 
Curve 
Top 
(%) 
Human GH Agonist EC50 0.1426  1.17  -2.5  96.0  
INCB018424 Antagonist IC50 556.0000 2.11 -18.84  101.1  
Somatropin Ph. Eur. Agonist EC50 0.1785  0.99  -0.6 127.7  
Somatropin Ph. Eur. Antagonist IC50 >0.01 - - - 
1:1 NOTA:somatropin Agonist EC50 0.1845  1.20  -0.2 149.9  
1:1 NOTA:somatropin Antagonist IC50 >0.01 - - - 
1:3 NOTA:somatropin Agonist EC50 0.2609  0.80  -2.5 142.1 
1:3 NOTA:somatropin Antagonist IC50 >0.01 - - - 
1:10 NOTA:somatropin Agonist EC50 0.2776  0.86  -0.4 163.5  
1:10 NOTA:somatropin Antagonist IC50 >0.01 - - - 
 
4. DISCUSSION 
The thorough regulatory requirements for biopharmaceuticals have shifted the use of techniques and 
methods that were previously solely used for physicochemical characterization to a combined 
functionality characterization. For example, in the European Pharmacopoeia, SEC is generally used in 
the test for related substances of higher molecular mass in the protein monographs (e.g. Ph. Eur.8.8: 
01/2008:0951 [41]). Also MS is generally used for peptide mapping purposes or direct analysis of 
proteins, allowing identification of the substitution degree of the conjugate/post-translational 
modification, as well as identification of the modification hot spot [8, 11]. By the inclusion of a receptor 
or target within the sample, the functional quality characterization of the product can be established: 
complexation, indicative for a functional product, shifts the elution volume to the left (HPRBC/SEC) or 
shifts the m/z values to higher values (native MS). 
During the HPRBC/SEC analysis, we observed mainly the 2:1 hGHBp:somatropin in conditions with 
molar excess of hGHBp, while in conditions with molar excess of somatropin, also the 1:1 
hGHBp:somatropin complex is detected. Somatropin contains two receptor binding sites, a high 
affinity site I and a low affinity site II [42, 43], which are mechanistically important in the concentration 
dependent binding that we observe in the SEC/HPRBC. After binding of receptor 1 to the high affinity 
site I, receptor 2 makes contacts on somatropin and on the somatropin-bound-receptor 1, yielding a 
2:1 complex. Especially in a biological context, only after the formation of a functional 2:1 complex, 
the receptor undergoes a conformational change, leading to a signal transduction cascade. 
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Native MS is nowadays an established technique during the drug discovery phases, such as during the 
chemical characterization of modified proteins [44], the characterization of protein-metal complexes 
destined for either diagnostic or therapeutic purposes [45], and, during the investigation of 
interactions between protein drugs with their therapeutic targets/physiological partners, including 
unmodified proteins and their modified versions [46-49]. In this study, the substitution degree species 
within the protein product were functionally evaluated for hGHBp binding, thereby complementing 
the information provided by SEC/HPRBC. 
In addition to these traditional techniques, also new emerging tools such as biosensors are making an 
evolution from lab bench equipment to work horses in the industrial settings. For example, we 
demonstrated that the binding kinetics of these NOTA-modified somatropins were not significantly 
different from somatropin using a SAW biosensor technique with an antibody ligand (KD between 15 
and 19 nM) (Chapter VI and reference [50]). 
Finally, we used a classical cell assay with full length receptor. We observed a similar potency and 
efficacy of the NOTA-modified somatropins compared to somatropin, meaning that the NOTA-
modified somatropins are functional in a biological context and thus confirm our previous results from 
HPRBC/SEC and native MS. The NOTA-conjugation hotspot within somatropin is K70, followed by K158, 
and with a lower reactivity K140 and K172 [8]. Based on the crystal structure of hGHBp2:hGH (Figure 8), 
K172 is pointed to the receptor binding site I and has the potential to sterically hinder the receptor 
after modification with NOTA. Using mutational studies, Cunningham et al. demonstrated that K172 is 
a binding hotspot within site I [42]. A reduced affinity for GHR was also observed after conjugation of 
K172 with PEG5000 [51]. Compared to PEG with an average molecular weight of 5000 Da, the NOTA 
addition here is much smaller (449.5 Da). The other identified lysine residues prone to conjugation 
show enough conformational freedom to have no direct interference with receptor binding. Our 
results show that all investigated products, including species with a substitution degree of 4 NOTAs, 
can bind to the receptor and hence display receptor binding-functionality. 
Thus, we have investigated the in vitro functionality of the NOTA-modified somatropins on two levels: 
(i) on molecular level using hGHBp (HPRBC/SEC and native MS), with emphasis on the switch from 
classical physicochemical characterization techniques to more functionality characterization, and (ii) 
on cellular level by the detection of activation/inhibition of the GHR-signal transduction cascade in a 
biological context. 
5. CONCLUSION 
HPRBC/SEC and native MS demonstrated that all different NOTA-substituted somatropins, including 
gallium chelated NOTA-moieties, were able to bind the hGHBp. Native MS showed binding of the 
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products with a substitution degree of 4 NOTAs. The hGHR bioassay using the JAK2 target, 
demonstrated a similar potency (179-228 pM) and efficacy (127-163%) of all investigated compounds 
(i.e. somatropin and the NOTA-modified samples), in which the potency and efficacy were not 
significantly different. The use of molecular techniques HPRBC/SEC and native MS, as well as a cell 
assay complemented the obtained results to evaluate the functional quality of the NOTA-modified 
somatropins. We demonstrated that techniques such as SEC and MS, classically used in the 
physicochemical characterization of proteins, have a potential use in the functionality evaluation in 
drug discovery, development and quality control settings. 
 
Figure 8: Position of the conjugation hotspots (Lys-70, Lys-158, Lys-140 and Lys-172, all in red stick 
representation) on somatropin (orange) within the hGHBp2:somatropin complex (PDB: 3HHR). 
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SUPPLEMENTARY INFORMATION  
S1: SDS-PAGE analysis of hGHBp 
S2: SEC column comparison 
S3: Python source code 
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S1: SDS-PAGE analysis of hGHBp 
A 12% Criterion™ TGX™ Precast Midi Protein Gel, 18 well (Bio-Rad Laboratories nv, Belgium) was used 
for the SDS-PAGE analysis of the hGHBp sample (1 μg). The molecular weight marker ‘Precision plus 
protein all blue standards’ (Bio-Rad Laboratories) was used to estimate the molecular weight of the 
compounds. Compounds were visualized with the fluorescent Sypro Ruby gel stain after gel fixation 
and scanned using a Versadoc imaging system (Bio-Rad Laboratories). Next to hGHBp (a); also larger 
impurities or hGHBp oligomers were detected (b). 
 
 
Figure S1: SDS-PAGA analysis of the hGHBp sample. On the left the molecular weight of the marker is 
indicated. (a) hGHBp and (b) higher molecular weight impurities or hGHBp oligomers. 
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S2: SEC column comparison 
 
Table S2: SEC column comparison 
Specifications Column 1 Column 2 
Column BioSep-SEC-S 2000 YMC-Pack Diol-120 
Recommended MW range 1,000 – 300,000 Da 5,000 – 100,000 Da 
Dimensions 7.8 (i.d.) x 300 mm 4.6 (i.d.) x 150 mm 
Pore size 145 Å 120 Å 
Particle size 5 μm 3 μm 
Surface area Info not available 330 m²/g 
Recommended pH Range 2.5-7.5 5.0-7.5 
Chemical modifications Deactivated silica 1,2-dihydroxypropane derivatised silica 
Carbon load (%C) Info not available 7% 
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S3: Python source code 
 
Crop data and to CSV 
# -*- coding: utf-8 -*- 
""" 
Created on Fri Jul 15 12:09:00 2016 
@author: BartDS 
""" 
import pandas as pd 
import os 
# Input 
data_folder = "C:\Users\BartDS\Desktop\Project\Data\\" # Make sure to end the string with \\ 
#%% 
# List all the xlsx files in the data_folder 
data_files=[] 
for file_name in os.listdir(data_folder): 
    if file_name.endswith('.xlsx') and file_name.startswith('S'):  
        data_files.append(file_name) 
 
#%% Load all the data 
#os.chdir(data_folder) 
data_files=['S5.xlsx'] 
for data_file in data_files: 
    df = pd.read_excel(data_file,sheet='Sheet1') 
    df.columns = ['x','y'] 
    df_cropped = df.ix[(df.x>=3000) & (df.x<=5000)] 
     
    data_file_new = data_file[:len(data_file)-5]+"_35cropped.csv" 
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    print "Following file is made: %s" %data_file_new     
     
    df_cropped.to_csv(data_file_new,index=False)    
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Peak detection 
 
# -*- coding: utf-8 -*- 
""" 
Created on Thu Jul 14 12:09:37 2016 
 
@author: BartDS 
""" 
 
import numpy as np 
import pandas as pd 
import os 
import matplotlib.pyplot as plt 
 
 
#%% === Import data === 
# Input 
data_folder = "C:\Users\BartDS\Desktop\Project\Data\\" # Make sure to end the string with \\ 
data_auto_files = 0     #0: Load only files in data_files (data_files is not used) 
                        #1: Load all the xlsx files in the data_folder 
data_files = 
["S1_cropped.csv","S2_cropped.csv","S5_cropped.csv","S8_cropped.csv"]#,"S11_cropped.csv"] 
 
# List all the xlsx files in the data_folder 
if data_auto_files == 1: 
    data_files=[] 
    for file_name in os.listdir(data_folder): 
        if file_name.endswith('.csv') and file_name.startswith('S'):  
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            data_files.append(file_name) 
 
#%% Load all the data 
os.chdir(data_folder) 
data_frames=[] 
data = pd.DataFrame() 
for data_file in data_files: 
    df = pd.read_csv(data_file) 
     
    data_frames.append(df) 
     
    ds = df.y 
    ds.index = df.x.values 
    name = data_file[:len(data_file)-12] 
    data[name] = ds 
     
    print "Following file is downloaded: %s" %data_file 
 
#Check that all indexes are available 
print "NaNs in the dataframe:" 
print str(data.isnull().sum()) 
print "If all 0 => Ok" 
 
#%% === Plot data === 
plot_data = 1   #0: don't plot the data 
                #1: plot the data 
 
if plot_data == 1: 
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Fitting models 
 
# -*- coding: utf-8 -*- 
""" 
Created on Mon Jul 25 10:41:29 2016 
 
@author: td309bds 
""" 
 
#%% Test 
import numpy as np 
from scipy.special import erfc 
import matplotlib.pyplot as plt 
 
#%% 
def exp_gaussian_model(x, pars): 
    A = float(pars[0])     # Amplitude 
    mu = float(pars[1])    # Center 
    sig = float(pars[2])   # Sigma 
    gam = float(pars[3])   # Gamma 
    f = A*gam/2*np.exp(gam*(mu-x+gam*sig**2/2.0))*erfc((mu+gam*sig**2-x)/np.sqrt(2)/sig) 
    return f 
 
def linear_model(x,pars): 
    m = pars[0]     # rico 
    y0 = pars[1]    # yo 
    f = m*x+y0 
    return f 
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def quadratic_model(x,par): 
    a = par[0] 
    b = par[1] 
    c = par[2] 
    f = a*x**2+b*x+c 
    return f 
 
#%% 
 
class DataCursor(object): 
    """A simple data cursor widget that displays the x,y location of a 
    matplotlib artist when it is selected.""" 
    def __init__(self, artists, tolerance=5, offsets=(-20, 20),  
                 template='x: %0.2f\ny: %0.2f', display_all=False): 
        """Create the data cursor and connect it to the relevant figure. 
        "artists" is the matplotlib artist or sequence of artists that will be  
            selected.  
        "tolerance" is the radius (in points) that the mouse click must be 
            within to select the artist. 
        "offsets" is a tuple of (x,y) offsets in points from the selected 
            point to the displayed annotation box 
        "template" is the format string to be used. Note: For compatibility 
            with older versions of python, this uses the old-style (%)  
            formatting specification. 
        "display_all" controls whether more than one annotation box will 
            be shown if there are multiple axes.  Only one will be shown 
            per-axis, regardless.  
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        """ 
        self.template = template 
        self.offsets = offsets 
        self.display_all = display_all 
        if not plt.cbook.iterable(artists): 
            artists = [artists] 
        self.artists = artists 
        self.axes = tuple(set(art.axes for art in self.artists)) 
        self.figures = tuple(set(ax.figure for ax in self.axes)) 
 
        self.annotations = [39] 
        for ax in self.axes: 
            self.annotations[ax] = self.annotate(ax) 
 
        for artist in self.artists: 
            artist.set_picker(tolerance) 
        for fig in self.figures: 
            fig.canvas.mpl_connect('pick_event', self) 
 
    def annotate(self, ax): 
        """Draws and hides the annotation box for the given axis "ax".""" 
        annotation = ax.annotate(self.template, xy=(0, 0), ha='right', 
                xytext=self.offsets, textcoords='offset points', va='bottom', 
                bbox=dict(boxstyle='round,pad=0.5', fc='yellow', alpha=0.5), 
                arrowprops=dict(arrowstyle='->', connectionstyle='arc3,rad=0') 
                ) 
        annotation.set_visible(False) 
        return annotation 
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    def __call__(self, event): 
        """Intended to be called through "mpl_connect".""" 
        # Rather than trying to interpolate, just display the clicked coords 
        # This will only be called if it's within "tolerance", anyway. 
        x, y = event.mouseevent.xdata, event.mouseevent.ydata 
        annotation = self.annotations[event.artist.axes] 
        if x is not None: 
            if not self.display_all: 
                # Hide any other annotation boxes... 
                for ann in self.annotations.values(): 
                    ann.set_visible(False) 
            # Update the annotation in the current axis.. 
            annotation.xy = x, y 
            annotation.set_text(self.template % (x, y)) 
            annotation.set_visible(True) 
            event.canvas.draw() 
     
""" 
x = np.linspace(-4,6,100) 
y0 = exp_gaussian_model(x,[1,0,1,1]) 
y1 = exp_gaussian_model(x,[1,-2,1,1]) 
y2 = exp_gaussian_model(x,[1,0,3,1]) 
y3 = exp_gaussian_model(x,[1,-3,1,0.25]) 
 
ylin_0 = linear_model(x,[1,1]) 
ylin_1 = quadratic_model(x,[1,1,0]) 
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#plt.plot(x,x) 
plt.plot(x,y0,'r') 
plt.plot(x,y1,'g') 
plt.plot(x,y2,'b') 
plt.plot(x,y3,'y') 
#plt.plot(x,np.exp(x)) 
#plt.plot(x,1/2*np.exp(1/2*(1-2*x))*erfc((1-x)/np.sqrt(2))) 
""" 
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CHAPTER IV 
 
 BLOOD-BRAIN BARRIER 
TRANSPORT KINETICS 
OF NOTA-MODIFIED 
SOMATROPINS 
 
  
 
“There is no scientific study more vital to man than the study of his own brain.  
Our entire view of the universe depends on it.”  
 
Francis Crick 
(°1916 - †2004, Molecular biologist, biophysicist and neuroscientist) 
 
 
 
 
 
 
 
Parts of this chapter were submitted for publication: 
 
Bracke N, Janssens Y, Wynendaele E, Maes A, Van de Wiele C, Sathekge M, De Spiegeleer B. Blood-
brain barrier transport kinetics of NOTA-modified somatropins (2016) 
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ABSTRACT 
Chemical modifications such as PEG, polyamine and radiolabelling on proteins can alter their 
pharmacokinetic behaviour and their blood-brain barrier (BBB) transport characteristics. NOTA, i.e. 
1,4,7-triazacyclononane-1,4,7-triacetic acid, is a bifunctional chelating agent that has attracted the 
interest of the scientific community for its high complexation constant with metals like gallium. 
Until now, the comparative BBB transport characteristics of NOTA-modified proteins versus 
unmodified proteins are not yet described. Therefore, somatropin (i.e. a recombinant human 
growth hormone), NOTA-conjugated somatropin and gallium-labelled NOTA-conjugated 
somatropin were investigated for their brain penetration characteristics (multiple time regression) 
in an in vivo mouse model to determine the blood-brain transfer properties. Within this model, the 
three compounds had a low influx into the mouse brain and were not significantly different from 
each other (Kin = 0.38 ± 0.14 μL/(g × min), 0.36 ± 0.16 μL/(g × min) and 0.28 ± 0.18 μL/(g × min), 
respectively). Capillary depletion indicated that more than 80% of the influxed compounds reached 
the brain parenchyma. All three compounds were in vivo stable in serum and brain during the time 
frame of the experiments. Our results show that modification of NOTA onto somatropin, including 
gallium chelation, does not lead to a changed pharmacokinetic profile at the blood-brain barrier. 
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CHAPTER IV 
BLOOD-BRAIN BARRIER TRANSPORT 
KINETICS OF NOTA-MODIFIED 
SOMATROPINS 
Main focus in this chapter: 
? Compare the blood-brain barrier transport kinetics of NOTA-modified somatropin versus 
unmodified somatropin in an in vivo mouse model: 
o blood-to-brain (multiple time regression influx); 
o brain distribution, i.e. parenchyma vs. capillaries (capillary depletion). 
? To characterize the tissue distribution of NOTA-modified somatropins. 
? To evaluate the in vivo metabolic stability. 
 
1. INTRODUCTION 
Protein biopharmaceuticals have marched their way into the medicine landscape since the approval 
of the first recombinant protein insulin, Humilin®, in 1982. Since then, further research on protein 
modifications, either engineered (e.g. polyethylene glycol (PEG)-ylation, drug-conjugation, 
radiolabelling), originating from the expression host (e.g. post-translational modifications (PTM)) or 
resulting from the manufacturing process, have gained the interest by the biopharmaceutical 
community. Chemical modifications change the physicochemical properties, hence, alter the 
pharmacologic activity and pharmacokinetic profile of the protein under investigation. For example, 
changed elimination via a combination of changed proteolysis, renal ultrafiltration, liver clearance 
and/or starvation by the immune system, as well as specific interaction and/or accumulation within 
tissues is observed for PEGylations [1, 2]. Also modifications of proteins with bifunctional chelating 
agents (BFCA) such as 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) allow the 
incorporation/chelation of radiometals (e.g. 68Ga and 67Cu) and conjugation onto a targeting ligand via 
a linker [3, 4], thereby opening the way for theranostic applications [3, 5, 6]. 
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Conjugating moieties typically target functional groups on proteins such as amine, carboxyl and 
sulfhydryl, which are generally present in multiple copies on the protein and which can lead to complex 
product outcomes [3, 7]. The conjugate-targeting ligand ratio or substitution degree can influence the 
target-binding functionalities, the in vivo stability, clearance and biodistribution [8-10].  
In general, the ability to freely cross the blood-brain barrier (BBB) depends on the physicochemical 
properties (e.g. molecular size, charge and lipophilicity) [11, 12] and is often a closed route for proteins. 
However, chemical modifications on proteins such as polyamine modifications have demonstrated a 
higher permeability at the BBB compared to their unmodified counterparts [13]. 
In this study, the model protein of interest is somatropin (i.e. a recombinant human growth hormone 
(rhGH), INN) modified with 2-S-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid 
(p-SCN-Bn-NOTA) moieties [7]. Currently, evidence points to the involvement of growth hormone (GH) 
and its receptor (GHR) on tumour progression [14-22]. The GHR internalizes after signal transduction 
[23] and nuclear GHR-localization is associated with different cancers [24-26], which makes GHR an 
interesting target to further explore for theranostic purposes.  
Previously, speculations were made on the passage of GH over the BBB, because expression of the 
GHR has been demonstrated in the central nervous system (CNS) (amongst others choroid plexus, 
hypothalamus, pituitary, hippocampus and putamen [27-29]) and administration of GH has established 
positive effects on the CNS (reviewed in [30, 31]). Pan et al. demonstrated that rat and mouse GH are 
characterized with a significant blood-to-brain influx transfer constant in rats [32]. Thus, can chemical 
modifications on proteins, such as NOTA moieties, influence the BBB transport and do they show a 
different behaviour once complexed with a metal? To our knowledge, the comparative BBB transport 
characteristics of NOTA-modified proteins versus unmodified proteins are not yet reported. We 
investigate here the blood-brain barrier behaviour of NOTA-modified somatropin and gallium-chelated 
NOTA-modified somatropin as model compounds. 
2. MATERIALS AND METHODS 
2.1. Chemicals and reagents 
Zomacton® 4 mg (Ferring, somatropin Ph. Eur.) was obtained from Ghent University Hospital (Ghent, 
Belgium) and p-SCN-Bn-NOTA was purchased from Macrocyclics Inc. (Dallas, TX, USA). Bovine serum 
albumin (BSA) was obtained from Merck KGaA (Darmstadt, Germany). Dermorphin was synthesised at 
Hanhong (Shanghai, China). Ultrapure water was purified with a quality of 18.2 MΩ.cm using an Arium 
611 purification system (Sartorius, Göttingen, Germany). For the purification of gallium-chelated 
NOTA-somatropins, the PD-10 sephadex G-25M column was obtained from GE healthcare (Diegem, 
Belgium). The Pierce® Pre-Coated iodination tubes, iodine-125 carrier free radionuclide and argent 
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filters used during radiolabelling of the compounds were purchased at Thermo Scientific 
(Erembodegem, Belgium), Perkin Elmer (Zaventem, Belgium) and Sterlitech (Kent, USA), respectively. 
The other chemicals and reagents were purchased at Sigma Aldrich (Diegem, Belgium): gallium 
trichloride, potassium chloride, calcium dichloride dihydrate, sodium lactate, magnesium sulphate, 
hydrated sodium dihydrogen phosphate, urethane, D-glucose, sodium hydroxide, trichloroacetic acid 
(TCA), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and protease inhibitor cocktail; 
VWR (Leuven, Belgium): disodium hydrogen phosphate dihydrate and sodium chloride; and AppliChem 
GmbH (Darmstadt, Germany): dextran. Gradient grade acetonitrile and trifluoroacetic acid (TFA) came 
from Fisher Scientific (Erembodegem, Belgium). 
2.2. Animals 
The animal experiments were performed according to the Ethical Committee principles of laboratory 
animal welfare and approved by our institute (Ghent University, Faculty of Veterinary Medicine, 
approval number EC2014/128). All efforts were made to minimize suffering. Female, Institute for 
Cancer Research, Caesarean Derived-1 (ICR-CD-1) mice of age 7-10 weeks and weighing 29-32 g, were 
obtained from Envigo RMS B.V. (Venray, Netherlands).  
2.3. Compounds under investigation 
The BBB behaviour of somatropin, 10:1 NOTA:somatropin and gallium-chelated 10:1 
NOTA:somatropin (or Ga-10:1 NOTA:somatropin) was investigated. The synthesis and analytical 
characterization of 10:1 NOTA:somatropin is described in reference [7]. The NOTA-moieties of 10:1 
NOTA:somatropin were chelated with gallium by incubating 1 mg of 10:1 NOTA:somatropin, dissolved 
in 500 μL ammonium acetate solution (0.1 M pH 5.5, supplemented with 0.2 mM acetylacetone) 
together with 1500 μL of a 571 μM gallium solution (285 μL of a 4 mM GaCl3 bulk solution in 0.1 M HCl 
added to 570 μL 0.05 M NaOH and 1140 μL ammonium acetate solution) and incubated for 1 h at 37°C 
in the dark, while shaking at 750 rpm. The sample was loaded onto a PD-10 column (previously rinsed 
using 25 mL of 25 mM phosphate buffer, pH 7.4) and eluted using 2 mL of a 25 mM phosphate buffer, 
pH 7.4. BSA and dermorphin were included as negative and positive controls in the multiple-time 
regression (MTR) study, both dissolved in 25 mM phosphate buffer pH 7. 
2.4. Radiolabeling of the compounds 
The radiolabelling of the compounds was performed using the Iodogen method [33-35]. In brief, the 
Pierce® Pre-Coated iodination tubes were pre-rinsed with 1 mL 25 mM phosphate buffer pH 7.4. Then, 
50 μL of a 1.1 mM NaI in 500 mM phosphate buffer pH 7.4 and 15 μL Na125I (eq. 1 mCi) were added in 
the Iodogen tubes, mixed and incubated for six minutes at room temperature. The iodonium solution 
was transferred to a tube containing 50 μg protein or peptide and the reaction was proceeded for six 
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minutes at room temperature. Purification (i.e. separation of the unbound iodonium vs. radiolabelled 
protein) was performed by adding 500 μL 25 mM phosphate buffer pH 7.4 to the reaction mixture, 
followed by filtration through an argent filter. The appropriate protein and peptide concentrations (i.e. 
30 000 cpm/μL for MTR and 10 000 cpm/μL for capillary depletion (CD)) were prepared using Lactated 
Ringer’s solution containing 1% of BSA (LR/BSA).  
2.5. Multiple-time regression analysis 
After anesthetization of the ICR-CD-1 mice by intraperitoneal injection with a 40% (m/V) urethane 
solution (3 g/kg), the jugular internalis vein and carotid artery were isolated and 200 μL of the 
compound solution was injected into the jugular vein. Blood was collected from the carotid artery at 
regular time points after injection (1, 1, 3, 5, 10, 12.5, 15 and 15 min; one time point per mouse and a 
total of eight mice per compound, which is in accordance to previous MTR designs reported by our 
group [35-39]), followed by immediate decapitation. This was done independently for each of the 
compounds (somatropin, 10:1 NOTA:somatropin, Ga-10:1 NOTA:somatropin and both controls). Next, 
the brains were collected and weighed, and serum was prepared by centrifugation of the blood at 
10 000 g for 15 min at 21°C. Radioactivity of the blood, serum and brain was measured using a Wallac 
Wizard automatic γ-counter (Perkin Elmer, Shelton, CT, USA). 
In order to determine the BBB permeability of the compounds, the ratio of the brain and serum 
concentration (μL/g) was plotted versus the exposure time (Θ) [40]. The exposure time is calculated as 
the integral of the concentration of compounds in the serum (Cp) from start (t = 0 min) to time T (i.e. 
the area under the curve), divided by the concentration of compound in serum at time T: 
 Θ ൌ ׬ େ౦ሺ୲ሻ∙ୢ୲େ౦ሺ୘ሻ
୘
଴  (1). Working with the exposure time instead of the experimental time, allows to correct 
for the serum radioactivity decay over time and represents the theoretical steady state serum 
concentration level. A linear model of the blood-brain transfer was used to derive the influx 
parameters as elaborated by Gjedde and Patlak [41-43]: 
஺೘ሺ௧ሻ
஼೛ሺ௧ሻ ൌ  ܭ௜௡ Θ ൅ ௜ܸ        (2) 
where Am(t) is the amount of radioactivity in brain (cpm/g) at time T, Cp(t) is the amount of radioactivity 
in serum (cpm/μL) at time T, Kin is the influx rate constant and Vi is the initial volume of distribution. 
2.6. Capillary depletion 
The CD method was performed to distinguish the distribution of the compounds (somatropin, 10:1 
NOTA:somatropin and Ga-10:1 NOTA:somatropin) between brain parenchyma and capillaries [35, 36, 
44, 45]. Each compound was injected in two anesthetized mice as described in the MTR section. Before 
decapitation at 10 minutes post injection, blood was collected from the abdominal aorta followed by 
cardiac perfusion with 20 mL LR buffer, after clamping the aorta and severing the jugular veins. Brains 
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were collected and radioactivity was measured, followed by homogenisation of the brain in 0.7 mL ice 
cold capillary buffer (10 mM HEPES, 141 mM NaCl, 4 mM KCl, 2.8 mM CaCl2, 1 mM MgSO4, 1 mM 
NaH2PO4 and 10 mM D-glucose, pH 7.4) and 1.7 mL of ice cold 26% m/V dextran solution in capillary 
buffer. The resulting homogenate was weighed and centrifuged at 4500 g for 30 min at 4°C. The pellet 
(i.e. capillaries) and supernatant (i.e. parenchyma and fat tissue) were weighed and measured in the 
γ-counter. Serum was prepared from the collected blood by centrifugation at 10 000 g for 15 minutes 
and measured in the γ-counter as well. The compartmental distribution was calculated as follows: 
ܨݎܽܿݐ݅݋݊௖௔௣௜௟௟௔௥௜௘௦ ௢௥ ௣௔௥௘௡௖௛௬௠௔ሺ%ሻ ൌ  ஺೎ೌ೛೔೗೗ೌೝ೔೐ೞ ೚ೝ ೛ೌೝ೐೙೎೓೤೘ೌ஺೎ೌ೛೔೗೗ೌೝ೔೐ೞା஺೛ೌೝ೐೙೎೓೤೘ೌ  ൈ100     (3) 
2.7. Tissue distribution after IV injection 
From the 15 minute time points from the MTR study, tissues (spleen, kidney, liver, lungs, heart and 
serum) were collected after decapitation, weighed (Wtissue) and radioactivity was measured in the γ-
counter (Atissue). The percentage of injected dose (i.d.) for each tissue was calculated as follows, with 
AIV injected the measured radioactivity of the MTR stock solution and Wmouse the weight of the injected 
mouse: 
% ݅. ݀. ൌ  ஺೟೔ೞೞೠ೐ ௐ೟೔ೞೞೠ೐⁄஺಺ೇ ೔೙ೕ೐೎೟೐೏ ௐ೘೚ೠೞ೐⁄  ൈ100       (4) 
2.8. In vivo stability 
The in vivo stability evaluation was performed according to Pan et al. [32]. Proteins in serum samples 
from the MTR study were precipitated by addition of 15% TCA. Supernatant and pellet, corresponding 
to degradation fragments and intact protein, respectively, were separated by a 30 minutes 
centrifugation step at 4000 g. The brains collected during the MTR study, were homogenized in 1 mL 
of ice cold LR/BSA solution and 10 μL protease inhibitor cocktail. This mixture was centrifuged for 
2 minutes at 4000 g and 500 μL of the supernatant was transferred into a new tube. Intact protein was 
precipitated by addition of 15% TCA, vortexed and separated from supernatant by a 30 min 
centrifugation step at 4000 g and 4°C. Radioactivity (A) of the supernatant and the pellet of brains and 
serum were measured in the γ-counter. The percentage intact protein was calculated as follows 
ܲ݁ݎܿ݁݊ݐܽ݃݁ ݅݊ݐܽܿݐ ݌ݎ݋ݐ݁݅݊ ൌ  ஺೛೐೗೗೐೟஺೛೐೗೗ ା ஺ೞೠ೛೐ೝ೙ೌ೟ೌ೙೟ (5). For the kinetic evaluation, the percentage of intact 
protein at one minute post injection was taken as a 100% reference. Assuming first-order kinetics, a 
linear regression analysis of the ln(percentage intact protein) versus the post-injection time was 
performed to calculate the half-lives of the somatropins in mouse serum and brain. 
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2.9. Statistics 
Regression analysis was performed using the least squares method. Regression lines of the MTR study 
were statistically compared using the Prism 5 software (Graphpad, La Jolla, USA). Slopes were not 
statistically significantly different if the P-value was greater than 0.05. 
 
 
3. RESULTS 
3.1. Blood-to-brain transport kinetics 
In Figure 1 and Table 1, the MTR results of somatropin, 10:1 NOTA:somatropin, Ga-10:1 
NOTA:somatropin and both controls are given. The investigated somatropins all showed a significant 
influx with a Kin between 0.28 and 0.38 μL/(g×min) and similar initial distribution volumes, i.e. Vi 
between 17.12 and 22.11 μL/g, which were not significantly different from each other (Figure 1A). The 
Vi resembles the effective vascular brain distribution volume of the protein including the protein in the 
vascular space and bound to or accumulated in capillary endothelial cells. Based on the peptide 
classification according to their BBB influx [46], somatropin, 10:1 NOTA:somatropin and Ga-10:1 
NOTA:somatropin have a low influx. 
The data of BSA and dermorphin (Figure 1B) demonstrated the validity of the results and were 
comparable to previous influx data published by our group [35-39] or found in literature [47]. Overall, 
the somatropins had a higher Kin and Vi value than the negative control BSA. 
Moreover, the serum pharmacokinetics were explored. A biexponential behaviour was observed 
showing a rapid distribution phase and a much slower elimination phase. No apparent difference in 
behaviour is observed between the different compounds. The serum pharmacokinetic behaviour is 
also consistent with pharmacokinetic studies in humans [48]. 
 
Table 1: Overview of the multiple time regression results, with the 65% confidence interval indicated. 
Parameter Somatropin 
10:1 
NOTA:somatropin 
Ga-10:1 
NOTA:somatropin 
BSA Dermorphin 
Kin (μL/(g × min)) 0.38 ± 0.14 0.36 ± 0.16 0.28 ± 0.18 0.13 ± 0.05 0.48 ± 0.09 
Vi (μL/g) 17.12 ± 2.60 20.28 ± 2.80 22.11 ± 3.05 15.12  ± 0.69 18.24 ± 1.64 
Kin = unidirectional influx rate 
Vi = initial brain distribution volume 
  CHAPTER IV – BLOOD-BRAIN BARRIER TRANSPORT KINETICS OF NOTA-MODIFIED SOMATROPINS 
 
 
123 
 
Figure 1: Multiple time regression curves of the exposure time versus the ratio of the brain and serum activity. 
A: Somatropin, 10:1 NOTA:somatropin and Ga-10:1 NOTA:somatropin. B: BSA and dermorphin, negative and 
positive controls respectively. Data were fitted using the linear Gjedde-Patlak model. 
 
 
 
3.2. Capillary depletion 
The compartmental distribution of the radiolabelled compounds in the brain was estimated using the 
capillary depletion method. In the CD method, a cardiac perfusion step washes out the residual 
radioactivity in the brain vasculature, thereby allowing to distinguish between compounds that have 
reached the brain parenchyma and compounds that are trapped in the capillaries. Correction for 
leakage of 125I-GH from the vascular compartment during CD processing using labelled albumin was 
not performed, as the compound distribution volume values obtained were comparable to previous 
obtained results, where negligible albumin tissue ratios were obtained [32]. The parenchymal fraction 
amounted 80% for somatropin, while 82% and 81% were obtained for 10:1 NOTA:somatropin and Ga-
10:1 NOTA:somatropin, respectively (Figure 2).  
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Figure 2: Capillary depletion compartmental distribution results normalized for brain weight (mean absolute 
amounts in μl/g ±SEM, n=2), showing a very high brain parenchymal penetration for all investigated 
compounds. Atissue and Aserum are the measured activities in the concerned tissue and serum, respectively. 
 
3.3. Tissue distribution 
After 15 minutes post injection, both somatropin and 10:1 NOTA:somatropin were mainly found in 
serum, kidney and liver. Once gallium is complexed in 10:1 NOTA:somatropin, the compound was 
mainly distributed in serum (Figure 3). The tissue distribution of the positive and negative control 
corresponded well with previously obtained research results [35, 37-39]. 
 
 
Figure 3: Relative tissue distribution at 15 minutes post injection, expressed as the percentage of the injected 
dose (ID) (mean ± SEM, n=2). From left to right: brain, spleen, kidney, lungs, heart, liver and serum. A 100% ID 
indicates that the concentration of the compound within the tissue is the same as the mean concentration 
over the entire animal (i.e. a homogeneous distribution).  
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3.4. In vivo stability 
The in vivo stability was evaluated according to the TCA precipitation method of Pan et al. [32]. Using 
this method, a separation is made between intact protein (precipitate) and degradation products (e.g. 
metabolites (peptides) or free iodine as a result of deiodination; supernatant). A first-order kinetic is 
assumed in the calculation of the rate constant (k) and related half-life (Figure 4). The calculated 
metabolic half-lives were for all three compounds between 17 and 30 min in serum and brain.  
 
 
Figure 4: First-order kinetics of the in vivo stability in serum (left) and brains (right). Black: somatropin, gray: 
10:1 NOTA:somatropin and blue: Ga-10:1 NOTA:somatropin. Fitting results and calculated half-lives are shown 
in the insets. 
 
4. DISCUSSION 
The effect of NOTA-conjugation on the BBB transport characteristics of proteins, has not yet been 
described. The BBB is a unique, selective interface formed by the tight junctions between the 
endothelial cells that line the cerebral capillaries, as well as the metabolic barrier and the specific 
transport systems [49, 50]. Molecules that readily pass the BBB under normal conditions are 
traditionally explicitly small and lipophilic [51, 52]; however, saturable transport systems are described 
for different proteins, e.g. interleukins [53-56], tumour necrosis factor α [45] and interferons [57]. This 
means that molecules can diffuse passively through the BBB (mainly small, lipophilic molecules) or 
make use of a carrier- or receptor-mediated transport system as also for peptides and proteins [58]. 
Receptor-mediated transport systems are now strategies used for the transport of protein 
therapeutics across the BBB, e.g. bispecific antibodies with binding to the transferrin receptor (TfR) 
[59]. Some proteins however, do not pass this BBB and are here used as vascular markers, 
characterized by a negligible vascular brain distribution volume (on average 8.0 μL/g) [41, 60]. BSA is a 
known protein vascular marker, but radioiodination of BSA has been demonstrated to show some 
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nonspecific binding to cerebral capillaries in comparison to the tritiated form [61], explaining the 
observed brain influx and higher initial distribution volume (Vi = 15 μL/g) here. This also demonstrates 
the effect of chemical modifications on proteins and their behaviour at the BBB. In fact, molecular 
modifications on substances is one of the nine mechanisms influencing brain penetration of 
compounds, but unfortunately, the pharmacokinetic outcome is often difficult to predict [62]. As 
exemplified by Banks et al. [62], PEGylations can both enhance and reduce the BBB permeation. Also 
glucose modifications enhanced the BBB penetration, but these modifications did not target the 
expected glucose transporter GLUT1 [62, 63]. Therefore, the inclusion of a BBB permeability study is 
recommended to investigate the potential of drugs and their modification moieties to reach the CNS, 
with (i) intentional passage e.g. for treatment of CNS diseases [64] or (ii) unintentional passage e.g. to 
estimate non-selective tissue distribution in CNS during ligand-targeted radiopharmaceutical 
development. 
Rat GH was previously characterized by a low brain influx (Kin of 0.23 and 0.32 μL/(g×min) in mice and 
rat, respectively) [32]. We demonstrated that a recombinant, human GH (somatropin) with cross-
species reactivity (i.e. human ligand binds mouse receptor) [65, 66], has a similar low brain influx of 
0.38 ± 0.14 μL/(g×min) in the mouse model. The 10:1 NOTA:somatropin sample contains a mixture of 
products with different NOTA-substitution degrees and positional isomers [7]. No altered functional 
receptor binding potency was demonstrated for 10:1 NOTA:somatropin and Ga-10:1 
NOTA:somatropin compared to unmodified somatropin [67]. In this study, we could not demonstrate 
a significantly different BBB transport behaviour for these three compounds, indicating no BBB-
alteration after (Ga-chelated) NOTA-conjugation. Moreover, the compartmental distribution in the 
brain parenchyma and brain capillaries was also similar for the three compounds, with a higher 
parenchymal localisation (≥ 80%). From our results, we can conclude that for 10:1 NOTA:somatropin 
with or without gallium chelation, there was no significantly different BBB behaviour compared to 
unmodified somatropin. 
As seen from the tissue distribution after 15 minutes post injection, somatropin and 10:1 
NOTA:somatropin are highly distributed in serum, liver and kidney. The kidney is the main clearance 
site for GH [68], the liver is the main target site for GH action with GHR expression [69, 70]; and the 
extracellular part of the GHR, known as the growth hormone binding protein (GHBp), circulates 
separately in the blood at nanomolar concentrations, where it will bind with a substantial part of 
plasma GH (40-50%) [71-73]. Binding to GHBp can positively influence the serum half-life. The Ga-
chelated 10:1 NOTA:somatropin showed a different tissue distribution profile: significantly high serum 
levels were found and no preferential tissue uptake was observed. 
Next to the tissue distribution, also the in vivo metabolic stability was evaluated which can contribute 
to the serum half-lives. All three compounds (somatropin, 10:1 NOTA:somatropin and Ga-10:1 
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NOTA:somatropin) were relatively stable during the 15 minutes time period of the MTR experiment 
with metabolic half-lives between 17-30 minutes in serum and brain. Because the compounds were 
labelled with 125I and the TCA precipitation method was used (precipitate vs. soluble radioactivity), no 
direct conclusions could be made for the in vivo stability of the lysine-isothiocyanate(linker)-NOTA 
conjugation and the Ga-NOTA chelation. However, isothiocyanates are amine-reactive groups, form 
thiourea bonds onto lysine residues and are more stable than other amine-reactive linkers such as NHS 
esters [4]. The Ga-NOTA chelate is characterized with a high complexation constant (Log(KML) = 31.0) 
[74] and remains intact in nitric acid over a period of 6 months [75], indicative for a high stability. 
Indeed, gallium-p-SCN-Bn-NOTA-peptide conjugates have been reported to be stable in serum for 
>90% over 4h, in the presence of apotransferrin [76]. 
GH has been related to effects in the CNS such as sleep, mood, cognitive function, memory but also on 
neuroprotection, appetite and feeding behaviour [30, 31, 77]. The differential expression of the GHR 
in the different brain regions support these functional observations. At this moment, data on GH 
mechanisms on brain function remains limited and has to be further elucidated. It is demonstrated 
that GH is locally secreted in the brains [78]. Our study confirms that systemic GH enters the brain after 
peripheral administration of GH [32]. Thus, to which extent does systemic endocrine GH contribute to 
the brain function in health and disease? The NOTA-modified somatropins offer opportunities not only 
for targeting of GHR-overexpressing tumours, but also for imaging toward the GH mechanistic actions 
in the brain. 
 
5. CONCLUSIONS 
The BBB transport properties of somatropin after NOTA-conjugation and gallium chelation were 
investigated. Somatropin, 10:1 NOTA:somatropin and Ga-10:1 NOTA:somatropin all showed a low 
brain influx rate within the in vivo BBB mouse model, which were not significantly different from each 
other. In comparison to somatropin and 10:1 NOTA:somatropin, both having a pronounced tissue 
distribution to liver, kidney and serum, Ga-10:1 NOTA:somatropin showed a somewhat different tissue 
distribution profile with a high serum level and no preferential tissue distribution. The compounds 
showed a relatively high in vivo metabolic stability during the timeframe of the study (T1/2 between 17-
30 minutes). Our results thus show that NOTA-modification, including gallium chelation, onto a protein 
characterized with a low brain influx, does not lead to a changed pharmacokinetic profile at the blood-
brain barrier. 
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“Everything should be made as simple as possible, but not simpler.”  
 
Albert Einstein 
(°1879 - †1955, Theoretical Physicist) 
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ABSTRACT 
Peptides are established scaffolds in the medicinal landscape. Compared to biopharmaceuticals, 
they are generally characterized with lower production costs and higher quality consistency 
(synthetic versus recombinant production). Moreover, they are inherently smaller than proteins 
which positively affects the tissue/tumour penetration. The potential of somatropin-derived 
peptides (SDPs) as new entities that can bind the growth hormone receptor (GHR) was started to 
being explored in this study. The selection of the SDPs was based on the sequences covering the 
binding interface to the receptor. SDP2 showed high receptor binding potential based on an in silico 
docking simulation study. Chemical characterization revealed a purity of more than 95%, except 
for SDP1 (90%). The in vitro metabolic stability of the SDPs was determined as well, and all peptides 
were stable in brain, liver and serum (T1/2 > 15 min). The metabolites were also identified in serum 
and brain homogenates and showed different cleavage sites within the peptide sequences of SDP1-
5. SDP6 was found to be highly stable without detection of any metabolites. The functionality 
toward human growth hormone binding protein (hGHBp)/GHR binding was evaluated using native 
MS and the GHR bioassay; however, under our experimental conditions, we could not detect 
interaction of the SDPs to the receptor. In parallel to the pharmacodynamic activity, two peptides 
(SDP2 and SDP6) were selected based on their position within somatropin and their metabolic 
stability profile for a first pharmacokinetic evaluation with emphasis on the BBB transport. Both 
peptides showed a significant brain influx, with SDP6 (Kin = 1.43 μL/(g x min)) and SDP2 (Kin = 
0.13 μL/(g x min)) classified as a high and very low BBB influx, respectively. Based on our results, 
we can conclude that the GHR-binding potential of the selected SDPs is very low, requiring 
adaptations for further exploration.  
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CHAPTER V 
SELECTION AND CHARACTERIZATION OF 
SOMATROPIN-DERIVED PEPTIDES 
Main focus in this chapter: 
? To rationally select somatropin-derived peptides (SDPs). 
? To chemically characterize the SDPs and to evaluate the metabolic degradation kinetics in 
different biological matrices, with identification of the main protease-susceptible peptide 
bonds. 
? To evaluate their in vitro functionality toward receptor binding. 
? To characterize the blood-brain barrier transport of two selected SDPs. 
 
1. PROTEIN-DERIVED PEPTIDES 
Biopharmaceuticals have successfully been applied to target protein-protein interactions (PPIs). 
Compared to small molecules, which generally bind into small pockets with a surface area of 300-
1000 Å2, PPIs are characterized with surface areas of 1500-3000 Å2 and are genuine more flat [1, 2]. 
Mutational studies have revealed that most of the interaction energy is contributed by a small region 
on the protein and resembles a small subset of residues, i.e. the binding hotspot [3]. These hotspots 
can lie in close proximity (Figure 1), but can also be divided over the total binding surface. Due to their 
size and 3D structure, proteins target these large binding surfaces with high affinity and remarkable 
selectivity. 
Peptides, defined as molecules with 50 amino acids or less, have found their way in the medicinal 
landscape. Their entrance in clinical studies knows an exponential growth and resulted in different 
marketing approvals so far [4, 5]. Compared to biopharmaceuticals, they are characterized with lower 
production costs (synthetic vs. recombinant production) [6], they are inherently smaller than proteins 
which positively affects the tissue/tumour penetration and own a greater storage stability [7]. 
Moreover, they allow the incorporation of unnatural building blocks, which creates a broader 
spectrum of chemical and functional diversity. Therapeutic peptide scaffolds are typically derived from 
(i) naturally occurring peptides or fragments from larger proteins in plants, animals or humans, 
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(ii) genetic or recombinant libraries and (iii) chemical libraries [8, 9]; and are applied in agonist or 
antagonist format [10].  
 
Figure 1: Protein-protein interaction hotspots within the protein (adopted from reference [2]). Results are 
from alanine-scanning mutational analysis (replacing each amino acid, in turn, with alanine) on the contact 
surfaces of four pairs of interacting proteins. Colour coding amino-acid residues, from red (the most-disruptive 
changes) to green (those having little or no effect), represent the resultant change in the binding free energy 
compared with interactions involving the wild-type protein (∆∆G).  
 
In this part of the doctoral research, we explore the potential of somatropin-derived peptides (SDP) as 
new theranostic alternatives. This approach is substantiated by current indications that GH 
endogenously acts as a prohormone, hence resulting in “cryptic” peptides. GH fragments produced in 
vivo (with or without translational modifications) or in vitro by proteolysis, or prepared by chemical 
synthesis have shown multiple and diverse biological activities [11]. For example, fragment 1-134 was 
recombinantly produced by the insertion of a stop codon after residue 134 and inclusion of a point 
mutation C53S and demonstrated anti-angiogenic effects [12]. Also functional studies on synthetic GH 
fragments are reported. Peptides 95-133 [13] and 108-129 [11, 14] both demonstrated mitogenic 
activity and a distinct binding site than GH; peptide 177-191 has similar activities than GH (lipolytic and 
antilipogenic) [15]. Next to these synthetic peptides, also two endogenous occurring GH fragments, as 
a result of GH catabolism, were experimentally found: fragments 1-43 and 44-191 [16]. Some critics 
assign them as a result of extraction artefacts in the process of preparation from pituitary gland or 
serum. Fragment 1-43 (5 kDa) was isolated from pituitary extracts and detected in serum [17, 18]; 
however, no binding to GHR was observed [19]. Fragment 44-191 (17 kDa) was also detected in blood 
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circulation and pituitary. It showed low affinity to the GHR and possessed diabetogenic effects [20]. 
Next to these two fragments, also two-chain GH forms were isolated from the pituitary (reviewed in 
[21]). These two-chain forms are cleaved and (sometimes) missing a part of its sequence, but are still 
linked together by the disulphide bonds. For example, form α3 misses sequence 135-146 and form α2 
misses sequence 135-140; however, both are still functionally active with α3 as the most potent form 
[21-23]. 
The primary site on GH prone to proteolysis is situated between amino acid 134 to 150 [24-26] 
(Figure 2). This was shown after in vitro digestion with the serine prote(in)ases plasmin, subtilisin and 
thrombin [25], which resulted in a two-chain form, conformationally similar to the undigested 
molecule [27]. The two-chain form generated by plasmin cleavage consisted of residues 1-134 and 
141-191 linked by a single disulphide bond between residues 53 and 165 [28], and showed an 
unaltered biological potency. The cleaved fragment 135-140 (TGQIFK) was not included in functionality 
studies. Subtilisin digestion resulted in a mixture of three major cleaved forms [29]: S1: two-chain form 
with removal of fragment 140-149, S2: two-chain form with removal of fragment 140-146 and S3: two-
chain form with removal of fragment 140-146, including deamidation of Asn-152. The S1 form was the 
most active in dogs causing hyperglycaemia and hyperinsulinemia [29]. By reduction and alkylation of 
the subtilisin digest, the N-terminal 1-139 fragment showed specific binding to and mitogenicity in the 
NB2 rat lymphoma cell line [30]. Also the subtilisin cleaved GH, when administered to GH deficient 
men, was more active in its metabolic actions in men [31]. Digestion of hGH with thrombin resulted in 
a more specific hydrolysis, giving a single cleavage and producing a hormone representing the full 
primary structure of the active hormone (residues 1 - 134 and 135 - 191) [27]. These two fragments 
are also generated by kallikreins, i.e. serine proteases expressed in diverse tissues and also in the 
pituitary [32]. Also other studies using the poor-substrate-specific aspartic protease pepsin at low pH 2 
are reported [33]. This resulted in the selective cleavage of the Phe44-Leu45 peptide bond. The 
relevance of this study is that GH is exposed to the acidic environment of the cell (A-state structure: 
similar to native GH but regions of unfolding in the loop regions [34]). There are also several proteolytic 
fragments identified by in vitro proteolysis in rat thyroid tissue [35]. The first cleavage is between 
Tyr143-Ser144, then between Tyr42-Ser43, liberating the N-terminal peptide 1-42. Two other metabolites 
were formed as a result of the deletion of peptides Lys140-Tyr143 and Ser144-Phe146 from the large loop 
region. The proteolytic cleavage sites described above are schematically shown in Figure 2.  
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Figure 2: In vitro proteolysis of somatropin. (A) Reported in vitro proteolytic sites of growth hormone. (B) 
Crystal structure of somatropin (PDB: 3HHR) with site prone to proteolysis indicated in blue (residue: 134-150). 
 
In this study, SDPs were rationally selected based on the interacting residues of somatropin to the 
GHR, as the binding hotspot is concentrated on GH and GHR [3, 36]. The peptides as such were docked 
on the receptor, giving a first idea on the GHR-binding potential. In vitro and in silico somatropin digests 
as well as data from literature were evaluated to demonstrate the novelty of the selected SDPs. The 
SDPs were chemically characterized as well as their metabolic stability was determined in different 
tissues, with identification of the metabolites in serum and brain homogenates. In parallel, the 
pharmacodynamics (hGHBp/GHR binding capacity) and pharmacokinetics (BBB transport 
characteristics and tissue distribution) were characterized. 
 
 
2. MATERIALS AND METHODS 
2.1. Chemicals, reagents and equipment 
Zomacton® 4 mg, (Ferring, somatropin Ph.Eur.) was obtained from the Ghent University Hospital 
(Ghent, Belgium) and human growth hormone binding protein (hGHBp) from MyBiosource (San Diego, 
USA). The SDPs were from China Peptides (Shanghai, China) and dermorphin was synthesised at 
Hanhong (Shanghai, China). The enzymes for peptide mapping, L-1-tosylamide-2-phenylethyl 
chloromethyl ketone (TPCK)-treated trypsin solution, immobilized chymotrypsin solution and S. aureus 
V8 protease, were purchased at Pierce (Erembodegem, Belgium) and Sigma Aldrich (Diegem, Belgium). 
Insulin degrading enzyme (IDE), proprotein convertase 1 (PC1) and proprotein convertase 2 (PC2) were 
from R&D Systems (Minneapolis, USA). PD-10 sephadex G-25M columns were acquired from GE 
Healthcare (Diegem, Belgium). Water was purified in-house using an Arium Pro VF TOC purification 
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system (Sartorius, Göttingen, Germany), yielding 18.2 MΩ*cm and ≤ 5 ppb TOC quality water. Other 
chemicals and solvents were purchased from Merck (Overijse, Belgium), Sigma Aldrich (Diegem, 
Belgium), Biosolve (Valkenswaard, The Netherlands) or Fischer Scientific (Erembodegem, Belgium), all 
high quality (>98% purity) and/or HPLC/MS grade. The iodine-125 carrier free radionuclide was from 
Perkin Elmer (Zaventem, Belgium). 
The HPLC–UV–MS apparatus used for the somatropin proteolytic digest analysis, SDP chemical 
characterization and identification of the SDP metabolites, consisted of a Spectra System separations 
module, a Finnigan LCQ Classic ion trap mass spectrometer in positive ion mode (all Thermo, San José, 
CA, USA) equipped with a Waters 2487 dual wavelength absorbance UV detector (Waters, Milford, 
MA, USA) and Xcalibur 2.0 software (Thermo, San José, CA, USA) for data acquisition, as well as Thermo 
BioWorks software (San José, CA, USA) for protein identification. The purity analysis and in vitro 
stability study was conducted on a HPLC-UV system equipped with a Waters Alliance 2695 separation 
module and a Waters 2996 PDA detector, with Empower 3 software for data handling (Waters, Milford, 
USA). The kinetic metabolic analysis of SDP4-6 in serum was conducted on a U(H)PLC system directly 
coupled to a Waters Xevo TQ-S detector (both from Waters, Milford, USA). Native MS studies were 
conducted on a Waters Synapt G2-Si high-resolution quadrupole time of flight mass spectrometer 
(Waltham, MA) equipped with a LockSpray dual electrospray ion source. The PathHunter Cytosolic 
Tyrosine Kinase (CTK) assay with JAK2 target was from DiscoverX (Fremont, USA). 
2.2. Autodock simulations 
Docking simulations were performed using AutoDock 4.2, release 4.2.3 [37]. In these simulations, 
position, global orientation and conformation of the ligand (peptide/somatropin fragment) were 
varied in search for plausible binding places in the protein target binding site (here the extracellular 
part of the GHR). To limit the number of degrees of freedom, bond lengths and angles and the 
backbone of the peptide were kept rigid, but torsion angles in the peptide side chains were flexible. 
No degrees of freedom were relaxed in the GHBp protein target (rigid body docking). The full 
conformational space was then sampled stochastically (i.e. randomly, instead of exhaustively since the 
number of degrees of freedom is simply too big) and interesting peptide conformations (‘poses’) were 
located by a genetic algorithm followed by a local refinement, based on an empirical free energy 
scoring function [37]. The generated docked peptide poses were then clustered on structural similarity, 
as measured by distance (root-mean square deviation (RMSD)) between the poses. Highly populated 
clusters and clusters with low binding energies indicated possible ‘hits’ and were reported and further 
analysed. 
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2.3. In silico somatropin digestion 
The SitePrediction webtool was used to explore proteolytic cleavage sites in the GH substrate [38, 39] 
(http://www.dmbr.ugent.be/prx/bioit2-public/SitePrediction/). Cleavage sites with >95% specificity 
were reported. 
2.4. In vitro proteolytic digestions of somatropin 
Proteolytic digests using trypsin, chymotrypsin and S. aureus V8 protease were performed using similar 
methods as previously reported in [40]. For IDE, PC1 and PC2, S-carboxymethylation of cysteine 
residues of somatropin and purification on the PD10 column was identical to the other enzymes. Then, 
0.5 mL of the 2 mL PD10 eluent (equals 0.25 mg somatropin) was added to each 1.3 μL IDE (specific 
activity: >1,000 pmol/min/μg), 20 μL PC1 (specific activity: >8 pmol/min/μg) and 7.2 μL PC2 (specific 
activity: >60 pmol/min/μg). Digestion was performed at 37°C while gently shaking at 300 rpm for the 
defined period of time in a thermomixer comfort (Eppendorf, Hamburg, Germany). One hundred 
microliter samples were taken after 0 h, 4 h, 24 h and 48 h and the reaction was stopped by addition 
of 20 μL of formic acid (FA) to the sample. The samples were analysed by LC–MS as described in the 
peptide mapping section of reference [40]. 
2.5. LC-MS analysis 
A Vydac Everest C18 column (4.6 x 250 mm, 5 μm) with suitable guard column (Grace, Lokeren, 
Belgium) and mobile phases A: 0.1% (m/V) FA in 95/5 (V/V) H2O/ACN and B: 0.1% (m/V) FA in 5/95 
(V/V) H2O/ACN, were selected for separation of SDP1 and SDP3-6. Because SDP2 had no retention 
under the applied conditions, an adaptation to the method was made by using the prevail organic acid 
column (4.6 x 250 mm, 5 μm) (Grace, Lokeren, Belgium) with suitable guard column to obtain longer 
retention. Both columns were thermostated at 40°C and a fixed injection volume and flow rate of 20 
μL and 0.5 mL/min were applied, respectively. The linear gradient program started with a 2 min 
isocratic hold at 100% (V/V) A, followed by a linear gradient to 60% (V/V) A + 40% (V/V) B at 32 min. 
The method also included a rinsing step at 100% B, followed by returning to the initial conditions and 
re-equilibration. The total run amounted 50 minutes. UV detection was at 210 nm and the MS 
parameters were as described in reference [40] (peptide mapping section). Prediction of peak identity 
was performed upon comparison of m/z values with the SEQUEST algorithm of the Thermo BioWorks 
software (San José, CA, USA). Peptides with probability of more than 95% were reported and 
individually verified.  
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2.6. HPLC-UV analysis 
Each sample was separated on a Vydac Everest C18 column (4.6 x 250 mm, 5 μm) with suitable guard 
column (Grace, Lokeren, Belgium) using chromatographic parameters as described in Section 2.5, 
using TFA instead of FA as acidic modifier. SDP2 had sufficient retention using these conditions. UV 
detection was performed from 190 to 400 nm, whereas quantification was performed at 210 nm. 
2.7. U(H)PLC-MRM analysis 
The analytical stability was evaluated for each peptide under the experimental conditions over a time 
frame of 165 min. The percentage analytical stability was calculated for each compound separately 
relative to a reference at t0 min:  
% ݎ݁ܿ݋ݒ݁ݎݕ ൌ  ௔௥௘௔ ௥௘௙௘௥௘௡௖௘ ௧భలఱ ೘೔೙௔௥௘௔ ௦௔௠௣௟௘ ௧బ ೘೔೙  ൈ 100       (1) 
Sample prep - The peptides SDP4, SDP5 and SDP6 were analysed simultaneously, i.e. in the same serum 
sample. The in vitro metabolization was performed as described in Section 2.8, with sampling adapted 
to 100 μL of sample added to 300 μL ACN and 0.1% TFA. Prior to injection, the samples were diluted in 
DruQuaR diluent to prevent adsorption to glass vials, by diluting 12 μL supernatant ad 2.0 mL diluent 
(i.e. 100 ng/mL).  
U(H)PLC-MRM mass spectrometry method - A 2.1 X 100 mm reverse phase column (Waters, Acquity 
UPLC BEH C18, 1.7 μm) maintained at 45 ± 5°C was used for separation by a U(H)PLC system directly 
coupled to a Waters Xevo TQ-S detector. A 2.0-μl sample was injected at a flow rate of 0.5 mL/min. 
The gradient program was as follows (A: 90:5:5 H2O:ACN:DMSO containing 0.1% (m/V) FA and B: 5:90:5 
H2O:ACN:DMSO containing 0.1% (m/V) FA): isocratic flow of 100% A was performed for 1.5 min, 
followed by a linear gradient over 5 min of 100% A (V/V) to 40% A(V/V) + 60% B (V/V). After the elution 
at 6.5 min, the column was washed with a 100% B flush and reverted to the initial state. The run was 
terminated at 15 min. The MS unit was operated in electrospray positive ionization mode. Nitrogen 
was used as the nebulizing gas and argon was used as the collision gas. Instrument settings were as 
follows: source and desolvation temperature, 500°C each; cone and desolvation gas flow, 150 and 1000 
l/h respectively. Acquisition was performed in the multiple reaction monitoring (MRM) mode and 
monitored from 1.5 min to 6.5 min (< 1.5 min and > 6.5 min to waste). Cone and capillary voltage, 
collision energy and mass transitions are given in Table 1. Data were acquired using MassLynx software 
(V4.1 SCN 843, Waters, Milford, MA, USA). A typical combined MRM overlay chromatogram is shown 
in Figure 3. 
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Table 1: MRM transitions and parameters. 
Parameter SDP4 SDP5 SDP6 
MRM 700.67 > 821.08 744.32 > 651.44 1157.41 > 803.26 
Capillary voltage (kV) 2.0 3.0 2.5 
Cone voltage (V) 45 32 25 
Collision energy (eV) 20 20 37 
 
 
Figure 3: Combined UHPLC-MS/MS overlay chromatogram, normalised to the largest peak (SDP5). 
 
2.8. Stability study of the SDPs 
The in vitro stability of the SDPs was determined in buffer, serum and in selected tissue homogenates 
(liver, kidney and brain) according to standard protocols [41, 42]. The protein content of each 
homogenate was determined using the Pierce Modified Lowry Protein Assay method (Thermo 
Scientific) to generate a stock solution with a protein concentration of 0.6 mg/mL by dilution in Krebs-
Henseleit buffer (KH) (pH 7.4, Sigma-Aldrich). In brief, 150 μL of a 1 mg/mL peptide solution, dissolved 
in KH buffer (pH 7.4) was added to 500 μL of KH buffer, serum or tissue extract (375 μL of tissue 
homogenate + 225 μL of Krebs-Henseleit buffer (pH 7.4) = 225 μg of protein in total) and incubated at 
37°C while shaking at 750 rpm. Aliquots of 100 μL were sampled after 0, 15, 30, 60 and 120 min of 
incubation into tubes containing an equal volume of TFA (1% V/V) in acetonitrile and immediately 
subjected to 95°C for 5 min, followed by flash cooling in an ice bath for 30 min. The samples were 
finally centrifugated at 20 000 g for 5 min at 5°C prior to HPLC-UV or U(H)PLC-MRM analysis (see 
below). Blank control solutions (placebo samples) were prepared as described above, but without 
addition of peptide.  
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The half-life was determined as:        (2) 
with the slope derived from the curve of the natural logarithm of the percentage of the amount at the 
start of the incubation, i.e. t = 0 min, versus time.  
The formed metabolites during incubation of the peptides in serum or brain were identified. Time 
points were chosen between approximately one or two half-lives as determined in the kinetic 
evaluation. In case of a half-live of >120 minutes, t120 min was chosen as time point. Quantification 
occurred via ion-extracted chromatography (IEC) of the most abundant peptide charge responses. 
Peptide metabolite responses were normalized to the sum of all responses. 
2.9. Native MS 
The native MS method was essentially similar as previously described in [43]. For the peptides, a fixed 
concentration of 666 nM was used and 365 nM for hGHBp, dissolved in a 25 mM ammonium acetate 
solution pH 6.8-7.0. The percentage of free hGHBp was calculated as follows (using charge states: z=10-
12): 
%௙௥௘௘ ௛ீு஻ ൌ  ௛ீு஻  ௜௢௡ ௜௡௧௘௡௦௜௧௜௘௦೎೚೘೛೗೐ೣ ೞೌ೘೛೗೐௛ீு஻௣ ௜௢௡ ௜௡௧௘௡௦௜௧௜௘௦ೞ೔೙೒೗೐ ೛ೝ೚೟೐೔೙ ೞೌ೘೛೗೐      (3) 
2.10. In vitro GHR bio-assay 
The PathHunter Cytosolic Tyrosine Kinase (CTK) Functional Assay (JAK2 target) was used for the 
profiling of the SDPs in agonist and antagonist format as described in [43]. For the peptides, a 
concentration range between 0.5 nM - 10 μM was evaluated. 
2.11. In vivo pharmacokinetic characterization at the blood-brain barrier 
Animals 
Female, Institute for Cancer Research, Caesarean Derived-1 (ICR-CD-1) mice of age 7-10 weeks and 
weighing 29-32 g, were obtained from Envigo RMS B.V. (Venray, Netherlands). The animal experiments 
were approved by our institute (Ghent University, Faculty of Veterinary Medicine, approval number 
EC2014/128). All efforts were made to minimize suffering and to reduce the number of animals used. 
Experiments were performed according to the Ethical Committee principles of laboratory animal 
welfare. 
Radiolabelling of the peptides 
Peptides SDP6 and SDP2 were radiolabelled according to the chloramine T (CAT) and Bolton Hunter 
(BH) methods, respectively. The radiolabelling of SDP6 was performed by adding 20 μL of a 0.56 mg/mL 
slope
ln(2)
t1/2 ??
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NaI solution (in 0.5 M phosphate buffer pH 7.5) to 50 μL of a 1 mM peptide SDP6 solution (in 25 mM 
phosphate buffer pH 7.5), 17 μL of Na125I that correspond to 1 mCi and 30 μL of CAT solution (1 mg/mL 
CAT in 25 mM phosphate buffer pH 7.5). After 40 sec incubation, the reaction was stopped by addition 
of 30 μL of a 2 mg/mL Na2S2O5 solution (in 25 mM phosphate buffer pH 7.5). The radiolabelling of SDP2 
was performed by adding 10 μL of a 4.5 mg/mL NaI solution (in 0.5 M phosphate buffer pH 7.5) to 
15 μL of BH solution (i.e. approximately 30 nmol BH reagent in ACN), 17 μL of Na125I and 15 μL of CAT 
solution (4 mg/mL in 25 mM phosphate buffer pH 7.5). After 60 sec, the reaction was stopped by 
addition of 15 μL of a 8 mg/mL Na2S2O5 solution. Then 50 μL of a 1 mM SDP2 peptide solution is added 
to the I-labelled BH and the mixture is incubated overnight at room temperature. The mono-iodinated 
peptide fractions were isolated by injecting the reaction mixtures on a radio-HPLC and collecting the 
radioactive peptide content. The radio-HPLC apparatus consisted of a LaChrom Elite L-2130 pump with 
degasser (flow rate: 1 mL/min), a LaChrom Elite L-2300 column oven set at 40°C, a LaChrom Elite L-
2400 UV-detector set at 215 nm (all Hitachi, Tokyo, Japan), a Rheodyne 7725i manual injector with a 
100 μl sample loop (Rheodyne, Rohnert Park, CA, USA), a Berthold LB500 HERM radioactivity detector 
(Berthold Technologies, BadWildbad, Germany) equipped with EZChrom Elite version 3.1.7 software 
for data acquisition (Scientific Software, Pleasanton, CA, USA) and a fraction collector FC 203 (Gilson 
International BV, Den Haag, The Netherlands). For separation, a Vydac Everest C18 (250 × 4.6 mm, 
5 μm particle size) column (Grace, Lokeren, Belgium) was coupled to the HPLC system. Mixtures of 
95/5 (V/V) H2O/ACN supplemented with 0.1% (V/V) TFA (A) and 5/95 (V/V) H2O/ACN supplemented 
with 0.1% (V/V) TFA (B) were used to create appropriate gradients for the separation of the iodinated 
forms. The mono-iodinated peptide fractions were isolated and concentrated by nitrogen drying. The 
appropriate peptide concentrations (i.e. 30 000 cpm/μL for multiple-time regression analysis (MTR) 
and 10 000 cpm/μL for capillary depletion (CD)) were prepared using Lactated Ringer’s solution 
containing 1% of BSA (LR/BSA). The labelling of the negative control BSA and positive control 
dermorphin is described in [44]. 
Multiple time regression analysis and capillary depletion 
Multiple time regression analysis and capillary depletion were performed as described in [44].  
2.8. Statistics 
Regression lines were computed using the least squares method. 
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3. RESULTS 
3.1. Selection of somatropin-derived peptides 
Our objective is to select peptides that bind to the GHR. Since the functional binding epitope on GH 
and GHR is located in a concentrated position (and not scattered throughout the entire binding 
interface) [3, 45], we aim to target this position in site I as well as the binding interface at site II. Based 
on the crystal structure of De Vos et al. [46] and Sundstöm et al. [47], there are four fragments within 
GH that represent the binding epitope and are reported to contain the greater part of the interacting 
residues [47]. For site I, these are residues 41-68 (loop between helix 1 and 2) and residues 167-175 
(helix 4, C-terminal part) (Figure 4). For site II, these are residues 1-16 (N-terminus) and residues 103-
119 (helix 3) (Figure 4). 
 
 
Figure 4: Interacting residues (red) from GH to the extracellular part of the GHR. Orange: GH. Dark blue: GHR 1. 
Light blue: GHR 2. Upper row: site I, lower row: site II. 
 
A docking simulation was performed for each of the peptide fragments to the extracellular part of the 
receptor. In this docking simulation, relying on a genetic algorithm and local search algorithm, global 
position and orientation of the peptide, as well as side chain conformations were exhaustively sampled 
in search for a peptide pose with optimal binding position on GHR (Figure 5). 
The docking simulations predicted marginally positive binding energies (lowest binding energy: +0.79 
kcal/mol) for peptide 1-16. In addition, all poses were predicted to bind outside the active site of GHR. 
For peptide 41-68, highly unfavourable binding energies were observed (lowest binding energy: +12.21 
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kcal/mol) and no clusters whatsoever could be analysed in the ensemble of structures generated by 
the docking simulations. Based on these simulations, this peptide did not in silico interact with the 
protein. Peptide 103-119 also had positive binding energies (lowest binding energy: +4.65 kcal/mol) 
and was docked outside the GHR active site. For peptide 167-175, on the other hand, several clusters 
were successfully identified in the ensemble of the simulated docking poses. The poses that were part 
of these clusters had negative, favourable binding energies (ranging from -1 to -3 kcal/mol) and 
bounded either one of the symmetry-equivalent protein active sites. This peptide clearly had in silico 
binding potential to GHR. 
 
 
Figure 5: Docking simulation results of the peptide fragments to the GHR. Black: extracellular part of GHR; red: 
location and conformation of the original full peptide as determined in the crystal structure (PDB: 3HHR); blue, 
cyan, orange and green: prototypical peptide poses for highly populated clusters, or for clusters with the 
lowest mean binding energy. 
 
Each peptide that represent the binding interface to the receptor was selected with additionally one 
or two amino acids to the left and right of the fragment, justified to offer the “core” more structural 
integrity and protection from exopeptidases (Table 2). The additional amino acids were based on the 
flanking amino acids in the somatropin sequence. For the N-terminal fragment (SDP4), we also 
included an additional N-terminal methionine in our peptide set (SDP5), which is not present in the 
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natural sequence. For fragment 167-175, which is situated in a groove within the receptor and was 
predicted as most promising peptide binder according to the docking simulations (Figure 5), we 
selected the sequence as such (SDP2) and with two additional residues at the left and right (SDP3). 
 
Table 2: Selected somatropin-derived peptides. 
Peptide Sequence Position within somatropin 
Binding 
site 
Molecular 
weight (Da) 
pI1 
SDP1 EQKYSFLQNPQTSLCFSESIPTPSNREETQQK 39-70 
Loop between 
helix 1 and 2 
Site I 
3746.0 4.6 
SDP2 RKDMDKVET 167-175 
C-terminal part 
helix 4 
1121.2 6.5 
SDP3 CFRKDMDKVETFL 165-177 
C-terminal part 
helix 4 
1631.9 6.5 
SDP4 FPTIPLSRLFDNAMLRAH 1-18 
N-terminal part 
Helix 1 
Site II 
2099.4 10.5 
SDP5 MFPTIPLSRLFDNAMLRAH M+1-18 
N-terminal part 
Helix 1 
2230.6 10.5 
SDP6 LVYGASDSNVYDLLKDLEEGI 101-121 Helix 3 2313.5 3.6 
1: pI was calculated via https://www.genscript.com/ssl-bin/site2/peptide_calculation.cgi 
 
 
Are our proposed SDPs novel? Based on the proteolytic digestions with trypsin, chymotrypsin, 
S. aureus protease V8 and IDE, the selected peptides were not directly generated as metabolites 
(Figure 6). No metabolites for PC1 and PC2 were detected. We also looked at the predicted enzymatic 
cleavage sites. GH is mainly produced in the pituitary gland and enters then the systemic circulation, 
which includes several enzymes responsible for the enzymatic cleavage of peptides and proteins either 
in a specific (part of proteolytic cascades and signal transduction) or non-specific (degradation during 
protein catabolism) way. Werle and Bernkop-Schnürch have made a list of typical blood 
proteases/peptidases, as well as enzymes from highly blooded organs such as the liver and kidney [53]. 
Based on predicted cleavage sites for these enzymes, we performed an in silico proteolytic digest on 
the GH sequence. The result is given in Figure S1 and demonstrate that there are many potential 
cleavage sites present. Cleavage hotspots, here defined as more than three potential cleavage sites for 
a single peptide bond, are R8-L9, R19-L20, Q22-L23, C33-A34, Q40-K41, R77-I78, R94-S95, K115-D116, 
R127-L128, R134-T135, R178-I179, R183-S184. These cleavage hotspots, together with the reported 
cleavage sites from literature, are mapped in Figure 6. Based on these data, the selected peptides are 
not likely to be metabolites from GH/somatropin, which underlines their novelty. 
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3.2. Chemical characterization of the SDPs 
The SDPs were synthesized using solid-phase peptide synthesis (SPPS), which can often result in 
peptide-related impurities such as deletion/insertion of amino acids, racemization, dimeric and 
oligomeric impurities [48]. Moreover, the detected major peak during chemical characterization steps 
is not always the ordered peptide [49, 50]. Therefore, in order to obtain reliable research results, it is 
imperative to perform a chemical characterisation of the compounds of interest, to verify its identity 
and to quantify its purity. We ordered the peptides with a requested purity of ≥ 95%, which is also the 
recommended target purity to perform ligand binding assays, in vitro bioassays, and in vivo studies 
[49]. 
Our analytical QC strategy is presented in Scheme 1. Both methods relied on established reversed 
phase chromatographic separations [49]. The purity was quantified using UV210 nm detection and a 
method containing TFA as acidic modifier. TFA was previously demonstrated to be generally superior 
over FA during peptide impurity profiling [51]; however, because TFA causes ion suppression during 
MS, FA was used for the MS method during the peptide identification. 
 
 
Scheme 1: Analytical strategy for the chemical characterization. 
 
For all six SDPs, the major peak was identified to be the ordered sequence by peak assignment in the 
MS and MS2 spectra (Figure 7). In Table 3, the purity of each peptide is given. All peptides were 
compliant with the requested purity (≥ 95%), except for SDP1, which again illustrates the need for a 
quality control of the compounds under investigation.  
 
Table 3: Purity results of the peptides. 
Peptide 
Purity results 
(%) 
Purity as stated on supplier CoA 
(%) 
SDP1 90 96 
SDP2 100 98 
SDP3 98 97 
SDP4 95 99 
SDP5 100 95 
SDP6 100 99 
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3.3. Stability 
Analytical strategy for the in vitro stability evaluation 
The analytical strategy for the stability evaluation is given in Scheme 2. The chemical stability was 
investigated in buffer during a 2 h time frame, as different functional experiments are carried out in 
physiological buffers in which we want to guarantee their stability. Peptides are often characterised 
with low intrinsic metabolic stability [41]; therefore, the in vitro metabolic stability of the SDPs was 
investigated in mouse brain, liver and kidney tissue homogenates as well as in mouse serum. These 
tissues are the most important compartments for enzymatic degradation during systemic circulation 
[52]. However, SDP4, SDP5 and SDP6 co-eluted with serum bulk components, which made the 
quantification using UV210 nm detection unreliable. For these three peptides in serum, we used a MRM 
method via mass spectrometry. The metabolites were also identified to evaluate if the core of the 
peptides remained intact. 
 
 
Scheme 2: Analytical strategy for the stability evaluation 
 
Especially when working at low concentrations (typically sub 100 ng/mL for MRM methods on our 
equipment), adsorption phenomena are more pronounced than working at high concentrations 
leading to non-linearity and sensitivity problems. Peptides have generally high adsorption properties 
and different approaches have already been described to counter adsorption, such as diluent type, 
container material, etc. [53-56].  
Using a classical diluent consisting of 50% (V/V) ACN in water and glass vials, we observed a decreasing 
peak area over time (Figure 8) without formation of new degradation peaks, which biased the kinetic 
evaluation of the metabolic stability. We developed a DruQuaR diluent which competed for reactive 
adsorption sites on glass vials and evaluated its suitability. No interfering substances were detected in 
blank solutions, indicative for the selectivity of our method. The peptides were all analytically stable 
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during the time frame of 165 minutes (recovery between 99 and 101%) and no significant decreasing 
trend was observed, confirming the suitability of this DruQuaR diluent. 
 
 
Figure 8: Typical peak area decay over time (SDP5, 100 ng/mL, 50:50 ACN:H2O (V/V) and DruQuaR diluent). 
 
 
Chemical stability 
The peptides were all stable during a time period of two hours in buffer, i.e. recovery of ≥ 90% 
(Table 4). For peptide SDP3, the peptide recovery was only 87%; however, no degradation peaks were 
detected (above the reporting threshold of 0.5%). Therefore, peptide SDP3 was considered as 
chemically stable as well.  
 
Table 4: Chemical stability results. 
Peptide Recovery (%) Degradation peaks observed 
SDP1 93 No 
SDP2 103 No 
SDP3 87 No 
SDP4 106 No 
SDP5 110 No 
SDP6 102 No 
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In vitro metabolic stability of the peptides: kinetics 
A first-order kinetic was considered in the calculation of the rate constant (k) and related half-life. If a 
peptide was found to be stable at the end of the experiment, i.e. > 90% relative to T0 min at 120 min for 
serum or a particular tissue homogenate, then the half-life was calculated using the 90% value: T1/2 of 
13 hours. The half-lives are presented in Table 5. 
The half-lives in mouse brain homogenate ranged from 2.42 h for SDP1 to 7.31 h for SDP5, to over than 
13 h for SDP2-4 and SDP6. The peptides remained relatively stable as well when they were incubated 
in mouse liver homogenate. The calculated half-lives varied between 1.54 h for SDP1 as least stable 
peptide to more than 13 h for SDP2. The peptides were the least stable in the kidney homogenate. The 
kidney half-life was 9.12 min for SDP4, 12.43 min for SDP5, 13.88 min for SDP3, 22.52 min for SDP1, 
44.98 min for SDP6 and 48.57 min for SDP2. Many peptides are filtered by the glomerulus, degraded 
and excreted, but also for GH, the main excretion site is the kidney. The hormone is eliminated through 
glomerular filtration with degradation in proximal tubule cells and GHR-mediated clearance [57]. Due 
to a significant interference with co-eluting placebo components, no immediate conclusions could be 
made for the stability of SDP4-6 in serum using the HPLC-UV method. Therefore, an MRM method was 
developed for simultaneous detection and quantification in serum samples. SDP6 was stable in serum 
(>13h), while serum half-lives of 1.21 h, 1.89 h, 1.49 h, 20.74 min and 17.86 min, were observed for 
SDP1-5, respectively. 
In general, the peptides were stable in brain, liver, kidney and serum (T1/2 > 9 min). For receptor site I, 
SDP6 was found to be the most stable and for receptor site II, SDP2 was characterized with the highest 
stability profile. 
 
Table 5: First order in vitro metabolic kinetic half-lives for SDP1-6. 
Tissue 
Half-life (min) 
SDP1 SDP2 SDP3 SDP4 SDP5 SDP6 
Brain 145.26 > 789 > 789 > 789 438.50 > 789 
Liver 92.27 > 789 169.40 155.48 172.30 549.73 
Kidney 22.52 48.57 13.88 9.12 12.43 44.98 
Serum 72.48 113.27 89.10 20.74 17.86 > 789 
 
In vitro metabolic stability of the peptides: identification 
The metabolites were further identified to verify if the interaction “core” of the peptides was stable in 
serum and brain, i.e. tissues included in the later pharmacokinetic studies. The identified metabolites 
are given in Table 6, with the parent peptide indicated in bold and the major metabolite in serum 
underlined. The MS2 spectra of the major metabolite of each peptide are given in Figure 9. The SDP6 
was stable and no metabolites were detected after 2h, which confirmed its high stability in brain and 
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serum as observed in the kinetic evaluation. The major cleavage site for SDP1 is at the peptide bond 
before and after F54, which was, according to our literature survey and in silico proteolytic cleave 
(Figure 6), not an expected metabolic site. This site lies in the middle of the peptide sequence and is 
predominantly in serum prone for degradation. Cleavage also occurred before K70, the C-terminal 
residue of the peptide. SDP2, SDP3, SDP4 and SDP5 contain several cleavage sites within their 
sequence. The major cleavage site for SDP2 and SDP3 is the same, i.e. after the first lysine residue 
which was also a previously observed cleavage site within somatropin (trypsin proteolytic digest) 
(Figure 6). The metabolite TIPLSRLFDNAMLRAH was only detected in serum for SDP5, while also 
detected in brain for SDP4. The main metabolite for SDP4 and SDP5 is the same; however, this major 
cleavage site was not found experimentally within full length somatropin (Figure 6).  
 
 
Figure 9: Typical MS2 spectra for the major metabolites in serum.  
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Table 6: Metabolites in mouse serum and brain tissue homogenate. 
Peptide RT (min) Metabolite ID1,2 Tissue 
SDP1 
15.99 FSESIPTPSNREETQQ Serum 
19.53 EQKYSFLQNPQTSLCF Serum & brain 
19.96 EQKYSFLQNPQTSLCFSESIPTPSNREETQQK Brain 
SDP2 
15.91 DKVET Serum & brain 
16.76 RKDMDKVET Serum & brain 
17.53 KDMDKVET Serum & brain 
18.05 MDKVET Serum 
18.88 DMDKVET Serum 
SDP3 
12.25 DMDKVET Serum 
12.73 FRKDMDKVET Serum 
17.82 KVETFL Brain 
18.14 FRKDMDKVETFL Serum & brain 
18.30 KDMDKVETFL Brain 
19.99 CFRKDMDKVETFL Serum & brain 
20.98 DMDKVETFL Serum 
SDP4 
20.59 IPLSRLFDNAMLRAH Serum 
21.44 TIPLSRLFDNAMLRAH Serum & brain 
22.18 TIPLSRLFDNAMLR Serum 
23.01 PLSRLFDNAMLRAH Serum & brain 
23.06 FPTIPLSRLFDNAMLRAH Serum & brain 
23.74 FPTIPLSRLFDN Brain 
24.09 FPTIPLSRLFDNA Brain 
24.20 FPTIPLSRLFD Brain 
26.03 FPTIPLSRLFDNAML Brain 
76.50 FPTIPL Serum 
SDP5 
21.65 TIPLSRLFDNAMLRAH Serum 
23.59 PLSRLFDNAMLRAH Serum & brain 
23.59 PTIPLSRLFDNAMLRAH Serum & brain 
23.64 MFPTIPLSRLFDNAMLRAH Serum & brain 
24.60 MFPTIPLSRLFDN Brain 
24.99 MFPTIPLSRLFDNA Brain 
25.01 MFPTIPLSRLFD Brain 
SDP6 27.10 LVYGASDSNVYDLLKDLEEGI Serum & brain 
1 Bold: parent peptide, underlined: major metabolite in serum (MS2 spectra see Figure 9). 
2 Reporting threshold of 0.5% relative abundancy was applicable. 
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3.4. Receptor binding study of selected somatropin-derived peptides 
Bioassay 
The GHR bioassay was applied in agonist and antagonist format using concentrations between 0.5 nM 
and 10 μM of SDP. The dose response curves are presented in Figure 10. None of the SDPs showed 
biological activity at a concentration of 10 μM or lower, indicating no formation of a functional receptor 
dimer for JAK2 signalling (agonist) or inhibition of functional receptor dimerization (antagonist). The 
peptides do not seem to bind to the somatropin/GHR interaction interface under our applied 
conditions, or at least, do not provoke an antagonistic and/or agonistic affect. 
 
 
Figure 10: Dose response curves of the hGHR bioassay in agonist (left) and antagonist format (right).  
 
 
Native MS 
Although no effects by the peptides were detected in the bioassay, one of the fundamental questions 
raised at this moment is if the SDPs are able to bind to the receptor at another site than somatropin 
or whether their binding doesn’t affect the effect of GH (antagonist mode) or receptor activation 
(agonist mode). Native MS is applicable not only for large molecules, but also for smaller fragments 
such as peptides. Combined with the target of interest, here hGHBp, we can determine the decrease 
in response after a complex is formed. For all compounds, no signals for a peptide:hGHBp complex 
were detected, as well as no significant decrease in free hGHBp responses (between 92%-118%) was 
observed in the complex samples compared to the single peptide/protein samples (Figure 11). For 
example in case of the NOTA modified somatropins, no free receptor was detected in the complex 
samples, which is indicative for a functional analyte [43]. 
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Figure 11: Overlay of a typical native MS spectra from the functional SDP study. Left: m/z range from 500-1500, 
right: m/z range from 2000-3000. Astrix: hGHBp, (*) z= 12, (**) z=11 and (***) z=10. 
 
 
3.5. Blood-brain barrier transport characterization and distribution 
Parallel to the in vitro functionality study, the pharmacokinetics were evaluated for two selected SDPs: 
peptides SDP2 and SDP6 represent the two receptor binding sites (site I and II, respectively) and were 
the most stable in brain homogenate and serum, rationalizing their selection.  
 
SDP6 has the most pronounced influx characteristics, having a calculated Kin of 1.43 μL/(g × min) 
(Table 7 and Figure 12), which was significantly higher than somatropin and the NOTA-modified 
somatropins [44]. The calculated Kin-value for SDP2 was 0.13 μL/(g × min). SDP6 showed a higher initial 
distribution volume, i.e. Vi = 25 μL/g, while this was lower for SDP2, i.e. 11 μL/g in comparison with 
other vascular markers [44]. Based on the peptide classification made by Stalmans et al. [58], peptide 
SDP6 has a high BBB influx and SDP2 a very low influx, the latter not significantly different from BSA.  
 
Table 7: Overview of the multiple time regression results, with the 65% confidence interval indicated. 
Parameter SDP2 SDP6 BSA Dermorphin 
Kin (μL/(g × min)) 0.13 ± 0.10 1.43 ± 0.28 0.13 ± 0.05 0.48 ± 0.09 
Vi (μL/g) 10.89 ± 1.17 25.41 ± 5.69 15.12  ± 0.69 18.24 ± 1.64 
Kin = unidirectional influx rate 
Vi = initial brain distribution volume 
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Figure 12: Linear regression curves of the exposure time versus the ratio of the brain and serum activity of the 
controls and peptides during the MTR experiments. BSA and dermorphin were evaluated as negative and 
positive controls. 
 
 
The radioactivity in serum (corrected for injected dose) was plotted versus time (see Figure 13). The 
activity in serum decreased in function of time, which i.a. indicated the tissue uptake or elimination of 
the 125I-labeled peptides. An estimation of the elimination rate constant was made, based on a one 
compartment model (Table 8). Under our experimental conditions, SDP2 showed no significant 
elimination, whereas the serum half-life was estimated to be 5.2 min for SDP6. 
 
Table 8: Overview of the pharmacokinetic elimination results. 
Peptide SDP2 SDP6 
kea (min-1) 0.026 0.134 
T1/2 (min) 26.670 5.161 
ake = elimination rate constant based on the one compartment model: ܿ ൌ ܿ଴ൈ݁ି௞೐௧. 
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Figure 13: 125I-serum levels during multiple time regression (left: linear y-scale; right: ln y-scale).  
 
In Figure 14, the tissue distributions of the radiolabelled peptides and both controls at approximately 
15 min post injection are visualized. Both SDP2 and SDP6 were mainly found in serum and to a lesser 
extent in the kidney. 
 
 
 
Figure 14: Tissue distribution at 15 minutes after IV-injection (mean ± SEM; n=2). 
 
In Figure 15, the distribution of the radiolabelled SDP2 and SDP6 in the brain is visualized. The results 
of the capillary depletion study, approximately 10 min after injection, indicated a clear influx into the 
brain parenchyma for SDP2 and SDP6: a high parenchymal activity of about 82% for SDP2 and about 
87% for SDP6 versus a relatively low capillary activity. Their long stability in brain, as demonstrated via 
the in vitro metabolic stability study, indicated that the peptides remain intact for a longer period once 
they have entered the brain parenchyma, hence, allow further penetration of the peptide into the 
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brain parenchyma. Also in serum, the peptides were stable during the time frame of our BBB 
experiment. Moreover, from the y-axis in Figure 15, it can also be derived that the amount of SDP6 
that enters the brain in a time span of 10 min is ten times higher than the SDP2 peptide.  
 
 
Figure 15: Compartmental distribution of SDP2 and SDP6 normalized to brain weight (mean absolute 
amounts in μl/g ± SEM, n=2).  
 
Based on our results, the SDPs showed no specific tissue distribution. However, SDP6 showed a clear 
brain influx which was significantly different from the negative control BSA. 
 
4. DISCUSSION 
Proteolytic cleavage of proteins can generate ‘hidden’ peptides, i.e. cryptic peptides or crypteins, with 
bioactivities that are often totally distinct to their parent protein or prohormone [59]. Also crypteins 
with a similar functionality than the parent protein have been identified. For example, the N-terminal 
tripeptide (glycine-proline-glutamate) derived from insulin-like growth factor-1 (IGF-1), circulates in 
plasma and brain tissue and is able to penetrate in the central nervous system (CNS) to act as a 
neuroprotectant [60, 61]. These crypteins expand the theranostic strategies to generate smaller 
fragments with changed properties (e.g. better tissue penetration) and are more easy to produce in a 
controlled way compared to their parent protein. GH circulates in different forms in our body and 
different studies have been undertaken to identify functional smaller fragments, indicating the 
prohormone potential of GH. Based on this and as we are interested in the GHR target, we specifically 
selected peptides that are positioned within the binding interface of somatropin. The selected SDPs 
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are new: they are not reported in literature or experimentally observed as metabolites. However, 
different studies have been undertaken to investigate the functionality of synthetic fragments. SDP6, 
positioned in site II of the GHR interface on somatropin, overlaps with the regions of the synthetically 
produced peptides 95-133 and 108-129 [11, 13, 14]. These synthetic peptides appear to bind to 
another site than GH. Indeed, using our in vitro functionality studies, we were not able to demonstrate 
binding of SDP6 to the hGHBp, which was also confirmed by the in silico docking simulation. Also the 
other SDPs did not show any binding or functionality towards hGHBp under our experimental 
conditions. Even the most potential peptide, as predicted by the docking study (i.e. SDP2), did not 
demonstrate binding functionality. During the native MS study, we worked at a concentration of 
666 nM SDP, identical to the concentrations used for somatropin and the NOTA-modified somatropins 
in native MS [43]. The KD of GH for GHBp is reported to be around 0.3 nM [62] and resulted in the 
detection of a 1:1 (NOTA-modified) somatropin:hGHBp interaction. As we do not see any interaction 
at these concentrations for the SDPs, hence, no significant altered mass balance in hGHBp, we can 
conclude that, if the SDPs interact with the hGHBp and assuming the complex remains intact during 
native MS analysis, the affinity is much lower than that of somatropin/GH. Further confirmation can 
be conducted using emerging techniques such as biosensors and circular dichroism (CD), as well as 
further exploration of adaptations to the proteins such as peptide-tetramers in analogy to the peptide 
dimers for erythropoietin receptor activation and the neurotensin-tetramers [63, 64]. 
During this study, special attention was given to the chemical characterization and metabolic stability 
of the peptides under investigation as well. We requested a purity of ≥ 95%; however, the purity of 
SDP1 was only about 90% as observed during the chemical characterization. It is already observed that 
impurities can lead to a biofunctional response instead of the peptide as such [65], thereby leading to 
false positive or negative outcomes and pointing to the importance of the quality of the compounds 
under investigation. 
In general, the BBB is still a hurdle for the development of effective therapies targeting diseases in the 
central nervous system (CNS) [66]. Therefore, the knowledge of the quantitative structure-activity 
relationship (QSAR) can contribute to the prediction of peptides which can cross the BBB. Our research 
group has compiled the BBB transport data from different peptides described in the literature in a 
Brainpeps database [67]. When we cluster our two peptides, SDP2 and SDP6, with the peptides 
reported in the Brainpeps database according to their chemo-molecular descriptors, we can clearly see 
that peptide SDP6 clusters together with pituitary adenylate cyclase-activating polypeptide-27, [Tyr10] 
Secretin-27, mouse obestatin, vasoactive intestinal peptide, Des-octanoyl ghrelin and ghrelin peptides 
(Figure 16). These peptides are all characterized with a Kin ≥ 0.40 μL/(g x min) and, according to the 
Stalmans classification [58], are categorized with a medium to higher BBB influx. This is in agreement 
with the results for SDP6 (Kin = 1.43 μL/(g x min)), which is characterized with a high BBB influx. The 
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chemical properties of SDP2 are not clustered with other Brainpeps peptides and for this peptide, no 
significantly different influx was detected compared to the vascular marker BSA. This first QSAR 
approach demonstrates the potential of models to predict the behaviour at the BBB of peptides. 
 
Figure 16: Chemical space of the Brainpeps peptides. 
 
5. CONCLUSIONS 
The potential of SDP as new therapeutic alternatives was explored. The selection of six SDPs was based 
on the sequences covering the binding interface to the receptor and their novelty was evaluated. The 
SDPs were chemically characterized and were more than 95% pure, except for SDP1 which had a purity 
of more than 90%. All peptides were stable in brain, liver and serum (T1/2 > 15 min) and a shorter half-
life was demonstrated in kidney homogenates. The metabolites were identified in serum and brain 
homogenates and demonstrated the presence of different cleavage sites within the core sequence of 
SDP1-5. SDP6 was extremely stable in the investigated tissues, no metabolites could be found in serum 
and brain homogenate. The functionality toward GHR/GHBp binding was evaluated using native MS 
and the GHR bioassay; however, the selected SDPs as such did not show binding to the GHR or hGHBp. 
Parallel to the in vitro functionality evaluation, two peptides (SDP2 and SDP6) were selected for a 
pharmacokinetic evaluation, based on the opposite binding interfaces with the receptor (site I and 
site II) and their highly stable metabolic profile. Both peptides did not show a specific tissue 
distribution, but SDP6 was characterized with a high BBB influx (Kin = 1.43 μL/(g x min)) and SDP2 with 
a very low BBB influx (Kin = 0.13 μL/(g x min)), the latter not significantly different from the vascular 
marker BSA. Based on our results, we can conclude that the GHR-binding potential of the selected SDPs 
is very low, requiring adaptations for further exploration.  
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SUPPLEMENTARY INFORMATION  
S1. In silico peptide mapping results 
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ABSTRACT 
With the recent successes of biopharmaceuticals, new bioanalytical tools are needed for the 
functional quality characterization of new biological entities and biosimilars towards marketing 
authorization approval and during the product life. Biosensors are emerging technologies in the 
pharmaceutical field in drug discovery, development and Quality Control (QC) stages; however, 
they are not yet included in any pharmacopoeia. Surface acoustic wave (SAW) biosensors allow the 
user to detect and quantify binding events, giving information not only on affinity (KD) and kinetics 
(kon and koff), but also on viscoelastic effects. We present here an analytical quality by design (aQbD) 
based approach using somatropin (rhGH, recombinant human growth hormone) and derivatives as 
model biotechnological drugs and an antibody interaction partner to evaluate the functional 
quality. Using techniques described in ICH Q2, Q5 and Q8-11, we evaluated the performance of this 
SAW biosensor technique from a pharmaceutical quality point of view. CMAs (Critical Method 
Attributes) such as sensitivity, selectivity and variability are evaluated as a function of different 
experimental variables using DoEs (design of experiments). We suggest qualification tests as well 
as SSTs (system suitability tests), as required by the pharmaceutical competent authorities and 
recommend the inclusion of biosensor techniques into the different pharmacopoeia and 
pharmaceutical guidelines. 
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CHAPTER VI 
SURFACE ACOUSTIC WAVE BIOSENSOR AS 
A FUNCTIONAL QUALITY METHOD IN 
PHARMACEUTICS 
Main focus in this chapter: 
? To demonstrate the utility of a surface acoustic wave (SAW) biosensor in the functional quality 
evaluation via an analytical quality by design (aQbD) based approach. 
? To stimulate the integration of biosensors and emerging techniques in pharmacopoeia and 
pharmaceutical guidelines. 
 
1. INTRODUCTION 
Biopharmaceuticals such as human growth hormone now represent approximately one in every four 
new pharmaceuticals coming on the market [1, 2]. After the expiry of their patents, the way is opened 
for the development of biosimilars, i.e. copy-versions of an already authorized biological medicinal 
product which are highly similar [3]. Many challenges come with the development and regulatory 
approval of biosimilars due to their magnitude (i.e. large primary structure with small variations 
possible), posttranslational modification (e.g. glycosylation), three-dimensional structure and protein 
aggregation. It is thus important to effectively demonstrate biosimilarity and therefore, there is an 
emerging demand for targeted analytical technologies in the regulatory approval of biosimilars [4]. 
A critical aspect in the regulatory approval of biosimilars is the side-by-side comparison at the level of 
functional quality, which is basically achieved by in vitro cell-based assays [5]. One of the parameters 
to be evaluated is the binding affinity, which is quantitatively measured as the dissociation constant 
(KD). Moreover, the European Medicines Agency (EMA) recommends the use of emerging technologies 
such as binding assays [6]. Biosensors are analytical devices, which use immobilized biological 
compounds or ligands for real time detection and/or functional characterization of analytes in samples 
[7]. They are applicable in many areas of drug discovery and development process [8-10] and can be 
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divided in different classes according to the mode of signal transduction such as optical, mass, 
electrochemical and thermal [11]. Within each of these individual classes, there are many variations in 
the instrument design. In practice, most analytical platforms in routine use optical sensing such as 
surface plasmon resonance (SPR) [12] and resonant waveguide grating [13], but also interferometric 
sensor systems are taking their position due to their high sensitivity [14, 15]. Several types of acoustic 
wave biosensors have transitioned from prototypes to robust commercial platforms [16-19] such as 
the bulk acoustic wave (BAW, e.g. quartz crystal microbalance (QCM)) and surface acoustic wave (SAW, 
e.g. love wave) sensors.  
Although the recognition of love wave biosensors was delayed due to the successes of optical and QCM 
sensors, the scientific and pharmaceutical interest in this technique is now growing for several reasons. 
First, within the acoustic wave biosensors, the love wave sensors are known for their high sensitivity. 
The wave is transmitted via an independent guiding layer (see below), thereby making operations 
possible at higher frequencies (80-300 MHz) [11] and establishing higher sensitivities (e.g. 19 pg/°mm2 
[19, 20]) compared to bulk waves in the substrate (e.g. QCM: 177 pg/Hz mm2 [21, 22]). Secondly, 
optical sensors measure only the refractive index (RI) change, which is correlated to the mass. The love 
wave sensor has two read outs: mass measured by phase changes and viscosity measured by amplitude 
changes [23-25]. This read out allows quantification of the viscoelastic properties and density of a 
protein layer [26], detection of protein conformational changes [27] and characterization of peptide-
lipid membrane interactions [28]. Thirdly, for several optical sensors such as SPR it is difficult to 
differentiate the surface RI changes (mass) from the bulk solution RI change, which makes analysis in 
complex samples (e.g. blood) difficult. Finally, SAW biosensors are also successfully applied in cell-
based label free assays [29, 30]. 
The transducer and the different parts of a love wave biosensor are shown in Figure 1. The SAW 
transducer is based on a nanogram sensitive technology that utilizes acoustic waves generated by 
oscillating a piezoelectric crystal quartz substrate. The waves are generated and measured by two 
interdigital transducers (IDT). An electric field is applied at the input IDT to generate an acoustic wave 
using the inverse piezoelectric phenomenon. After propagation through the substrate, the wave is 
reconverted into a measurable electric signal at the output IDT. In the love wave mode, the acoustic 
wave is guided through a single surface (i.e. the love wave effect). This physical effect was discovered 
by Love in 1911, who observed effects of an earthquake far from the epicentre, because the waves 
were guided through stratified geological plates. This same principle is being applied with love wave 
devices where the wave is propagated along a guiding layer. On top of the guiding layer, a sensitive 
layer is deposited on which the ligand is bound. Interactions between the immobilised ligand and 
analyte can cause modifications in the properties of the acoustic waves. Changes in amplitude are 
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related to viscoelastic and conformational characteristics, while mass changes on the surface cause 
phase shifts [11, 24, 31, 32]. 
 
 
Figure 1: Surface Acoustic Wave (Love wave mode) biosensor transducer (a) and components (b) (adopted 
from reference [19]). (a) Propagation of a mechanical wave along the z-axis is originated at the input IDT via 
an oscillating electrical field. The receiving output IDT converts the wave back into an electrical field. The love 
wave transducer is further equipped with a guiding layer and a sensitive layer, which allows the immobilization 
of ligands (e.g. antibodies). Depending on the type of sensor and the frequency, the penetration depth of the 
signal into the medium varies and the signal declines exponentially (inset). (b) Constituents of a biosensor. The 
sensor unit is composed out of the of the biosensor transducer and a flow cell which allows to run liquids over 
the surface. The liquid is pumped using a peristaltic or syringe pump. The sample is injected into the buffer 
stream using an injection valve or autosampler. 
 
The use of biosensors in pharmaceutics and GxP environments requires that these instruments and 
their generated data are reliable and suited for their purpose. Some commercial biosensor companies 
offer installation qualification (IQ), operational qualification (OQ) and preventive maintenance GxP 
packages, but no formal instrument qualification guidelines are included in any pharmacopoeia or 
provided by instances such as the European Directorate for the Quality of Medicines and Healthcare 
(EDQM). We report an analytical quality by design (aQbD) approach on a commercial SAW device to 
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obtain an analytical functional quality characterization method. Somatropin, or recombinant human 
growth hormone (rhGH), and derivatives containing NOTA-modifications [33] will be used as model 
compounds against a human growth hormone antibody (hGHAb) for the functional quality 
characterization in terms of binding affinity (KD) and kinetics (kon and koff). 
 
2. MATERIALS AND METHODS 
2.1. Materials and equipment 
Chemicals were purchased from Sigma-Aldrich (Diegem, Belgium) and Merck (Overijse, Belgium). 
Zomacton® 4 mg (Ferring, somatropin Ph. Eur.) was obtained via the Ghent University Hospital (Ghent, 
Belgium). Lyophilized NOTA-modified somatropin was in-house synthetized as described by Bracke et 
al. [33]. The monoclonal mouse antibodies against hGH (5 mg/ml) were purchased from Thermo Fisher 
Scientific (Aalst, Belgium). All aqueous solutions were prepared with ≥ 18.2 MΩ × cm quality water, 
obtained from an Arium 611 purification system (Sartorius, Göttingen, Germany). SAW experiments 
were performed with the five channel SAM®5 Blue from NanoTemper Technologies (München, 
Germany). Sensor chip, covered with a thin layer of gold, were also purchased from NanoTemper 
Technologies. All SAW experiments were performed at 22°C using HBS running buffer (10 mM HEPES 
(pH 7.4) and 150 mM NaCl) unless otherwise specified. The solutions intended for injection in the SAW 
biosensor were prepared in LoBind Eppendorf® tubes (VWR, Heverlee, Belgium) or in glass vials 
(Waters, Zellik, Belgium). Plastic vials were purchased at Grace (Breda, The Netherlands). Disposable 
PD-10 desalting columns were purchased at GE Healthcare (Diegem, Belgium). 
2.2. Preparation of a carboxymethylated dextran hydrogel chip 
The chips were first pre-cleaned by a 3 min ultrasonication in deionized water to remove salts and 
polar compounds, followed by 3 min in acetone and 3 min in isopropanol for the removal of lipophilic 
and non-polar compounds. The surface was dried in a stream of N2. To remove all organic residues 
from the gold layer, a chemical etching procedure was performed. The chip was immersed for 3 min 
in a freshly prepared boiling solution of 5:1:1 deionized water, ammonia and hydrogen peroxide at 
70°C [34-36]. Next the chip was rinsed in deionized water and dried in a stream of N2. 
Carboxymethylated (CM-) dextran hydrogel chip was prepared according to Löfås and Johnsson [37]. 
Briefly, a self-assembled monolayer with end-standing hydroxyl groups was formed by incubating the 
sensor chip in a 2 mM 11-mercapto-1-undecanol (MUD) ethanolic solution overnight. Afterwards the 
MUD modified chip was sonicated three times for 2 min in absolute ethanol. Activation of the –OH 
groups was achieved with 0.6 M epichlorohydrin in a 1:1 mixture of diglyme and 0.4 M NaOH solution. 
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After an incubation period of 4h, the chip was covered with a 0.303 g/ml dextran solution in 0.1 M 
NaOH. Finally the dextran hydrogel was carboxylated by covering the chip in a 1 M bromoacetic acid 
solution in 2 M NaOH for at least 20 h. The chip was rinsed with deionized water and air-dried. The 
chip was stored at 4°C in N2 environment to prevent microbial growth and chemical degradation. The 
CM-dextran hydrogel chips were used within the month. 
 
2.3. Method development 
Ligand immobilization 
Prior to the immobilization of ligand on a CM-dextran modified sensor chip, 10 μl of 0.1 % SDS was 
injected to wash away all non-specifically bound material on the chip followed by equilibration with 
HBS running buffer for 20 min.  
Immobilization of hGHAb or somatropins using amine coupling. The ligands were immobilized 
according to reference [38]: the chip was activated by injection of 130 μl of a 200 mM EDC and 50 mM 
NHS mixture at a flow rate of 12.5 μl/min. Three successive injections of 25 μg/ml hGHAb or 50 μg/ml 
somatropin (or derivatives) in 10 mM sodium acetate buffer pH 4.5 were carried out for 670 s to obtain 
an effective immobilization of the ligand. Finally, 130 μl of 1 M ethanolamine (pH 8.5) was injected to 
block the remaining active sites.  
Immobilization of hGHAb as somatropin:hGHAb-complex via amine coupling. A 1:1 molar equivalent 
somatropin:hGHAb solution was prepared to be immobilized directly to the surface using amine 
coupling as described before. The concentration of the complex was 25 μg/ml hGHAb and 4 μg/ml 
somatropin diluted in 10 mM sodium acetate buffer (pH 4.5).  
Immobilization of hGHAb via aldehyde coupling. Immobilization of hGHAb was performed according 
to reference [39, 40]. The sensor chip was activated with a 200 mM EDC and 50 mM NHS mixture and 
modified with a 87.5 μl-injection of 5 mM carbohydrazide in water. Any remaining active esters were 
inactivated with 130 μl injection of 1 M ethanolamine (pH 8.5). Multiple 140 μl injections of the 
oxidized-hGHAb (0.6 μg/ml) were performed in order to achieve an efficient immobilization. Finally, 
0.1 M sodium borohydride in 0.1 M sodium acetate buffer (pH 4.0) was injected for 20 min to stabilize 
the hGHAb-modified surface. 
Immobilization of hGHAb via protein G. 50 μg/ml protein G (in 10 mM sodium acetate buffer pH 4.5) 
was immobilized to the surface using amine coupling as described before. After the deactivation of the 
remaining active esters, hGHAb (25 μg/ml in HBS) was captured to protein G by three 140 μl injections. 
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Feasibility evaluation for SAW binding experiments 
For proteins, peptides or small molecules as ligand with known molecular weight, following equation 
is applied to estimate the feasibility of the method (1): 
X ൌ
୔ಽ ൈ୑୵ఽൈ୤
ୗ ൈ ୑୵ై
 ൐ 0.5 
୮୥
୫୫మ
       (1) 
Where, X: the theoretical area-concentration of bound analyte (in pg/mm2); PL: the phase shift (°) 
related to surface immobilized ligand; MwA is the molecular weight of the analyte (in pg/pmol); MwL 
is the molecular weight of the ligand (in pg/pmol); S: the conversion factor (or mass sensitivity) and is 
equipment specific (0.0515°mm2/pg) [19, 20]; f: binding stoichiometry (somatropin ligand f=0.5, 
hGHAb ligand f=2).  
This formula determines the maximum amount of analyte that can be detected, with the assumption 
that all binding sites of the immobilized ligand are available and active. This value has to exceed the 
equipment-specific limit of detection of 0.5 pg/mm2 [19, 20]. 
Relative ligand response 
The phase shifts from the different immobilization techniques were compared using normalized ligand 
response values, calculated as follows (2):  
RR% ൌ  
φୟ୬ୟ୪୷୲ୣ
φ୫ୟ୶ൗ ൈ 100       (2) 
Where, RR% = the relative ligand response (%); φanalyte = phase shift of analyte injection at 550s (°) and 
φmax = maximum phase shift upon analyte binding (°) i.e. phase shift if all immobilized ligands are 
occupied calculated with formula (1) (φ௠௔௫ ൌ  X ൈ ܵ). 
Percentage non-specific binding 
The non-specific binding of the interactions was expressed as the ratio of the BSA response to the 
analyte response (3):  
NSB% ൌ
 φ୆ୗ୅
φୟ୬ୟ୪୷୲ୣൗ  ൈ 100       (3) 
Where, NSB% = the relative amount of non-specific binding (%); φBSA = phase shift of 100 nM BSA 
injection at 550 s (°) and φanalyte = phase shift of 100 nM analyte injection at 550 s (°). 
Screening for regeneration condition 
A screening with different regeneration conditions was performed: 0.5% SDS, acetate buffer pH 4.5, 
0.5 M NaCl, 5% ethylene glycol, 1 mM NaOH and a mixture consisting of 25 mM NaOH and 0.05% SDS 
solution. After a 200 μl injection of 100 nM hGHAb, each regeneration solution was injected over the 
sensor chip surface for 60 s, followed by an equilibration time of 5 min.  
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The regeneration efficiency (RE%) of the different conditions was calculated (Figure 2), using t2 at 50 s 
prior analyte injection, t1 at approximately 300 s post analyte injection and t3 at approximately 300 s 
post regeneration injection (4): 
 
RE ሺ%ሻ ൌ
୼஦  ୰ୣ୥ୣ୬ୣ୰ୟ୲୧୭୬
୼஦  ୧୬୲ୣ୰ୟୡ୲୧୭୬
ൈ100       (4) 
 
REሺ%ሻ ൌ
஦ ୟ୤ୣ୰ ୟ୬ୟ୪୷୲ୣ ୧୬୨ୣୡ୲୧୭୬ ሺ୲భሻି ஦ ୟ୤୲ୣ୰ ୰ୣ୥ୣ୬ୣ୰ୟ୲୧୭୬ ሺ୲యሻ 
஦ ୟ୤୲ୣ୰ ୟ୬ୟ୪୷୲ୣ ୧୬୨ୣୡ୲୧୭୬ ሺ୲భሻି ஦ ୠୣ୤୭୰ୣ ୧୬୲ୣ୰ୟୡ୲୧୭୬ ሺ୲మሻ
ൈ100     (5) 
 
 
Figure 2: Regeneration efficiency (RE%) calculation. 
2.4. Functional quality characterization of somatropin and derivatives 
Somatropin and derivatives (ligand) were immobilized on a CM-dextran chip using amine coupling. The 
analyte hGHAb was diluted with HBS buffer in glass vials covering a concentration range between 
25 nM and 100 nM. Experiments were performed at a continuous flow rate of 20 μl/min using HBS 
running buffer. 200 μl of analyte was injected, followed by a 30 min dissociation and a regeneration 
step (i.e. 30 μl injection of 25 mM NaOH and 0.05% SDS, followed by two 30 μl buffer injections). For 
the control experiments 100 nM BSA was injected under the same conditions, except for the 
regeneration step, which was carried out with 0.1% SDS. In addition, a blank injection (running buffer 
without analyte) was performed prior to each binding experiment and its response was subtracted 
from the analyte response. 
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2.5. Robustness test 
The Plackett-Burman design was performed on the somatropin:hGHAb method using three factors, i.e. 
surface concentration of immobilized ligand, flow rate and temperature. For each factor, three levels 
were considered, a nominal level (center points: 70.16 pg/mm2 ligand density, 20 μl/min flow rate and 
a temperature of 22°C) and two extreme levels (Figure 6A). 
Before the formal start of the robustness test, the carboxymethylated dextran modified sensor chip 
was used for immobilization of somatropin using amine coupling at a constant flow rate (12.5 μl/min) 
and temperature (22°C), using different injections of a 50 μg/ml somatropin solution, until the desired 
surface concentration of immobilized ligand was obtained. During the robustness test, HBS was used 
as running buffer at a constant flow rate and temperature (specified in Figure 6A) for the kinetic 
binding experiments with hGHAb analyte. 200 μl, 175 μl and 225 μl injection volumes were taken for 
the analytes at a flow rate of 20 μl/min, 17.5 μl/min and 22.5 μl/min, respectively. After each analyte 
injection, a dissociation time of 30 min was applied followed by regeneration as described in Section 
2.4.  
2.6. Data analysis 
The signal obtained from a SAW biosensor is related to perturbations in wave propagation arising from 
mass changes, viscoelastic and acoustoelectric effects on the sensing surface. The phase read out is 
sensitive to both mass and viscoelastic changes, while the amplitude read out is only sensitive to 
viscous distortions. The acoustoelectric effect can be neglected by the design of the sensor chip [20]: 
a shielding layer of gold on top of the delay line (between the two IDTs) reduces the cross-talk between 
the mechanical wave and the conductive buffer. The viscoelastic effect in the phase is neglected in 
case there is no amplitude change or during kinetic evaluation when the rate in bound mass (phase 
shift) is equal to the rate in amplitude damping as observed in our study (supplementary information 
SI1).  
The kinetic constants (kon and koff) and dissociation constants (KD) were determined by fitting the 
sensorgrams to a one-to-one binding model [41, 42]. Data represent the mean ? SEM of at least two 
measurements (n ? 2). 
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3. RESULTS AND DISCUSSION 
3.1. Analytical Target Profile and Quality Target Method Profile 
In contrast to product Quality by Design (QbD) as described in the ICH guideline Q8(R2) [43], which 
emphasis product understanding, analytical QbD is a systematic approach to analytical development 
that begins with predefined objectives and emphasizes result and process understanding and process 
control, based on sound science and quality risk management (Scheme 1). 
 
The analytical target profile (ATP) is a set of criteria that define what will be measured (e.g. the affinity 
between two proteins) and the performance criteria to be achieved by the measurement (e.g. 
precision), but without specifying the method itself [44]. Different analytical methods and/or 
techniques can thus be used, e.g. SPR or ITC. In our case, the analytical target profile (ATP) includes 
kinetic and affinity values (kon, koff, KD) obtained with sufficient precision, selectivity and sensitivity. 
Moreover, an analyst’s objective within the pharmaceutical realm is to consistently obtain reliable 
data, validated as suitable for the intended purpose. Depending on the application, users validate their 
procedures and methods [45], calibrate and/or qualify their instruments as part of the quality target 
method profile (QTMP) to comply with GLP/GMP requirements. Currently, there is a need for the 
inclusion of analytical instrument qualification (AIQ) guidelines in pharmacopoeia for biosensor assays 
such as SPR, QCM and SAW biosensors, which are currently lacking. The documented AIQ 
demonstrates that an instrument is fitted for its intended purpose and proves the validity of generated 
data. 
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Scheme 1: Analytical Quality by Design approach with examples for SAW biosensors. 
 
3.2. Critical method attributes 
Sensitivity, precision and selectivity are the critical method attributes (CMAs) for the SAW biosensor’s 
ATP, which are equivalent to the product critical quality attributes (CQA) in classical QbD approaches. 
A quantitative criterion for sensitivity is the equipment specific detection limit of 0.5 pg/mm2 [20]. A 
prediction of whether a certain molecule will cause a sufficient mass change to obtain a detectable 
signal is useful to estimate the feasibility of the method (Equation (1)). This is mainly determined by 
the mass sensitivity of the equipment. Moreover, the choice of ligand immobilization plays an 
important role for the signal magnitude: ligand immobilization does not always lead to active ligand; 
the analyte binding sites can be inactive or inaccessible [46]. Therefore, the remaining activity of the 
ligand can be quantitatively compared using the relative ligand response RR%. In other words, RR% is 
a normalized value to compare the binding capability of the same ligand between different 
immobilization techniques using a certain analyte concentration, thereby giving information on the 
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signal magnitude. This value, however, does not necessarily provide information on the absolute 
amount of active ligand. The absolute amount of active ligand can be calculated using analyte 
concentrations that saturate the surface. From a practical and economical point of view, it is not always 
feasible to obtain high analyte concentrations. Therefore, it is sufficient to use one analyte 
concentration to compare the RR% between different immobilization strategies during method 
development. 
Different immobilization procedures have been described for proteins and antibodies, which can be 
categorized in two main groups: random immobilization (e.g. amine coupling) and site-directed 
immobilization (e.g. aldehyde coupling using the branched oligosaccharide N-linked to asparagine 297 
present in the Fc region [47], capturing using protein G, immobilization of preformed analyte:ligand 
complexes). Figure 3A shows the surface immobilized ligand density as well as the theoretical area 
concentration of total bound analyte, all exceeding the theoretical limit of detection of 0.5 pg/mm². 
For hGHAb (amine) ligand, we report a ligand density of 165 pg/mm2, which is lower than 2.5 ng/mm2 
reported for a close-packed side-on monolayer of antibodies [46, 48, 49]. Moreover, direct amine 
coupling of hGHAb does not ensure that all the antigen-binding sites are available for analyte binding, 
hence, the random orientation of the ligands often results in loss of antigen binding capability (RR% = 
1.14 ± 0.23%) (Figure 3B) [50]. The feasibility test could not be applied to the immobilization of the 
complex, because the increased phase shift is a result of heterogeneous immobilization of both hGHAb 
and somatropin, so the response (PL) of hGHAb ligand immobilization is unknown. In case of 
immobilization with protein G, the capturing of hGHAb via protein G led to a significant descending 
drift of the baseline over time. The phase difference between the stabilized baseline and the response 
directly after the immobilization was 5.6 ? 0.3° (equals to 108.7 ? 11.7 pg/mm2). It is most likely that 
the captured hGHAb was dissociating from the protein G as the interaction with hGHAb is a non-
covalent affinity based interaction. Therefore, the amount of hGHAb was calculated after the baseline 
had stabilized. The density of immobilized hGHAb by aldehyde coupling was extremely low (21.3 ? 8.9 
pg/mm2). This method was therefore not further included in the method development. The theoretical 
amount of bound analyte was highest for the somatropin immobilized ligand method compared to 
hGHAb immobilized methods. 
The selectivity was quantitatively expressed as NSB% using a negative control protein (e.g. BSA). The 
NSB% expresses the proportion of an analyte signal related to non-specific binding, such as interaction 
with the dextran layer and gold. The NSB% should preferably be as low as possible (Figure 3B), such as 
we report for protein G captured hGHAb ligand. In general, it should be below 10 - 20%, and if the non-
specific binding makes up more than half of the total binding, it will be very difficult to get quality data. 
The distance between the CM-dextran hydrogel surface and the sample flow increases when a linker 
molecule like protein G is used. This explains the lower adsorption effects to the sensor surface and 
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the lower NSB (NSB% = 3.0 ± 1.5%). Moreover, the recombinant protein G that was used is truncated 
(i.e. the BSA binding sites are deleted); no interaction with BSA is theoretically possible. Although 
orientated immobilization results in the highest binding capacity [46, 51], the binding capacity of 
hGHAb captured via protein G was unexpectedly low (RR% = 12.7 ± 0.7%). Most likely this is caused by 
the dissociation of the hGHAb-protein G complex after immobilization. Because the NSB was low for 
somatropin immobilized methods (NSB% = 2.4% ± 0.6) and the relative ligand response the highest 
(illustrated in Figure 3C), we used this approach as the final immobilization method. 
 
 
Figure 3: Quantitative evaluation of the CMAs. A. Surface immobilized ligand density as well as the theoretical 
area concentration of bound analyte for the different immobilization methods with hGHAb and somatropin 
ligand. B. Normalized response values (RR%, left) and percentage non-specific binding (NSB%, right) for the 
different immobilization methods. C. Illustration of specificity between hGHAb-ligand and somatropin-ligand 
immobilized surfaces (amine coupling) using analyte and BSA (negative control). 
 
The interaction between somatropin (ligand) and hGHAb (analyte) was studied (Figure 4) using the 
phase signal. In most antigen-antibody binding experiments, a simple 1:1 model is applied [52, 53]. 
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This model resulted in an average dissociation constant (KD ± SD) of 15.7 ± 1.6 nM with a model 
variability less than 6.2% and R2 of more than 0.95. The precision of the method is expressed as the 
relative standard deviation (RSD) on the averaged KD obtained from at least two channels (n≥2). For 
the somatropin:hGHAb method the precision was 10.3% (n=2). Moreover, three different somatropin 
derivatives with increasing substitution degrees were investigating using this SAW method. The 
dissociation constants (KD) were not significantly different from each other for 1:1, 3:1 and 10:1 
NOTA:somatropin (ANOVA; p>0.05) (Figure 4), with precision of 13.5% (n=5), 7.5% (n=5) and 18.3% 
(n=5), respectively. 
 
 
Figure 4: Functional quality analysis of somatropin and derivatives using hGHAb analyte. A. Typical 
sensorgrams for somatropin and 10:1 NOTAsomatropin ligands. B. Overview of the average binding constants 
(KD) and kinetic parameters (kon and koff) including standard deviation (n= number of experiments). 
 
In general, two medicinal products are considered therapeutically equivalent if their biological effect 
ratio is between 0.8 and 1.2. After simulation of the biological effect (E) using the simplified formula 
ܧ ൌ  
ா೘ೌೣ ൈ஼
ா஼ఱబ ା஼
 [with Emax: maximal effect (100%), C: concentration biological (1-300 nM) and EC50 equals 
KD], the RSD of the dissociation constant (KD) can be as high as 13-20% to still ensure a therapeutically 
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equivalent effect. In other words, as a rule of thumb, two medicinal products are considered 
therapeutically equivalent if their KD does not differ by more than 80%, all other biological 
characteristics assumed identical. Moreover, the reported maximum concentration (Cmax) for 
somatropin after administration of different short-acting formulations to healthy adults currently lies 
between 1 nM and 5 nM [54]. At these low concentrations, the allowed KD variability may be even 
larger before a significant clinical effect (i.e. outside the 80-120% effect) is expected. 
 
3.3. Risk management: critical method parameters 
The critical method parameters (CMP) that have an impact on the proposed CMA can be investigated 
by use of risk management tools such as failure mode and effect analysis (FMEA), assigning risk priority 
numbers (RPN) and construction of cause and effect diagrams [55]. For example, the SAW biosensor’s 
CMPs were categorized according to personnel, reagents, operations/measurement, environment, 
equipment and materials/consumables in an Ishikawa diagram (Figure 5A). 
As always required in the regulated pharmaceutical field, personnel should be trained and qualified to 
perform experiments with a SAW biosensor. The presence of a quality system including standard 
operating procedures (SOP) is thus very important.  
The quality of the reagents can influence the results obtained with bioassays [56]. When new running 
buffer is prepared, small variations in pH, salt or buffer concentration can influence the baseline and 
hence, the experimental variability.  
A measurement parameter is for example regeneration, which is included in case of incomplete 
dissociation of analyte from surface bound ligand (i.e. signal does not return to baseline). This step is 
included after each analyte binding cycle to remove all bound analyte from the ligand, while 
maintaining the ligands’ activity. Screening for an appropriate regeneration condition was performed 
for the hGHAb:somaropin method with 0.5% SDS, acetate buffer pH 4.5, 0.5 M NaCl, 5% ethylene 
glycol, 1 mM NaOH. None of those conditions was able to return the signal back to baseline (RE% less 
than 20%). A small drop was observed with 0.5 % SDS. Further optimization to a mixture of 25 mM 
NaOH:0.05% SDS was able to regenerate the surface (RE% of nearly 100%) without loss of activity [51].  
Environmental conditions like room temperature, humidity, vibrations and air circulation can also 
influence the variability in obtained kinetic constants. Therefore, the instrument should be installed 
on e.g. an anti-vibration surface designed for precision laboratory instruments.  
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Figure 5: Risk analysis. A. Cause and effect analysis of biosensors. B. Illustration of the importance of 
consumables such as plastic vails. Phase signals from water contained in plastic or glass vials over a 12 hour 
time frame. Water was used as running solution. 
 
As part of equipment specific CMP, the SAW equipment includes a fluidic system with a syringe pump. 
Although syringe pumps require refilling and are less suited for gradient elutions such as applied in 
HPLC, they provide the most precise and accurate delivery of fluids as well as pulsation-free and 
persistently stable flows [57]. Based upon similar HPLC pump qualification guidelines (see SI2), a 
specification limit of ± 2.0% on flow rate deviation was currently proposed (qualification results 
enclosed in SI3 Table 3.1).  
The SAW biosensor contains five channels in order to perform five measurements at the same time on 
one sensor chip. A comparison of the mean phase signals and signal scattering among different sensor 
elements was performed using glycerol solutions (SI2). The channel divergences have a RSD% less than 
2.0% in all the studies (SI3 Figure), which underline the analytical capability of the surface acoustic 
wave biosensor. The latter agrees well to the previous reported variations on channel divergence [57]. 
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Injector precision and carry-over was evaluated based on the EDQM guidelines for HPLC equipment 
(SI2). The precision of the phase response was evaluated with repetitive injections of 5% glycerol for 
each channel. The RSD of the phase shift areas (PSA) of all injections in the sensorgram was below 1.0% 
(SI3 Table 2). For carry-over, the percentage of the PSA corresponding to glycerol in the blank injection 
was below 1.0% for all channels compared to a previous injected 5% glycerol sample (SI3 Table 2). 
High quality materials and consumables are critical. The chip quality is evidently a critical aspect, e.g. 
the state of the plain gold surface has a major impact on the modification. The sensitive area may be 
damaged by erosion of gold and the physical properties (e.g. wettability) may have changed [58]. 
Heterogeneity of the CM-dextran hydrogel can occur, which can result in different dextran hydrogel 
densities and therefore, different surface ligand immobilization quantities. Moreover, not only the 
chip, but also other consumables used will influence the analytical outcome, e.g. the vials used 
containing the analyte solutions. The use of plastic vials can give unwanted signals as demonstrated by 
incubation of water in plastic PP vials compared to water signals obtained from glass vials (Figure 5B). 
3.4. Method Operable Design Region 
The method operable design region (MODR), equivalent to analytical design space (aDS), is a science 
and risk based, multivariate approach to evaluate effects of various CMPs on CMAs and hence the ATP. 
Typically DoE (Design of Experiment), such as response surface designs (RSD), is used to find ranges for 
instrument operating parameters, to understand sample preparation variations and variations of 
method precision. 
Because a low variability is a prime aim of an analytical QbD, it is important that an analytical method 
is reproducible in different laboratories or under different circumstances which can be simulated in a 
robustness test. The Plackett-Burman design (PBD) is designed to investigate to which degree small 
but deliberate variations in potentially critical method parameters effect the results [59]. For example, 
the factors investigated in the robustness evaluation of the hGHAb based method were concentration 
of immobilized ligand (somatropin), flow rate and temperature (Figure 6A). A rational choice of the 
levels applied in the design is critical. Based on the somatropin immobilization results (Figure 3), a 99% 
confidence interval was taken to determine the ‘extreme’ levels for the surface-bound ligand 
concentrations (here, approximately [60.92 pg/mm2;71.02 pg/mm2]). For the levels of the flow rate, 
we were bound to the limitations of the equipment: a lower and upper level of 17.5 μl/min and 22.5 
μl/min were taken. For the selection of the extreme temperature levels, the temperature of 22°C as 
used in the somatropin-hGHAb method was taken with a ± 10% margin, which is in the range of the 
surface-bound ligand concentration and flow rate levels. We found that the proposed MODR had no 
significant effect on the dissociation constant (KD). However, a slight negative effect of surface-bound 
ligand concentrations on the kon and koff kinetic parameters was observed (Figure 6B). 
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3.5. Control strategy 
The control strategy includes the definition of the operating range of CMPs, which is dependent on the 
criticality level of the factor and based upon the DoE results, e.g. maintaining flow rate between 17.5 
and 22.5 μl/min in the somatropin-hGHAb method. Moreover, inclusion of additional instrument 
checks such as system suitability tests (SSTs) help ensure that the required data is reliable. For example, 
the specificity of a binding assay can easily be monitored by inclusion of a 100 nM BSA injection. 
Comparison with a standardized reference analyte hGHAb solution (100 nM) indicates that at 
equilibrium (i.e. at 550s) a difference in phase shift of 5° is required to be obtained. 
 
3.6. Continual improvement 
Once the SAW biosensor method is developed and has demonstrated performance and stability, 
continuous improvement fundamentally aims to reduce the common-cause variability over kinetic 
data. Control charts and capability analysis provides the analyst with a measure how well his biosensor 
method is performing relative to the analytical requirements.  
 
 
Figure 6: Plackett-Burman robustness test for a SAW biosensor. A. Selected factors and effects. B. Contour plot 
representation of surface immobilized ligand and flow rate effect on kon and koff (at constant temperature of 
22°C). 
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4. CONCLUSION 
The concepts described in ICH Q2, Q5 and Q8-Q11, commonly referred to as Quality by Design (QbD), 
are nowadays applied to the development of analytical methods. Although these approaches offer 
more flexibility for analytical methods, they require (i) high degree of process, product and analytical 
method understanding and (ii) robust quality systems. We have outlined the different aspects of aQbD 
with specific examples for SAW biosensors from a pharmaceutical quality point of view. We suggest 
instrument qualification tests such as injector repeatability as well as SSTs (system suitability tests) e.g. 
specificity evaluation, as required by the pharmaceutical competent authorities and recommend the 
inclusion of these analytical biosensor techniques into the different pharmacopoeia and 
pharmaceutical guidelines. 
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SUPPLEMENTARY INFORMATION  
S1. Viscoelastic wave perturbation 
S2. Instrument qualification methodology 
S3. Instrument qualification results 
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S1. Viscoelastic wave perturbation 
The viscoelastic effect in the phase signal can be ignored during kinetic studies when the rate in bound 
mass (phase) is equal to the rate in amplitude damping (Figure S1). The amplitude damping upon 
analyte binding is caused by the intrinsic viscoelasticity of the bound analyte.  
 
 
Figure S1: Binding of hGHAb analyte to 1:1 NOTAsomatropin (ligand) 
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S2. Instrument qualification methodology 
Qualification of the external pump unit 
The flow rate was set between 12.5 - 100 μl/min and the time needed to fill the volumetric flask up to 
the mark (V = 2 ml) was measured and recorded. The measured flow rate was calculated as follows: 
f ൌ  
V ∗ 60
t
 
Where, f: measured flow rate (in ml/min); t: elapsed time to fill up to the mark of the volumetric flask 
(s); V: volume of the volumetric flask (ml). 
The deviation was calculated as follows: 
D ൌ
f െ F
F
∗ 100Where, 
Where, D: deviation (%); f: measured flow rate (ml/min); F: set flow rate (ml/min). 
 
Qualification of the sensor unit 
The sensor unit consisting of i.a. the interdigital transducers (IDTs), sensor chip and electrical contacts, 
was qualified with the following concentrations of glycerol (m/V): 0% (blank = water), 1%, 2%, 5%, 10%, 
20%, 30%. Water was used as running solution at a continuous flow rate of 20 μl/min and at constant 
temperature of 20°C. A chip with a plain gold layer was inserted in the instrument and equilibrated for 
5 min. 80 μl of each sample were injected, followed by a 5 min equilibration during which only water 
was passed over the surface. The mean phase shift signal at 60s after injection of a single glycerol 
concentration was calculated over the five independent sensor channels as well as the RSD. 
 
Qualification of the autosampler unit 
The injector repeatability was investigated using six successive injections of 5% glycerol. Carry-over 
was investigated by successive injections of 5% glycerol and running solution (i.e. water). The same 
experimental parameters as described above were applicable. The phase shift areas (PSA) were 
calculated from -60s pre-injection until 110s post-injection using: 
PSA ൌ  ෍ ቆ
ሺy୧ ൅ y୧ିଵሻ
2
∗ ሺx୧ െ x୧ିଵሻቇ
୬
୧ୀଵ
  
The mean PSA of the six injections with 5% glycerol (injector repeatability) over each channel was 
individually calculated as well as the RSD. For carry-over, the ratio was calculated by dividing the PSA 
corresponding to glycerol in the blank injection by the glycerol response from the 5% glycerol sample.  
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S3. Instrument qualification results 
 
Table S3.1: Flow rate accuracy of the external pump unit 
Set flow rate (μl/min) 
Measured flow rate 
(μl/min) 
Deviation (%) |Deviation| 
12.5 12.50 0.03 0.03 
20 20.00 0.02 0.02 
40 39.95 -0.13 0.13 
40 40.13 0.33 0.33 
60 60.12 0.20 0.20 
60 59.58 -0.70 0.70 
100 99.75 -0.25 0.25 
  Average 0.24 
  99% confidence interval [0.01; 0.46] 
 
 
 
 
Table S3.2: Qualification of the autosampler unit 
 Injector repeatability Injector carry-over 
 Mean PSA (°) RSD (%) Ratio peak areas (%) 
Channel 1 585.09 0.63 0.42 
Channel 2 589.90 0.15 0.45 
Channel 3 599.02 0.17 0.36 
Channel 4 614.37 0.30 0.41 
Channel 5 619.16 0.29 0.54 
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Figure S3.1: Channel divergences (RSD) in phase and amplitude signals upon different glycerol 
concentrations. A. Phase signal channel divergence (n=5). B. Amplitude signal channel divergence (n=5). 
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“The best way to have a good idea is to have lots of ideas”  
 
Linus Pauling 
(°1901 - †1994, Chemist and biochemist) 
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CHAPTER VII 
BROADER INTERNATIONAL CONTEXT, 
RELEVANCE & FUTURE PERSPECTIVES 
1. BROADER INTERNATIONAL CONTEXT AND RELEVANCE 
At the start of this project, the functional quality of the molecules was a key concept of our research 
group. The functional quality evaluates not only the chemical composition of the compounds, but also 
relates this knowledge to its biological/medicinal functionality. It is a two-way concept: the 
functionality determines the required quality characteristics (QbD principles), but also the quality 
influences the functionality (e.g. enhanced toxicity or decreased efficacy due to increased impurities). 
Moreover, this approach makes quality less spatio-temporal dependent. This concept of appropriate 
quality is valid not only for discovery and R&D stages, but also during the whole life cycle of the 
medicinal product. The following paragraphs position the obtained research results within a broader 
international context and relates their relevance to separate social and scientific fields. 
 
Improving the lives of millions of people around the world is the ultimate goal of research and industry. 
The broad medicinal product landscape, i.e. from small molecule to biologics, allows the treatment of 
many diseases and the visualization of diverse targets. As the patents of these small molecules and 
biologics expire, the generics and biosimilars are coming into play. Also me-too (i.e. new agents against 
known targets) and biobetters (i.e. biologics with improved characteristics e.g. efficacy, 
pharmacodynamics or pharmacokinetics) broadens the strategic route for the pharmaceutical 
development. In general, during discovery, R&D and commercial productions, the costs of 
biologics/biosimilars currently exceeds the costs of small molecule drugs/generics, as their production 
and characterization is considered more challenging. One clone can lead to different structural variants 
originating from truncations and post-translational modifications during expression, 
chemical/enzymatic processing and manufacturing. Not only the chemical characterization should be 
aimed for, but also as early as possible the functional characterization, i.e. is the compound (and all its 
variants) under investigation able to adequately bind to the target(s) of interest? Our methodologies 
of high performance receptor binding chromatography/size exclusion chromatography (HPRBC/SEC) 
and native MS, can be applied on standard equipment used for the physicochemical characterization 
of biologics, thereby evaluating their target binding capacity. The functionality results are comparable 
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to the cellular assays which are generally more time consuming (e.g. time for culturing/growing cells). 
The in vitro techniques can also replace/reduce the in vivo experiments, thereby contributing to the 
“Three Rs” principle for animals used for scientific purposes. In fact, the “Three Rs” principle is a firm 
legal requirement in the EU [1].  
The inherent complexity of biologics leads to shifts in technological advancements, in regard to more 
specialised characterization technologies and methods which can encounter the complexity of these 
macromolecular structures. For example, the commercialisation of the SAW biosensor is very recent 
(sales started in 2010) and transformation of this equipment to a GMP compliant system is so far not 
set. Moreover, these emerging technologies have not been translated to pharmacopoeia or regulatory 
guidelines and the industry has to struggle with the build in of these new techniques within their 
pharmaceutical quality system. Analytical quality by design (aQbD) is a tool applicable for new 
emerging technologies such as biosensors. 
 
These functional characterization techniques in combination with physicochemical characterization 
can also be applied for the detection of “substandard, spurious, falsely labelled, falsified and 
counterfeit (SSFFC)” as defined by the WHO [2]. It is a worldwide problem that is situated not only in 
developing and low income countries, but also affects the western industrialized countries. The SSFFC 
medicinal products profit from the globalization, information access and freedom of the individual. 
They can be found on unregulated websites and in illegal street markets, but have also found their way 
into pharmacies, clinics and hospitals. For their detection, in some cases, we cannot rely on the 
packaging alone, but also need a thorough analysis to determine their “status” [3-5]. However, not 
only the excipients can have an impact on the stability of biopharmaceuticals [6], but also their three 
dimensional structure can dictate its functionality. For example, an altered three-dimensional 
structure can be the result of a disulphide bond exchange between cysteines leading to a loss of activity 
[7, 8]. The more traditional analytical techniques can therefore lack the required sensitivity and 
selectivity to fully characterize their quality and/or origin and a functional characterization can be a 
useful addition. 
 
Cancer is still the major cause of death, with approximately 8.2 million deaths each year [9]. It is 
defined as a large group of diseases that can affect any part of the body, caused by abnormal cell 
growth with the potential to spread in the body. Cancer originate from the uncorrected transformation 
of one cell and is induced by the interaction between the person’s genetic factors and external agents 
such as infections (e.g. human papilloma virus), radiation and components of tobacco smoke [9]. The 
cancers that cause the most deaths are cancer from liver (745 000 deaths), stomach (723 000 deaths), 
colorectal (694 000 deaths), breast (521 000 deaths) and oesophageal cancer (400 000 deaths). In 2012 
  CHAPTER VII - BROADER INTERNATIONAL CONTEXT, RELEVANCE & FUTURE PERSPECTIVES 
 
 
207 
only, there were 14 million new cancer cases, and it is expected that this number will only increase in 
the next decades [10]. This harsh reality still drives the main focus of the pharmaceutical industry 
toward the therapeutic area ‘oncology’, for example, more than 30% of the FDA’s new drug approvals 
in 2015 have applications in oncology [11]. More patients are treated each year with chemotherapy in 
Europe, Japan and North America, but also newer markets such as China, Brazil, India, Turkey and 
Russia receive access to the most innovative therapies. Almost all international pharmaceutical 
companies are currently active in oncology (e.g. Amgen, Astra-Zeneca, Bristol-Myers-Squibb, Eli-Lilly, 
GlaxoSmithKline, Johnson & Johnson, Merck KGaA, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth). 
Also the diagnostic and therapeutic radiopharmaca, e.g. products from Bristol-Myers-Squibb and GE 
Medical, are important players. The model compounds in this project, NOTA-modified somatropins 
and somatropin-derived peptides have potentially a broad applicability in this field. The development 
of functional NOTA-modified somatropins as theranostics in cancer or growth hormone receptor 
(GHR)-related diseases is still in its infancy and a long way to clinical use is ahead. For the NOTA-
modified somatropins, the development builds further on somatropin which already has a marketing 
approval for indications, therefore makes it more efficient to develop derivatives for different 
applications. Although we did not aim for a novel pharmacokinetic and/or pharmacodynamic outcome, 
we introduced a bifunctional chelating agent NOTA to create a different functionality. From a 
regulatory point of view, the NOTA-modified somatropin is a new chemical entity. Applications follow 
the established regulatory pathways for a new chemical entity in both the US and the EU. However, it 
is clear that the risk/benefit assessment of NOTA-modified somatropins will regulatory-wise be less 
demanding compared to a total new entity. 
The GHR was introduced here as a potential target for the development of ligand-targeted antitumor 
medicines. In Belgium alone, there were 65,847 new cancer diagnoses in 2014, whereof 7,953 prostate 
cancer patients, 10,466 breast cancer patients and 2,925 melanoma cancer patients [12]; all cancers 
with a potential overexpression of the GHR. The somatropin derivatives can therefore be explored for 
diagnostic applications (e.g. imaging and prediction of individual tumour responsiveness), as well as a 
therapeutic applications (killing of the tumour), hence, contributing to the development of 
personalised medicines. Next to their direct medical potential application, the new NOTA-modified 
somatropins can be used for fundamental research with more long-term medical applicability. 
Different international research groups (e.g. the Perry group (University of Auckland, New Zealand), 
the Clayton group (University of Manchester, UK) and the Waters group (University of Queensland, 
Australia)) are investigating the physiological fundamentals of the pleiotropic GH/GHR system, 
including its immunological role: it enhances the bacterial killing capacity of PMN neutrophils, which is 
at least partly due to the stimulation of superoxide secretion [13-16]. 
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The somatropin derivatives can be further explored toward the detection and imaging of the  
(over-)expressed receptor in in vitro/ex vivo/in vivo models. Moreover, once the importance of 
somatropin in the brain is confirmed, the somatropin derivatives can also find useful applications there 
as well. Given the pleiotropic activity, this can be expanded in the future. 
 
Peptides are established entities that have found their place within the medicinal products [17]. 
Peptides offer a potentially higher selectivity, lower toxicity and wide range of chemical diversity 
compared to the small molecules. Compared to biologics, peptides can be produced via chemical 
synthesis in a more consistent and controlled way, and they don’t require time and cost consuming 
sub-culturing and upscaling of expression hosts as for biologics. From an economical point of view, the 
cheaper production cost will be reflected in the final lower pricing, making these type of medicinal 
products globally more affordable. The idea to select a peptide over a small molecule for targeting 
protein-protein interactions comes from the lack of the small grooves and clefts within the binding 
surface and the presence of larger and flatter surfaces, which are more difficult to target with a small 
molecule. Although we did not yet found functionality with our selected somatropin-derived peptides 
(SDP) under our experimental conditions, the idea of developing functional peptides (i.e. receptor 
binding functionality) from an endogenous or biopharmaceutical protein offers new scaffolds and 
therapeutic strategies for further exploration. Therefore, more research toward crypteins and active 
metabolites can offer new insights and applicability. 
 
Another hurdle in the analytics of peptides is adsorption, which results in inaccurate and imprecise 
quantification [18]. Developing strategies like the DruQuaR diluent offers a broad applicability for 
research and industrial settings.  
 
Finally, during this research the emphasis was made on the blood-brain barrier (BBB), because we 
highly encourage the inclusion of the BBB transport characterization in research and pharmaceutical 
development. For example, the Brainpeps database is a collection of all reported BBB peptides and 
amounts only 223 peptides [19]. This demonstrates that still too less is known on the 
pharmacodynamic and pharmacokinetic properties of peptides and protein compounds at the BBB. 
The more this barrier is included in studies, the more effective the rational development will be for 
therapies targeting diseases in the central nervous system (CNS).  
 
To conclude, our project goal and objectives resulted in a broad application potential in research and 
industrial settings.  
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2. FUTURE PERSPECTIVES 
Our research goal was centralised around two groups of model compounds derived from somatropin, 
i.e. NOTA-modified somatropins and somatropin-derived peptides, for the functional quality 
evaluation toward theranostic applications. Despite their chemical complexity, the NOTA-modified 
somatropins behaved functionally similar as unmodified somatropin in terms of pharmacodynamic 
(target-binding functionality) and pharmacokinetic (BBB kinetics) profiles. However, are these 
compounds selective for targeting GHR-overexpressing cells and tumours in vivo? And what are the 
possible next steps? 
The concept of Paul Ehrlich’s “magic bullet” has been translated to describe drugs that go straight to 
their intended target cells via the selective interaction between a ligand and the receptor or antigen 
expressed on the target cell [20]. However, their development requires further investigation of some 
pathophysiological properties of solid tumours. Ligand-targeted antitumor medicines, such as 
macromolecules and nanoparticles (with diameters of <600 nm), can benefit from the enhanced 
permeability and retention (EPR) effects [21]. Due to this effect, compounds tend to accumulate much 
more in tumours via ‘untargeted’ passive diffusion than in normal tissues as a result of abnormal and 
leaky tumour vasculature. However, this favourable effect is heterogenous among tumours and within 
patients [22, 23]. Additionally, once passed through the tumour vasculature, other barriers are 
sometimes present which need to be overcome such as muscle cell layers, endothelial cell layers and 
a high interstitial fluid pressure to reach the target cells [24, 25]. Also the investigation of a possible 
binding-site-barrier, i.e. binding to the first receptors the ligand encounters which results in the 
limitation of further penetration into the tumour [26].  
Another essential step in the evaluation of the NOTA-modified somatropins is the in vivo specificity, 
i.e. the determination of the biodistribution in animal models (e.g. mouse xenograft) or patients to 
assess the ratio of compound uptake in tumours versus normal tissue [27]. Knowledge on the in vivo 
specificity allows to predict toxicity and dose requirements [28]. However, care should be taken to 
translate data from in vivo animal studies to a human context. Tumours of 1 cm in diameter grown in 
rodents within 2-3 weeks can differ significantly from tumours developed in patients, which would 
take more than a year to reach that size. As a result, the architecture of the tumour (e.g. vasculature, 
barrier, pressure) is often very different [23].  
The ultimate goal of personalized medicines is to predict the patients response to a targeted 
treatment. Based on genomic and molecular abnormalities specific to certain types of cancer, an 
individual patient therapy can be selected [29]. For example, 20-25% of the breast cancers are HER2 
positive and for some positive cancers, treatment with trastuzumab (Herceptin) can be beneficial [30, 
31]. The development of diagnostic and therapeutic, or theranostic, personalized medicines goes often 
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hand in hand [32]. Chelation of the NOTA-modified somatropins with 67Ga and 68Ga offers single 
photon emission computed tomography (SPECT) and positron emission tomography (PET) diagnostic 
applications for the imaging of GHR-overexpressing tumours as well as to monitor the tumour 
accumulation (which is dependent on tumour penetration) for preselection of patients. We suggest to 
start this research with one type of cancer in which the GHR is definitely overexpressed. If confirmed 
(also with metastases), then therapeutic use can be explored with, for example, 90Y-labeled NOTA-
modified somatropins. Yttrium-90 is a pure β-emitter with a high energy and a particle range of up to 
12 mm, which makes it suitable for the irradiation of large tumours [33]. However, the complexation 
stability of 90Y within the NOTA bifunctional chelating agent (BFCA) is very important as radioyttrium 
is rapidly directed to the bone. Moreover, yttrium-labelled NOTA-modified somatropin and gallium-
labelled NOTA-modified somatropin can have a different pharmacodynamic and pharmacokinetic 
outcome. Therefore, these studies should need to be considered as well.  
To conclude, further research is required to confirm, quantitate and more understand our current 
research results and explore these compounds in vivo by preclinical studies (mouse xenograft, ADMET, 
etc.) and phase 0/I human clinical trials.  
 
In order to conduct pharmacokinetic (ADMET) studies and to generate bioavailability data, a 
bioanalytical method development is required to quantify the NOTA-modified somatropins in different 
matrices (e.g. plasma, tissue, etc.). Nowadays, LC-MS/MS approaches are replacing traditional ligand 
binding assays for the bioanalytical determination of protein-based biopharmaceuticals [34]. However, 
several analytical challenges lie ahead in the development phases. Many other proteins are aberrantly 
present in plasma such as serum albumin (millimolar range), as well as endogenous growth hormone 
(picomolar range) [35]. Therefore, emphasis should be made on sample preparation and the selectivity 
of the method, as well as on the other requirements for bioanalytical method validation [36]. 
 
Are the SDPs a “no go” for further development of ligand-targeted antitumor medicines? One of the 
objectives for ligand-targeted antitumor medicines is a relatively high affinity interaction between the 
compound(s) under investigation and the target [37]. Although we have not immediately found a 
peptide binder to the target of interest, the SDPs are still an option, but not so straightforward and 
thus, require more focused research (and more time). For example, peptide-mers such as peptide-
tetramers can be investigated in analogy to the peptide dimers for erythropoietin receptor activation 
and the neurotensin-tetramers [38, 39]. These examples show that an inactive peptide can be 
converted into a weak agonist, that peptide-mers can have an increased binding affinity to the receptor 
and that peptides-mers can show an increased metabolic half-life. Another strategy that can be applied 
in the search for somatropin-derived peptide binders is a combination of proteolytic digestion of 
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somatropin, which is then used as analyte for SPR or SAW biosensor binding studies using an 
immobilized hGHBp combined with mass spectrometry for identification [40]. 
To conclude, our research has formed the basis for the development of somatropin-derived peptides. 
Due to the general properties of peptides, we believe that further investigation toward the 
development of those peptides is a promising direction to take. 
 
The BBB influx and brain distribution (parenchyma versus capillaries) was characterized for the NOTA-
modified somatropins and the SDPs. A clear significant influx was demonstrated for the compounds 
under investigation together with a high parenchymal distribution. A question that remains 
unanswered is the mechanism used to penetrate into the brains. Further pharmacodynamic studies 
can be explored to characterize the transport mechanism at the BBB. Moreover, the in vivo BBB study 
of selected SDPs demonstrated peptides characterized with a very low influx and a high influx. Our 
laboratory has developed a Brainpeps database collecting the BBB transport data from literature [19]. 
The larger a dataset is, the more accurate one can extract the quantitative structure-activity/property 
relationship (QSAR) toward BBB influx. The data from the Brainpeps database together with our in-
house BBB data can attribute to the rational design of peptide drugs targeting the central nervous 
system (CNS).  
Somatropin is related to several effects in the brain and our results confirm that systemic administered 
somatropin derivatives pass the BBB. Therefore, the NOTA-modified somatropins offer opportunities 
for imaging of the GH mechanistic actions in the brain. Moreover, it is reported that aging results in 
increased BBB permeability [41] and evidence points to a link between this dysfunction and 
promotion/progression of Alzheimer’s and Parkinson’s disease [41-43]. The impact of the somatropin 
derivatives in these highly permeable barrier conditions can be explored as well. 
 
As the complexity of biologics exceeds those of the classical small molecules, there is a growing need 
to develop new technologies, techniques and methods for their detailed pharmaceutical quality 
characterization. Indeed, several emerging technologies have proven their value, but the integration 
within GMP/GLP environments is hampered by the lack of pharmaceutical guidelines and their 
inclusion in pharmacopoeia. Therefore, we performed a regulatory quality research on a SAW 
biosensor using an analytical Quality by Design approach. This aQbD approach can be further explored 
to other emerging techniques such as circular dichroism (CD), an optical technique used to quantify 
the secondary structure of a protein or peptide, which is currently under investigation in different labs 
including DruQuaR. 
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In conclusion, our research is only the start of exploring the use of NOTA-modified somatropins and 
somatropin-derived peptides in GHR related diseases and actions. Moreover, we highly stimulate the 
inclusion of emerging techniques such as biosensors in pharmacopoeia and pharmaceutical guidelines 
and more data about protein and peptide BBB.  
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SUMMARY & GENERAL CONCLUSIONS 
With the growing evidence that growth hormone (GH) is involved in tumour progression and that the 
growth hormone receptor (GHR) is overexpressed on different tumours and cell lines, this research 
was focused on the functional quality of somatropin (i.e. recombinant GH) derivatives for theranostic 
applications: 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)-modified somatropins and 
somatropin-derived peptides (SDPs). 
As introduced in Chapter I, somatropin is a protein and falls under the umbrella of the biologics, a 
complex class within the medicinal products. Inherent to their size and way of production, these 
products own a large variability which require more advanced analytical strategies in order to 
chemically and functionally characterize these products. Moreover, NOTA is a bifunctional chelating 
agent that allows the incorporation of radiometals for therapeutic or single-photon emission 
computed tomography/positron emission tomography (SPECT/PET)-research. However, when 
conjugated to proteins, extra variability is introduced, which require in depth analysis on the functional 
impact. Indeed, the presence of multiple reactive sites on biomolecules used for chemical 
modifications during conjugation reactions, can lead to complex product mixtures. Therefore, the 
chemical composition of the synthesized NOTA-modified somatropins was first investigated. In 
Chapter II, we analytically characterized the products originating from three different synthesis 
procedures (i.e. equimolar (1:1 NOTA:somatropin), three times (3:1 NOTA:somatropin) and ten times 
(10:1 NOTA:somatropin) molar excess of NOTA compared to somatropin). Using complementary 
analytical techniques, i.e. direct analytical and bottom-up approaches, the results were confirmed. The 
1:1 NOTA:somatropin synthesis procedure yielded the highest mono-NOTA-somatropin fraction (42%) 
with less higher order substitution degrees (≥2 NOTAs, 12%), while 10:1 NOTA:somatropin contained 
more higher order substitution degrees (47% with 3 NOTAs). Lys-70 followed by Lys-158 were the most 
reactive towards p-SCN-Bn-NOTA and Lys-140 and Lys-172 were the less reactive lysine residues. This 
result was supported by the in silico calculated lowest pKa value of 8.3 for Lys-70. Moreover, gallium 
chelation of NOTA-somatropin resulted in a 100% complexation.  
Are the NOTA-modified somatropins functional in in vitro settings? Using high performance receptor 
binding/size exclusion chromatography (HPRBC/SEC) and native MS techniques in chapter III, we 
demonstrated that different NOTA-substituted somatropins, including gallium chelated NOTA-
moieties, were able to dimerize the human growth hormone binding protein (hGHBp) and that 
products with a substitution degree of 4 NOTAs were functional for hGHBp-binding. The human GHR 
bioassay, a cell-based functional assay with full length receptor using the JAK2 target, demonstrated a 
similar efficacy (127-163%) and potency (179-228 pM) of all investigated compounds (i.e. somatropin 
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and the NOTA-modified samples), in which the potency and efficacy were not significantly different. 
Furthermore, we demonstrated that techniques such as SEC and MS, classically used in the 
physicochemical characterization of proteins, have a potential use in the functionality evaluation in 
drug discovery, development and quality control settings. 
In general, modifications on proteins can not only affect receptor/target binding; however, they can 
also result in a different pharmacokinetic profile. One of the barriers of interest is the blood-brain 
barrier (BBB). Currently, the knowledge on the influence of bifunctional chelators when conjugated 
onto proteins, such as somatropin, and their BBB transport behaviour is limited. Therefore, the 
influence of NOTA-modified proteins on the blood-brain barrier (BBB) behaviour was investigated in 
chapter IV using an in vivo mouse model. Somatropin, 10:1 NOTA:somatropin and Ga-10:1 
NOTA:somatropin all showed a low brain influx rate (Kin = 0.38 ± 0.14 μL/(g × min), 0.36 ± 0.16 μL/(g × 
min) and 0.28 ± 0.18 μL/(g × min), respectively), which were not significantly different from each other. 
Capillary depletion was performed to investigate the distribution within the brain and resulted in a 
high parenchymal brain distribution (> 80%) for all compounds. Somatropin and 
10:1 NOTA:somatropin had a pronounced tissue distribution to liver, kidney and serum, while Ga-10:1 
NOTA:somatropin showed a somewhat different tissue distribution profile with a high serum level and 
no preferential tissue distribution. Furthermore, the compounds showed a relative high in vivo 
metabolic stability during the timeframe of the study (T1/2 between 17-30 minutes). Our results show 
that modification of NOTAs, including gallium chelation, onto a protein characterized with a low brain 
influx, does not lead to a changed pharmacokinetic profile at the blood-brain barrier. 
Next to the protein part within this thesis, also SDPs were investigated as these compounds are 
generally more cost-efficiently produced, more chemically under control and own higher tissue 
penetration properties. The potential of SDPs as new alternatives was explored in chapter V with the 
central research question ”Can somatropin-derived peptides be theranostic alternatives for their 
protein counterpart?”. First, a chemical and stability characterization of selected SDPs (SDP1-6) was 
performed and revealed a purity of more than 90% as well as a high chemical and metabolic stability: 
all peptides were stable in buffer, brain, liver and serum (T1/2 > 15 min). Then, the functionality toward 
GHR/GHBp binding was evaluated using native MS and the GHR bioassay; however, under our 
experimental conditions, we could not detect interaction of the SDPs to the receptor. In parallel, two 
peptides (SDP2 and SDP6) were selected based on their position within somatropin and their metabolic 
stability profile for a first pharmacokinetic evaluation with emphasis on the BBB transport. Both 
peptides showed a significant brain influx in the in vivo mouse model, with SDP6 (Kin = 1.43 ± 0.28 μL/(g 
x min)) and SDP2 (Kin = 0.13 ± 0.10 μL/(g x min)) classified as a high and very low BBB influx. Based on 
our results, we can conclude that the GHR-binding potential of the selected SDPs is very low, requiring 
adaptations for further exploration. 
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In line with the DruQuaR tradition, a regulatory quality aspect of this research is included. In 
chapter VI, we focused on emerging techniques which contribute to the functional quality assessment 
of biopharmaceuticals. More specifically, we investigated the applicability of a Surface Acoustic Wave 
(SAW) biosensors within the functional quality control. SAW biosensors allow the user to detect and 
quantify molecular binding events, giving information not only on affinity (KD) and kinetics (kon and koff), 
but also on viscoelastic effects. Using an analytical Quality-by-Design (aQbD) approach, the 
performance of the SAW biosensor was evaluated from a pharmaceutical quality point of view, using 
somatropin and NOTA-derivatives as model biotechnological drugs and an antibody interaction 
partner. CMAs (Critical Method Attributes) such as selectivity and variability were evaluated as a 
function of different experimental variables using DoEs (design of experiments). We suggested 
qualification tests as well as SSTs (system suitability tests), as required by the pharmaceutical 
competent authorities and recommend the inclusion of biosensor techniques into the different 
pharmacopoeia and pharmaceutical guidelines and their implementation within functional quality 
assessments. 
Finally, in chapter VII, we discussed the broader international context, relevance and future 
perspectives related to this research. The different topics handled in this research contributed to a 
broad potential application of the used model compounds and functional quality techniques/vision in 
research and industrial settings. Our research was only the start of exploring the use of NOTA-modified 
somatropins and somatropin-derived peptides in GHR related diseases. Moreover, we also highly 
stimulate the inclusion of emerging techniques such as biosensors in pharmacopoeia and 
pharmaceutical guidelines, as well as the generation of more data on proteins, peptides and their BBB 
behaviour. 
Overall, this research contributed to the development of NOTA-modified somatropin derivatives with 
similar pharmacodynamic (target-binding functionality) and pharmacokinetic (BBB kinetics) profiles as 
the unmodified somatropin. This knowledge is highly appreciated for the further development of 
ligand-targeted antitumor medicines toward GHR-overexpressing tumours. 
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“Het allerbelangrijkste is nooit te stoppen met vragen.” 
 
Albert Einstein 
(°1879 - †1955, TheoreƟcal Physicist) 
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SAMENVATTING & ALGEMENE CONCLUSIES 
Steeds meer aanwijzingen duiden erop dat groeihormoon (GH) betrokken is bij tumorprogressie, 
alsook dat de groeihormoonreceptor (GHR) wordt overgeëxpresseerd op verschillende tumoren en 
tumorcellijnen. Met dit gegeven richtte dit onderzoek zich op de functionele kwaliteit van somatropine 
(recombinant GH) derivaten voor theranostische applicaties: 1,4,7-triazacyclononaan-1,4,7-
triazijnzuur (NOTA)-gemodificeerde somatropines en somatropine afgeleide peptiden (SAP’s).  
Zoals geïntroduceerd in hoofdstuk I, is somatropine een proteïne en valt het onder de paraplu van de 
biologics, een complexe klasse binnen het geneesmiddelen landschap. Inherent aan hun grootte en de 
manier van productie, bezitten deze producten over een grote variabiliteit. Deze producten hebben 
bijgevolg ook meer nood aan geavanceerde analytische strategieën om hun chemische samenstelling 
en functionaliteit te karakteriseren. Bovendien is NOTA een bifunctioneel chelerend middel dat de 
opname van radiometalen voor therapeutisch of single-photon emission computed tomography 
(SPECT) / positron emissie tomografie (PET)-onderzoek mogelijk maakt. Echter, wanneer geconjugeerd 
aan proteïnen, wordt er extra variabiliteit gegenereerd, waardoor er een diepgaande analyse nodig is 
die de functionele impact van deze modificaties kwantificeert. Inderdaad, de aanwezigheid van 
meerdere reactieve plaatsen op biomoleculen gebruikt voor chemische modificaties tijdens conjugatie 
reacties, kunnen leiden tot complexe productmengsels. Daarom werd de chemische samenstelling van 
de gesynthetiseerde NOTA-gemodificeerde somatropines eerst onderzocht. In hoofdstuk II werden de 
producten afkomstig van drie verschillende syntheseprocedures (equimolaire (1:1 
NOTA:somatropine), driemaal (3:1 NOTA: somatropine) en tienmaal (10: 1 NOTA: somatropine) 
molaire overmaat aan NOTA ten opzichte van somatropine) analytisch gekarakteriseerd. Gebruik 
makende van complementaire analytische technieken, meer bepaald directe analysen en bottom-up 
benaderingen, werden de resultaten bevestigd. De 1:1 NOTA:somatropine syntheseprocedure leverde 
de hoogste mono-NOTA somatropine fractie (42%) en minder hoge orde substitutiegraden (≥2 NOTA’s, 
12%), in vergelijking met 10:1 NOTA:somatropine dat meer hogere orde substitutiegraden (47% met 3 
NOTA’s) bevatte. Lys-70 gevolgd door Lys-158 waren het meest reactief ten opzichte van p-SCN-Bn-
NOTA en Lys-140 en Lys-172 waren minder reactieve lysine residuen. Deze vaststelling werd 
ondersteund door de in silico berekende laagste pKa-waarde van 8,3 voor Lys-70. Bovendien 
resulteerde gallium chelatie van NOTA-somatropine in een 100% complexeringsefficiëntie.  
Zijn NOTA gemodificeerde somatropines functioneel in in vitro opstellingen? Met behulp van hoge 
performantie receptor binding / gelpermeatiechromatografie (HPRBC/SEC) en natieve MS technieken 
in hoofdstuk III, hebben we aangetoond dat NOTA-gemodificeerde somatropines, waaronder ook met  
gallium gecheleerde NOTA-groepen, het humane GH-bindend proteïne (hGHBp) dimeriseren alsook 
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dat producten met een substitutiegraad van 4 NOTAs functioneel waren voor hGHBp-binding. De 
humane GHR bioassay, een cel-gebaseerde functionele assay met volledige lengte receptor en gebruik 
makend van de JAK2 target, toonde een gelijkaardige werkzaamheid (127-163%) en potentie (179-
228 pM) aan van alle onderzochte verbindingen (somatropine en NOTA-gemodificeerde stalen), 
waarbij de potentie en werkzaamheid niet significant verschillend waren. Verder hebben we 
aangetoond dat technieken zoals SEC en MS, klassiek gebruikt in de fysicochemische karakterisering 
van eiwitten, een potentiële toepassing hebben in de functionaliteitsevaluatie tijdens de ontdekking, 
ontwikkeling en kwaliteitscontrole van geneesmiddelen. 
In het algemeen kunnen modificaties op proteïnen niet enkel de receptor/target binding beïnvloeden; 
echter, ze kunnen ook resulteren in een verschillend farmacokinetisch profiel. Eén van de barrières 
van interesse is de bloed-hersenbarrière (BBB). Tot op heden is de kennis over de invloed van 
bifunctionele chelatoren wanneer geconjugeerd aan proteïnen, zoals somatropine, en hun BBB 
transport gedrag beperkt. Daarom werd de invloed van NOTA modaliteiten op proteïnen en het gedrag 
op de BBB in hoofdstuk IV onderzocht door middel van een in vivo muismodel. Somatropine, 10:1 
NOTA:somatropine en Ga-10:1 NOTA:somatropine vertoonden allen een lage herseninflux kinetiek (Kin 
= 0.38 ± 0.14 μL/(g × min), 0.36 ± 0.16 μL/(g × min) en 0.28 ± 0.18 μL/(g × min), respectievelijk), die 
bovendien niet significant verschillend waren van elkaar. Capillaire depletie werd uitgevoerd om de 
distributie binnen de hersenen te onderzoeken en resulteerde in een hoge parenchymale 
hersendistributie (>80%) voor alle componenten. Somatropine en 10:1 NOTA:somatropine vertoonden 
daarnaast een duidelijke weefselverdeling in de lever, nieren en serum, terwijl voor Ga-
10:1 NOTA:somatropine een iets andere distributie werd aangetoond met een hoge serumspiegel en 
geen preferente weefselverdeling. Verder, vertoonden alle componenten een relatief hoge in vivo 
metabolische stabiliteit tijdens de periode van de studie (T1/2 tussen 17-30 minuten). Onze resultaten 
lieten zien dat NOTA-modificaties, waaronder ook gallium chelatie, op een proteïne gekenmerkt door 
een lage hersenen influx, niet leidt tot een veranderd farmacokinetisch profiel ter hoogte van de bloed-
hersenbarrière. 
Naast het proteïne luik in dit proefschrift werden ook SAP’s onderzocht, gezien deze verbindingen over 
het algemeen goedkoper te produceren zijn, chemisch gezien meer onder controle zijn en over hogere 
weefsel-penetrerende eigenschappen beschikken. Het potentieel van SAP's als nieuwe alternatieven 
werd onderzocht in hoofdstuk V met de centrale onderzoeksvraag "Kunnen somatropine-afgeleide 
peptiden theranostische alternatieven zijn voor hun proteïne tegenhanger?”. Eerst werd een 
chemische en stabiliteitskarakterisatie uitgevoerd van geselecteerde SAP’s (SDP1-6), wat een 
zuiverheid van meer dan 90% onthulde, alsook een hoge chemische en metabolische stabiliteit: alle 
peptiden waren stabiel in buffer, hersenen, lever en serum (T1/2> 15 min). Daarna werd de 
functionaliteit voor hGHR/hGHBP binding geëvalueerd met behulp van natieve MS en de hGHR 
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bioassay; echter, onder onze experimentele omstandigheden konden we geen interactie van de SAP's 
aan de receptor aantonen. In parallel werden twee peptiden (SDP2 en SDP6) geselecteerd op basis van 
hun positie binnen somatropine en hun metabole stabiliteitsprofiel voor een eerste farmacokinetische 
evaluatie met de nadruk op BBB transport. Beide peptiden toonden een significante herseninflux in 
een in vivo muismodel, met SDP6 (Kin = 1.43 ± 0.28 μL/(g x min)) en SDP2 (Kin = 0.13 ± 0.10 μL/(g x min)) 
geclassificeerd als een hoge en zeer lage BBB-influx. Op basis van onze resultaten kunnen we 
concluderen dat het GHR-bindend vermogen van de geselecteerde SAP’s zeer laag is, waardoor 
aanpassingen aan deze peptiden nodig zijn om verder te exploreren. 
In lijn met de DruQuaR traditie werd een regulatoir kwaliteitsaspect van dit onderzoek geïncludeerd. 
In hoofdstuk VI hebben we ons gericht op de opkomende technieken die bijdragen aan de functionele 
kwaliteitsbeoordeling van biofarmaca, meer bepaald, "Zijn Surface Acoustic Wave (SAW) biosensoren 
nieuwe toepasbare instrumenten binnen de functionele kwaliteitscontrole?”. SAW biosensoren laten 
de gebruiker toe om interacties te detecteren en te kwantificeren, waardoor niet alleen informatie 
wordt bekomen over affiniteit (KD) en kinetiek (kon en koff), maar ook over viscoelastische effecten. Door 
middel van een analytische kwaliteit-door-design (aQbD) gebaseerde benadering werden de prestaties 
van de SAW biosensor geëvalueerd vanuit een farmaceutisch kwaliteitsoogpunt, met behulp van 
somatropine en NOTA-derivaten als model biotechnologische geneesmiddelen en een antilichaam 
interactie partner. KMA (kritische methode attributen), zoals selectiviteit en variabiliteit, werden 
geëvalueerd in functie van de verschillende experimentele variabelen met behulp van DoEs (Design of 
Experiments). We stelden onder andere kwalificatietesten en SSTs (systeem geschiktheidstesten) voor, 
zoals vereist door de farmaceutische bevoegde autoriteiten, en bevelen de opname van de biosensor 
technieken aan in de verschillende farmacopees en farmaceutische richtlijnen, alsook hun toepassing 
binnen de functionele kwaliteitsevaluaties. 
Tenslotte werd in hoofdstuk VII de bredere internationale context, relevantie en 
toekomstperspectieven van dit onderzoek besproken. De verschillende thema's behandeld in dit 
onderzoek dragen bij aan een brede potentiële toepassing van onze modelcomponenten en 
functionele kwaliteitstechnieken/visie in onderzoek en industriële omgevingen. Ons onderzoek zit 
momenteel in de beginstadia van het exploreren van het gebruik van NOTA-gemodificeerde 
somatropines en SAP’s in GHR gerelateerde ziekten. Bovendien stimuleren we de opname van nieuwe 
technieken zoals biosensoren in farmacopees en farmaceutische richtlijnen, alsook het genereren van 
meer gegevens over eiwitten, peptiden en hun BBB gedrag. 
We kunnen dus besluiten dat dit onderzoek heeft bijgedragen tot de ontwikkeling van NOTA-
gemodificeerde somatropine derivaten, waarvan de bestudeerde farmacodynamische (target-
bindende functionaliteit) en farmacokinetische (BBB kinetiek) aspecten niet verschillend waren van 
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ongemodificeerd somatropine. Deze kennis is zeker van belang voor de verdere ontwikkeling van 
ligand-gerichte anti-tumor medicatie bedoeld tegen GHR-overexpresserende tumoren. 
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“Research workers must stimulate one another intellectually. Research 
must be their hobby. What is nicer than being able to earn your living 
by practicing your hobby?” 
 
Paul Janssen  
(°1926 - †2003, Founder of Janssen Pharmaceutica) 
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